US20220259182A1 - Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof - Google Patents
Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof Download PDFInfo
- Publication number
- US20220259182A1 US20220259182A1 US17/437,989 US202017437989A US2022259182A1 US 20220259182 A1 US20220259182 A1 US 20220259182A1 US 202017437989 A US202017437989 A US 202017437989A US 2022259182 A1 US2022259182 A1 US 2022259182A1
- Authority
- US
- United States
- Prior art keywords
- amino
- pyrazol
- methyl
- compound
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 249
- -1 pyrazolyl-amino-pyrimidinyl Chemical class 0.000 title claims description 80
- 239000000203 mixture Substances 0.000 title description 180
- 150000001448 anilines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 189
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 106
- 201000010099 disease Diseases 0.000 claims description 67
- 125000005842 heteroatom Chemical group 0.000 claims description 57
- 229910052739 hydrogen Inorganic materials 0.000 claims description 48
- 239000001257 hydrogen Substances 0.000 claims description 48
- 229910052736 halogen Inorganic materials 0.000 claims description 47
- 150000002367 halogens Chemical class 0.000 claims description 47
- 229910052760 oxygen Inorganic materials 0.000 claims description 45
- 229910052717 sulfur Inorganic materials 0.000 claims description 43
- 208000035475 disorder Diseases 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 229910052757 nitrogen Inorganic materials 0.000 claims description 33
- 125000001931 aliphatic group Chemical group 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 125000004432 carbon atom Chemical group C* 0.000 claims description 25
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 25
- 150000002431 hydrogen Chemical group 0.000 claims description 24
- 229910052698 phosphorus Inorganic materials 0.000 claims description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 20
- 229910052731 fluorine Inorganic materials 0.000 claims description 17
- VGDHASRIHHJRJM-UHFFFAOYSA-N CC(C#N)(COC1=CC=C(C=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C)C Chemical compound CC(C#N)(COC1=CC=C(C=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C)C VGDHASRIHHJRJM-UHFFFAOYSA-N 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 229910052801 chlorine Inorganic materials 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- UJAIDVIMEUFMHJ-UHFFFAOYSA-N C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC=C(OCC(C#N)(C)C)C=C1)C Chemical compound C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC=C(OCC(C#N)(C)C)C=C1)C UJAIDVIMEUFMHJ-UHFFFAOYSA-N 0.000 claims description 13
- 239000003085 diluting agent Substances 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 13
- 230000001404 mediated effect Effects 0.000 claims description 13
- OFCXYOZSKZQGOT-UHFFFAOYSA-N 1-[[4-[2-[(1-cyclopropylpyrazol-4-yl)amino]-5-methylpyrimidin-4-yl]anilino]methyl]cyclopropane-1-carbonitrile Chemical compound C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC=C(C=C1)NCC1(CC1)C#N)C OFCXYOZSKZQGOT-UHFFFAOYSA-N 0.000 claims description 12
- QZPUWSJWUFTQKV-UHFFFAOYSA-N C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC=C(OCC2(CCC2)C#N)C=C1)C Chemical compound C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC=C(OCC2(CCC2)C#N)C=C1)C QZPUWSJWUFTQKV-UHFFFAOYSA-N 0.000 claims description 12
- VBNCTGSYGQOITA-UHFFFAOYSA-N CC(C#N)(COC1=CC=C(C=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCN(CC1)C)C Chemical compound CC(C#N)(COC1=CC=C(C=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCN(CC1)C)C VBNCTGSYGQOITA-UHFFFAOYSA-N 0.000 claims description 12
- DPPBPASJVKVITI-UHFFFAOYSA-N CC=1C(=NC(=NC=1)NC=1C=NN(C=1)C)C1=CC=C(OCCC#N)C=C1 Chemical compound CC=1C(=NC(=NC=1)NC=1C=NN(C=1)C)C1=CC=C(OCCC#N)C=C1 DPPBPASJVKVITI-UHFFFAOYSA-N 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 12
- 208000027866 inflammatory disease Diseases 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 9
- ALZNPIMMVQMLQH-UHFFFAOYSA-N C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(OCC(C#N)(C)C)C=C1)F)C Chemical compound C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(OCC(C#N)(C)C)C=C1)F)C ALZNPIMMVQMLQH-UHFFFAOYSA-N 0.000 claims description 8
- NTNUPYTWXIEQJN-UHFFFAOYSA-N C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(OCC2(CC2)C#N)C=C1)F)C Chemical compound C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(OCC2(CC2)C#N)C=C1)F)C NTNUPYTWXIEQJN-UHFFFAOYSA-N 0.000 claims description 8
- BXQZSFQBGSSQLX-UHFFFAOYSA-N C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C=1C=C2CC(COC2=CC=1)C#N)C Chemical compound C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C=1C=C2CC(COC2=CC=1)C#N)C BXQZSFQBGSSQLX-UHFFFAOYSA-N 0.000 claims description 8
- HGNUWSGUGFEGMA-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C)C1=CC=C(OCC(C#N)(C)C)C=C1 Chemical compound ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C)C1=CC=C(OCC(C#N)(C)C)C=C1 HGNUWSGUGFEGMA-UHFFFAOYSA-N 0.000 claims description 8
- VBTXXVQJKWUPSH-UHFFFAOYSA-N FC1=C(OCC(C#N)(C)C)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C(C(F)(F)F)C Chemical compound FC1=C(OCC(C#N)(C)C)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C(C(F)(F)F)C VBTXXVQJKWUPSH-UHFFFAOYSA-N 0.000 claims description 8
- ILCRWPDFUQOCIP-UHFFFAOYSA-N FC1=C(OCC(C#N)(C)C)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCOCC1 Chemical compound FC1=C(OCC(C#N)(C)C)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCOCC1 ILCRWPDFUQOCIP-UHFFFAOYSA-N 0.000 claims description 8
- SBMNKBYWMXUUMK-UHFFFAOYSA-N FC1=C(OCC2(CC2)C#N)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCOCC1 Chemical compound FC1=C(OCC2(CC2)C#N)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCOCC1 SBMNKBYWMXUUMK-UHFFFAOYSA-N 0.000 claims description 8
- WYSYSOJTJPTIPL-UHFFFAOYSA-N FC1=C(OCCC#N)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C Chemical compound FC1=C(OCCC#N)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C WYSYSOJTJPTIPL-UHFFFAOYSA-N 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- CGQUPRPRIQMYMU-UHFFFAOYSA-N 1-[[4-[2-[[1-(1-acetylpiperidin-4-yl)pyrazol-4-yl]amino]-5-methylpyrimidin-4-yl]-2-fluorophenoxy]methyl]cyclopropane-1-carbonitrile Chemical compound C(C)(=O)N1CCC(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(OCC2(CC2)C#N)C=C1)F)C CGQUPRPRIQMYMU-UHFFFAOYSA-N 0.000 claims description 7
- IKTWRNBGMIINKZ-UHFFFAOYSA-N C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC=C(OC2CC(C2)C#N)C=C1)C Chemical compound C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC=C(OC2CC(C2)C#N)C=C1)C IKTWRNBGMIINKZ-UHFFFAOYSA-N 0.000 claims description 7
- ARQFVMOQDGURLH-UHFFFAOYSA-N C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C=1C=CC(=NC=1)OCC1(CC1)C#N)C Chemical compound C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C=1C=CC(=NC=1)OCC1(CC1)C#N)C ARQFVMOQDGURLH-UHFFFAOYSA-N 0.000 claims description 7
- KLWTUEHMYJOWDL-UHFFFAOYSA-N CC(C#N)(C(C)OC1=CC=C(C=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCOCC1)C Chemical compound CC(C#N)(C(C)OC1=CC=C(C=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCOCC1)C KLWTUEHMYJOWDL-UHFFFAOYSA-N 0.000 claims description 7
- HDYTWTGDZWCFJO-UHFFFAOYSA-N CC(C#N)(COC1=CC=C(C=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCOCC1)C Chemical compound CC(C#N)(COC1=CC=C(C=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCOCC1)C HDYTWTGDZWCFJO-UHFFFAOYSA-N 0.000 claims description 7
- GFELJJZXEOYXHN-UHFFFAOYSA-N CC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CCN(CC1)C)C1=CC=C(C=C1)NCC1(CC1)C#N Chemical compound CC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CCN(CC1)C)C1=CC=C(C=C1)NCC1(CC1)C#N GFELJJZXEOYXHN-UHFFFAOYSA-N 0.000 claims description 7
- KFUURECKHOTWQK-UHFFFAOYSA-N FC1=C(OCC2(CC2)C#N)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCN(CC1)C Chemical compound FC1=C(OCC2(CC2)C#N)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCN(CC1)C KFUURECKHOTWQK-UHFFFAOYSA-N 0.000 claims description 7
- WCPGOZVPINFFLT-UHFFFAOYSA-N 1-[[4-[2-[[1-[1-(cyclopropanecarbonyl)piperidin-4-yl]pyrazol-4-yl]amino]-5-methylpyrimidin-4-yl]-2-fluorophenoxy]methyl]cyclopropane-1-carbonitrile Chemical compound C1(CC1)C(=O)N1CCC(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(OCC2(CC2)C#N)C=C1)F)C WCPGOZVPINFFLT-UHFFFAOYSA-N 0.000 claims description 6
- AMESQYYVSNZPHR-UHFFFAOYSA-N FC1=C(OCC(C#N)(C)C)C=CC(=C1)C1=NC(=NC=C1F)NC=1C=NN(C=1)C1CCOCC1 Chemical compound FC1=C(OCC(C#N)(C)C)C=CC(=C1)C1=NC(=NC=C1F)NC=1C=NN(C=1)C1CCOCC1 AMESQYYVSNZPHR-UHFFFAOYSA-N 0.000 claims description 6
- XHKAJGRDQTZUAY-UHFFFAOYSA-N FC1=C(OCC2(CC2)C#N)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCN(CC1)C(=O)C1(CC1)C Chemical compound FC1=C(OCC2(CC2)C#N)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCN(CC1)C(=O)C1(CC1)C XHKAJGRDQTZUAY-UHFFFAOYSA-N 0.000 claims description 6
- QASKICLIFGYFHT-UHFFFAOYSA-N FC1=C(OCC2(CC2)C#N)C=CC(=C1)C1=NC(=NC=C1F)NC=1C=NN(C=1)C1CCOCC1 Chemical compound FC1=C(OCC2(CC2)C#N)C=CC(=C1)C1=NC(=NC=C1F)NC=1C=NN(C=1)C1CCOCC1 QASKICLIFGYFHT-UHFFFAOYSA-N 0.000 claims description 6
- JCZLVOSWCMZYMJ-UHFFFAOYSA-N 1-[[4-[5-chloro-2-[(1-piperidin-4-ylpyrazol-4-yl)amino]pyrimidin-4-yl]anilino]methyl]cyclopropane-1-carbonitrile Chemical compound ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CCNCC1)C1=CC=C(C=C1)NCC1(CC1)C#N JCZLVOSWCMZYMJ-UHFFFAOYSA-N 0.000 claims description 5
- WQZFFFAAWDLCKS-UHFFFAOYSA-N 3-[2-fluoro-4-[5-methyl-2-[(1-piperidin-4-ylpyrazol-4-yl)amino]pyrimidin-4-yl]phenoxy]-2,2-dimethylpropanenitrile Chemical compound FC1=C(OCC(C#N)(C)C)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCNCC1 WQZFFFAAWDLCKS-UHFFFAOYSA-N 0.000 claims description 5
- JKSRVVPXABOCQD-UHFFFAOYSA-N C(#N)CN1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(OCC(C#N)(C)C)C=C1)F)C Chemical compound C(#N)CN1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(OCC(C#N)(C)C)C=C1)F)C JKSRVVPXABOCQD-UHFFFAOYSA-N 0.000 claims description 5
- ONVDZVVLFYPSNG-UHFFFAOYSA-N C(C)(=O)N1CCC(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(OCC(C#N)(C)C)C=C1)F)C Chemical compound C(C)(=O)N1CCC(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(OCC(C#N)(C)C)C=C1)F)C ONVDZVVLFYPSNG-UHFFFAOYSA-N 0.000 claims description 5
- ATRKPWNUKYFYAT-UHFFFAOYSA-N C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(C=C1)NCC(C#N)(C)C)F)C Chemical compound C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(C=C1)NCC(C#N)(C)C)F)C ATRKPWNUKYFYAT-UHFFFAOYSA-N 0.000 claims description 5
- FEPOZFFDYLNJDK-UHFFFAOYSA-N C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(OCC2(CC2)C#N)C(=C1)F)F)C Chemical compound C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(OCC2(CC2)C#N)C(=C1)F)F)C FEPOZFFDYLNJDK-UHFFFAOYSA-N 0.000 claims description 5
- XGROGDOMSFJUDR-UHFFFAOYSA-N C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(OCC2(CC2)C#N)C=C1)F)F Chemical compound C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(OCC2(CC2)C#N)C=C1)F)F XGROGDOMSFJUDR-UHFFFAOYSA-N 0.000 claims description 5
- PLHGOKKHQKQEJD-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CC1)C1=CC(=C(C=C1)N(CC(C#N)(C)C)C)F Chemical compound ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CC1)C1=CC(=C(C=C1)N(CC(C#N)(C)C)C)F PLHGOKKHQKQEJD-UHFFFAOYSA-N 0.000 claims description 5
- ZSXVWKSRPCWHJJ-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CC1)C1=CC(=C(OCC2(CC2)C#N)C=C1)F Chemical compound ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CC1)C1=CC(=C(OCC2(CC2)C#N)C=C1)F ZSXVWKSRPCWHJJ-UHFFFAOYSA-N 0.000 claims description 5
- CTWHZLQJBPQQJK-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CCOCC1)C1=CC(=C(OCC(C#N)(C)C)C=C1)F Chemical compound ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CCOCC1)C1=CC(=C(OCC(C#N)(C)C)C=C1)F CTWHZLQJBPQQJK-UHFFFAOYSA-N 0.000 claims description 5
- XXTSEXVPCYNBBM-UHFFFAOYSA-N FC1=C(OCC(C#N)(C)C)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCN(CC1)C Chemical compound FC1=C(OCC(C#N)(C)C)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCN(CC1)C XXTSEXVPCYNBBM-UHFFFAOYSA-N 0.000 claims description 5
- VGIGJQGEJWBWDP-UHFFFAOYSA-N FC1=C(OCC2(CC2)C#N)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)CCOC Chemical compound FC1=C(OCC2(CC2)C#N)C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)CCOC VGIGJQGEJWBWDP-UHFFFAOYSA-N 0.000 claims description 5
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims description 5
- 238000011200 topical administration Methods 0.000 claims description 5
- MUWXWFRPSZMMAM-UHFFFAOYSA-N C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(C=C1)N(C)CC1(CC1)C#N)F)C Chemical compound C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(C=C1)N(C)CC1(CC1)C#N)F)C MUWXWFRPSZMMAM-UHFFFAOYSA-N 0.000 claims description 4
- ZRPZYEDYXKQGTK-UHFFFAOYSA-N CC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CCOCC1)C=1C=CC(=NC=1)OCC1(CC1)C#N Chemical compound CC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CCOCC1)C=1C=CC(=NC=1)OCC1(CC1)C#N ZRPZYEDYXKQGTK-UHFFFAOYSA-N 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- DMMSCBAJFRSOOJ-UHFFFAOYSA-N CC1=CN=C(N=C1C2=CC(=C(C=C2)OCC(C)(C)C#N)F)NC3=CN(N=C3)CCOC Chemical compound CC1=CN=C(N=C1C2=CC(=C(C=C2)OCC(C)(C)C#N)F)NC3=CN(N=C3)CCOC DMMSCBAJFRSOOJ-UHFFFAOYSA-N 0.000 claims description 3
- JAMNHZBIQDNHMM-UHFFFAOYSA-N pivalonitrile Chemical compound CC(C)(C)C#N JAMNHZBIQDNHMM-UHFFFAOYSA-N 0.000 claims description 3
- DCEHKPSFVNIFDH-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CC1)C1=CC=C(OCC(C#N)(C)C)C=C1 Chemical compound ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CC1)C1=CC=C(OCC(C#N)(C)C)C=C1 DCEHKPSFVNIFDH-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 20
- 238000002360 preparation method Methods 0.000 abstract description 13
- 229940122245 Janus kinase inhibitor Drugs 0.000 abstract description 10
- 230000003389 potentiating effect Effects 0.000 abstract description 5
- 208000037765 diseases and disorders Diseases 0.000 abstract description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 120
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 104
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 82
- 238000005160 1H NMR spectroscopy Methods 0.000 description 76
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
- 239000007858 starting material Substances 0.000 description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 239000007787 solid Substances 0.000 description 45
- 239000000047 product Substances 0.000 description 41
- 235000019439 ethyl acetate Nutrition 0.000 description 40
- 239000000243 solution Substances 0.000 description 36
- 125000003118 aryl group Chemical group 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 32
- 125000001072 heteroaryl group Chemical group 0.000 description 32
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000000706 filtrate Substances 0.000 description 24
- 239000000651 prodrug Substances 0.000 description 23
- 229940002612 prodrug Drugs 0.000 description 23
- 239000004698 Polyethylene Substances 0.000 description 22
- 239000012043 crude product Substances 0.000 description 22
- 150000003839 salts Chemical class 0.000 description 22
- 239000003921 oil Substances 0.000 description 21
- 235000019198 oils Nutrition 0.000 description 21
- 239000012044 organic layer Substances 0.000 description 21
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 20
- 238000002953 preparative HPLC Methods 0.000 description 20
- 0 [1*]c1cnc(Nc2ccn([2*])c2)nc1C1=C[Y]=C(*[4*])C=C1[3*] Chemical compound [1*]c1cnc(Nc2ccn([2*])c2)nc1C1=C[Y]=C(*[4*])C=C1[3*] 0.000 description 19
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 19
- 238000004293 19F NMR spectroscopy Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000000460 chlorine Substances 0.000 description 18
- 238000001816 cooling Methods 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 17
- 125000000753 cycloalkyl group Chemical group 0.000 description 17
- 125000006413 ring segment Chemical group 0.000 description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 17
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 16
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- 239000003480 eluent Substances 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- KMSWFVSXBMWVIT-UHFFFAOYSA-N 1-cyclopropylpyrazol-4-amine Chemical compound C1=C(N)C=NN1C1CC1 KMSWFVSXBMWVIT-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- QCIKJNCYPRDVQN-UHFFFAOYSA-N (1-cyanocyclopropyl)methyl methanesulfonate Chemical compound CS(=O)(=O)OCC1(C#N)CC1 QCIKJNCYPRDVQN-UHFFFAOYSA-N 0.000 description 12
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 12
- 108010024121 Janus Kinases Proteins 0.000 description 12
- 102000015617 Janus Kinases Human genes 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 12
- 125000001188 haloalkyl group Chemical group 0.000 description 12
- 125000004404 heteroalkyl group Chemical group 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 11
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 239000012267 brine Substances 0.000 description 11
- 125000004452 carbocyclyl group Chemical group 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- 239000012453 solvate Substances 0.000 description 11
- XMHFZVYKNRRPMO-UHFFFAOYSA-N (2-cyano-2-methylpropyl) methanesulfonate Chemical compound N#CC(C)(C)COS(C)(=O)=O XMHFZVYKNRRPMO-UHFFFAOYSA-N 0.000 description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical group NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 125000003710 aryl alkyl group Chemical group 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 10
- 229910000024 caesium carbonate Inorganic materials 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 150000002148 esters Chemical group 0.000 description 10
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- ASQOQJYHIYYTEJ-GBESFXJTSA-N (1r,7s,9as)-7-decyl-2,3,4,6,7,8,9,9a-octahydro-1h-quinolizin-1-ol Chemical compound O[C@@H]1CCCN2C[C@@H](CCCCCCCCCC)CC[C@H]21 ASQOQJYHIYYTEJ-GBESFXJTSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 201000004681 Psoriasis Diseases 0.000 description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 9
- 239000011593 sulfur Substances 0.000 description 9
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 9
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 8
- GHMPDNOAATUJEL-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(C4CC4)c3)ncc2C)ccc1OCC1(C#N)CC1 Chemical compound Cc1cc(-c2nc(Nc3cnn(C4CC4)c3)ncc2C)ccc1OCC1(C#N)CC1 GHMPDNOAATUJEL-UHFFFAOYSA-N 0.000 description 8
- WWUVZVUNJVQNQH-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(C4CCOCC4)c3)ncc2C)ccc1OCC(C)(C)C#N Chemical compound Cc1cc(-c2nc(Nc3cnn(C4CCOCC4)c3)ncc2C)ccc1OCC(C)(C)C#N WWUVZVUNJVQNQH-UHFFFAOYSA-N 0.000 description 8
- TZCLESXNUVIGLQ-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(C4CCOCC4)c3)ncc2C)ccc1OCC1(C#N)CC1 Chemical compound Cc1cc(-c2nc(Nc3cnn(C4CCOCC4)c3)ncc2C)ccc1OCC1(C#N)CC1 TZCLESXNUVIGLQ-UHFFFAOYSA-N 0.000 description 8
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 239000007832 Na2SO4 Substances 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 8
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 8
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- GZZNBQLBGSVOOZ-UHFFFAOYSA-N 1-(oxan-4-yl)pyrazol-4-amine Chemical compound C1=C(N)C=NN1C1CCOCC1 GZZNBQLBGSVOOZ-UHFFFAOYSA-N 0.000 description 7
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 125000004438 haloalkoxy group Chemical group 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- 239000010452 phosphate Chemical group 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- DQXNTSXKIUZJJS-UHFFFAOYSA-N 2,4-dichloro-5-methylpyrimidine Chemical compound CC1=CN=C(Cl)N=C1Cl DQXNTSXKIUZJJS-UHFFFAOYSA-N 0.000 description 6
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical group C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical group [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 6
- SNGYYMHUCHONNX-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(C4CC4)c3)ncc2C)ccc1N(C)CC(C)(C)C#N Chemical compound Cc1cc(-c2nc(Nc3cnn(C4CC4)c3)ncc2C)ccc1N(C)CC(C)(C)C#N SNGYYMHUCHONNX-UHFFFAOYSA-N 0.000 description 6
- GQSLZHKORKDQNK-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CC=C(C=C1)NCC1(CC1)C#N)C Chemical compound ClC1=NC=C(C(=N1)C1=CC=C(C=C1)NCC1(CC1)C#N)C GQSLZHKORKDQNK-UHFFFAOYSA-N 0.000 description 6
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 206010047642 Vitiligo Diseases 0.000 description 6
- 208000017733 acquired polycythemia vera Diseases 0.000 description 6
- 125000003368 amide group Chemical group 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 206010028537 myelofibrosis Diseases 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 125000003367 polycyclic group Chemical group 0.000 description 6
- 208000037244 polycythemia vera Diseases 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 6
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 6
- TVPVAGUBJCNUSJ-UHFFFAOYSA-N 1,1-diazidoguanidine Chemical group [N-]=[N+]=NN(C(=N)N)N=[N+]=[N-] TVPVAGUBJCNUSJ-UHFFFAOYSA-N 0.000 description 5
- LBGSWBJURUFGLR-UHFFFAOYSA-N 1-methylpyrazol-4-amine Chemical compound CN1C=C(N)C=N1 LBGSWBJURUFGLR-UHFFFAOYSA-N 0.000 description 5
- ZUIRWAMLHRIUMG-UHFFFAOYSA-N 4-(4-ethoxyphenyl)-5-methyl-n-(1-methylpyrazol-4-yl)pyrimidin-2-amine Chemical compound C1=CC(OCC)=CC=C1C1=NC(NC2=CN(C)N=C2)=NC=C1C ZUIRWAMLHRIUMG-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 206010052779 Transplant rejections Diseases 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 125000002877 alkyl aryl group Chemical group 0.000 description 5
- 125000004414 alkyl thio group Chemical group 0.000 description 5
- 125000005110 aryl thio group Chemical group 0.000 description 5
- 125000004104 aryloxy group Chemical group 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 239000004202 carbamide Chemical group 0.000 description 5
- 125000005884 carbocyclylalkyl group Chemical group 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 201000001981 dermatomyositis Diseases 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 5
- 125000004043 oxo group Chemical group O=* 0.000 description 5
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 5
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical group [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 5
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 5
- 125000005864 sulfonamidyl group Chemical group 0.000 description 5
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical group [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 5
- 125000004962 sulfoxyl group Chemical group 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 4
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 4
- FFYHTORWEVTRQI-UHFFFAOYSA-N 2-fluoro-4-[5-methyl-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]phenol Chemical compound Cc1cnc(Nc2cnn(C)c2)nc1-c1ccc(O)c(F)c1 FFYHTORWEVTRQI-UHFFFAOYSA-N 0.000 description 4
- XFPUBVMTDFAWET-UHFFFAOYSA-N 4-(3-fluoro-4-methoxyphenyl)-5-methyl-n-(1-methylpyrazol-4-yl)pyrimidin-2-amine Chemical compound C1=C(F)C(OC)=CC=C1C1=NC(NC2=CN(C)N=C2)=NC=C1C XFPUBVMTDFAWET-UHFFFAOYSA-N 0.000 description 4
- GXMWMFMIRUGTJU-UHFFFAOYSA-N 4-(3-fluoro-4-propan-2-yloxyphenyl)-5-methyl-n-(1-methylpyrazol-4-yl)pyrimidin-2-amine Chemical compound C1=C(F)C(OC(C)C)=CC=C1C1=NC(NC2=CN(C)N=C2)=NC=C1C GXMWMFMIRUGTJU-UHFFFAOYSA-N 0.000 description 4
- JPOLYMVDWGPVDL-UHFFFAOYSA-N 4-(3-fluoro-4-propoxyphenyl)-5-methyl-n-(1-methylpyrazol-4-yl)pyrimidin-2-amine Chemical compound C1=C(F)C(OCCC)=CC=C1C1=NC(NC2=CN(C)N=C2)=NC=C1C JPOLYMVDWGPVDL-UHFFFAOYSA-N 0.000 description 4
- ZTWPAHYYUKKVOV-UHFFFAOYSA-N 4-(4-ethoxy-3-fluorophenyl)-5-methyl-n-(1-methylpyrazol-4-yl)pyrimidin-2-amine Chemical compound C1=C(F)C(OCC)=CC=C1C1=NC(NC2=CN(C)N=C2)=NC=C1C ZTWPAHYYUKKVOV-UHFFFAOYSA-N 0.000 description 4
- RXPVXAIBCOVDFE-UHFFFAOYSA-N 4-(4-ethoxy-3-fluorophenyl)-5-methyl-n-(1-propan-2-ylpyrazol-4-yl)pyrimidin-2-amine Chemical compound C1=C(F)C(OCC)=CC=C1C1=NC(NC2=CN(N=C2)C(C)C)=NC=C1C RXPVXAIBCOVDFE-UHFFFAOYSA-N 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- WJQBCLPMUZRFEB-UHFFFAOYSA-N C(#N)CN1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(OCC2(CC2)C#N)C=C1)F)C Chemical compound C(#N)CN1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(OCC2(CC2)C#N)C=C1)F)C WJQBCLPMUZRFEB-UHFFFAOYSA-N 0.000 description 4
- OAQJTCSEDPRILE-UHFFFAOYSA-N CC(=O)N1CCC(n2cc(Nc3ncc(C)c(-c4ccc(OCC5(C#N)CC5)c(C)c4)n3)cn2)CC1 Chemical compound CC(=O)N1CCC(n2cc(Nc3ncc(C)c(-c4ccc(OCC5(C#N)CC5)c(C)c4)n3)cn2)CC1 OAQJTCSEDPRILE-UHFFFAOYSA-N 0.000 description 4
- FVICPQYOCDMINC-UHFFFAOYSA-N COCCn1cc(Nc2ncc(C)c(-c3ccc(OCC(C)(C)C#N)c(C)c3)n2)cn1 Chemical compound COCCn1cc(Nc2ncc(C)c(-c3ccc(OCC(C)(C)C#N)c(C)c3)n2)cn1 FVICPQYOCDMINC-UHFFFAOYSA-N 0.000 description 4
- ZBUDYYCYMQFWEG-UHFFFAOYSA-N CS(=O)(=O)OC(C)C(C)(C)C#N Chemical compound CS(=O)(=O)OC(C)C(C)(C)C#N ZBUDYYCYMQFWEG-UHFFFAOYSA-N 0.000 description 4
- KYXIGKSZRCTJHY-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(C)c3)ncc2C)ccc1OCCC#N Chemical compound Cc1cc(-c2nc(Nc3cnn(C)c3)ncc2C)ccc1OCCC#N KYXIGKSZRCTJHY-UHFFFAOYSA-N 0.000 description 4
- GWFBYOBKZFMHNU-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(C4CC4)c3)ncc2C)ccc1OCC(C)(C)C#N Chemical compound Cc1cc(-c2nc(Nc3cnn(C4CC4)c3)ncc2C)ccc1OCC(C)(C)C#N GWFBYOBKZFMHNU-UHFFFAOYSA-N 0.000 description 4
- WBLIUQRVYNWHQP-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(C4CCN(C)CC4)c3)ncc2C)ccc1OCC1(C#N)CC1 Chemical compound Cc1cc(-c2nc(Nc3cnn(C4CCN(C)CC4)c3)ncc2C)ccc1OCC1(C#N)CC1 WBLIUQRVYNWHQP-UHFFFAOYSA-N 0.000 description 4
- SKBDNUMMMYCPPG-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CC(=C(C=C1)N(C)CC1(CC1)C#N)F)C Chemical compound ClC1=NC=C(C(=N1)C1=CC(=C(C=C1)N(C)CC1(CC1)C#N)F)C SKBDNUMMMYCPPG-UHFFFAOYSA-N 0.000 description 4
- JFYFGVAAVWSQMN-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CC(=C(OCC2(CC2)C#N)C(=C1)F)F)C Chemical compound ClC1=NC=C(C(=N1)C1=CC(=C(OCC2(CC2)C#N)C(=C1)F)F)C JFYFGVAAVWSQMN-UHFFFAOYSA-N 0.000 description 4
- JZFXCNASZMIRCU-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C)C1=CC=C(C=C1)O Chemical compound ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C)C1=CC=C(C=C1)O JZFXCNASZMIRCU-UHFFFAOYSA-N 0.000 description 4
- FNJVTBCAJHCCEO-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CCOCC1)C1=CC(=C(OCC2(CC2)C#N)C=C1)F Chemical compound ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CCOCC1)C1=CC(=C(OCC2(CC2)C#N)C=C1)F FNJVTBCAJHCCEO-UHFFFAOYSA-N 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- OTKFCAGUIGOTOR-UHFFFAOYSA-N FC=1C=C(C=CC=1O)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCN(CC1)C(=O)C1(CC1)C Chemical compound FC=1C=C(C=CC=1O)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCN(CC1)C(=O)C1(CC1)C OTKFCAGUIGOTOR-UHFFFAOYSA-N 0.000 description 4
- 208000007465 Giant cell arteritis Diseases 0.000 description 4
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102000042838 JAK family Human genes 0.000 description 4
- 108091082332 JAK family Proteins 0.000 description 4
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- ZVQZKKVIFKNFTL-UHFFFAOYSA-N benzyl 4-[4-[[4-[4-(2-cyano-2-methylpropoxy)-3-fluorophenyl]-5-methylpyrimidin-2-yl]amino]pyrazol-1-yl]piperidine-1-carboxylate Chemical compound CC(C)(COC(C=CC(C1=NC(NC2=CN(C(CC3)CCN3C(OCC3=CC=CC=C3)=O)N=C2)=NC=C1C)=C1)=C1F)C#N ZVQZKKVIFKNFTL-UHFFFAOYSA-N 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 206010025135 lupus erythematosus Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 206010043207 temporal arteritis Diseases 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 3
- AEVBPXDFDKBGLT-YOUFYPILSA-N (2s,3s,4r,5r)-n-[2-[4-(diethoxyphosphorylmethyl)anilino]-2-oxoethyl]-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolane-2-carboxamide Chemical compound C1=CC(CP(=O)(OCC)OCC)=CC=C1NC(=O)CNC(=O)[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 AEVBPXDFDKBGLT-YOUFYPILSA-N 0.000 description 3
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 3
- RSJDCHYFCGMIMM-UHFFFAOYSA-N 1-(1,1,1-trifluoropropan-2-yl)pyrazol-4-amine Chemical compound FC(C(C)N1N=CC(=C1)N)(F)F RSJDCHYFCGMIMM-UHFFFAOYSA-N 0.000 description 3
- FJZNNKJZHQFMCK-LRDDRELGSA-N 1-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-phenylurea Chemical compound C1(=CC(=CC(=C1[C@H]1[C@@H](C(=O)NC1)NC(=O)NC1=CC=CC=C1)F)OC)F FJZNNKJZHQFMCK-LRDDRELGSA-N 0.000 description 3
- MXPCZHSTOIKVST-UHFFFAOYSA-N 1-[3-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(2-hydroxyethoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=CC(N)=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OCCO)=C1 MXPCZHSTOIKVST-UHFFFAOYSA-N 0.000 description 3
- SZCBDIVMCGFVPW-UHFFFAOYSA-N 1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 SZCBDIVMCGFVPW-UHFFFAOYSA-N 0.000 description 3
- OXTVBHDILDPYAS-UHFFFAOYSA-N 1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(3-hydroxypropoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OCCCO)=C1 OXTVBHDILDPYAS-UHFFFAOYSA-N 0.000 description 3
- LWOZPMUKSDANLX-UHFFFAOYSA-N 1-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)anilino]methyl]cyclopropane-1-carbonitrile Chemical compound CC1(OB(OC1(C)C)C1=CC=C(C=C1)NCC1(CC1)C#N)C LWOZPMUKSDANLX-UHFFFAOYSA-N 0.000 description 3
- DHVSQDWAXNJIRT-UHFFFAOYSA-N 2-chloro-4-(4-ethoxyphenyl)-5-methylpyrimidine Chemical compound C1=CC(OCC)=CC=C1C1=NC(Cl)=NC=C1C DHVSQDWAXNJIRT-UHFFFAOYSA-N 0.000 description 3
- UNXCSOBDAFPESL-UHFFFAOYSA-N 3-[2-fluoro-N-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)anilino]-2,2-dimethylpropanenitrile Chemical compound FC1=C(C=CC(=C1)B1OC(C(O1)(C)C)(C)C)N(CC(C#N)(C)C)C UNXCSOBDAFPESL-UHFFFAOYSA-N 0.000 description 3
- HPCPBULFSFEWFJ-UHFFFAOYSA-N 3-[4-[2-[(1-cyclopropylpyrazol-4-yl)amino]-5-methylpyrimidin-4-yl]-2-fluoro-N-methylanilino]-2,2-dimethylpropanenitrile Chemical compound C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(C=C1)N(CC(C#N)(C)C)C)F)C HPCPBULFSFEWFJ-UHFFFAOYSA-N 0.000 description 3
- MVXAKOGJWVQPKC-UHFFFAOYSA-N 5-(3-ethynyl-5-fluorophenyl)-2-pyridin-2-yl-4,6,7,8-tetrahydro-[1,3]oxazolo[4,5-c]azepine Chemical compound FC1=CC(C#C)=CC(N2CC=3N=C(OC=3CCC2)C=2N=CC=CC=2)=C1 MVXAKOGJWVQPKC-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 3
- 208000026872 Addison Disease Diseases 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- JWLSBPLNGCZHCQ-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CC(=C(C=C1)NCC(C#N)(C)C)F)C Chemical compound ClC1=NC=C(C(=N1)C1=CC(=C(C=C1)NCC(C#N)(C)C)F)C JWLSBPLNGCZHCQ-UHFFFAOYSA-N 0.000 description 3
- YEHPBYLVJOLVHE-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CC1)C1=CC=C(C=C1)O Chemical compound ClC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CC1)C1=CC=C(C=C1)O YEHPBYLVJOLVHE-UHFFFAOYSA-N 0.000 description 3
- 208000015943 Coeliac disease Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- YCLHMTLXMJDXIE-UHFFFAOYSA-N FC1=C(C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C(C)C)O Chemical compound FC1=C(C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C(C)C)O YCLHMTLXMJDXIE-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- ZNSPHKJFQDEABI-NZQKXSOJSA-N Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 Chemical compound Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 ZNSPHKJFQDEABI-NZQKXSOJSA-N 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 206010034277 Pemphigoid Diseases 0.000 description 3
- 241000721454 Pemphigus Species 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- TXMRGRLLUIJYBI-UHFFFAOYSA-N [4-(4-aminopyrazol-1-yl)piperidin-1-yl]-(1-methylcyclopropyl)methanone Chemical compound C1CC(N2N=CC(N)=C2)CCN1C(=O)C1(C)CC1 TXMRGRLLUIJYBI-UHFFFAOYSA-N 0.000 description 3
- ZVARZJBRSJKONM-UHFFFAOYSA-N [O-][N+](C1=CN(C(CC2)CCN2C(OCC2=CC=CC=C2)=O)N=C1)=O Chemical compound [O-][N+](C1=CN(C(CC2)CCN2C(OCC2=CC=CC=C2)=O)N=C1)=O ZVARZJBRSJKONM-UHFFFAOYSA-N 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- IQEHWSFDBGYULJ-UHFFFAOYSA-N benzyl 4-(4-aminopyrazol-1-yl)piperidine-1-carboxylate Chemical compound NC1=CN(C(CC2)CCN2C(OCC2=CC=CC=C2)=O)N=C1 IQEHWSFDBGYULJ-UHFFFAOYSA-N 0.000 description 3
- RSDFQNIAFZFPEH-UHFFFAOYSA-N benzyl 4-[4-[[5-chloro-4-[4-[(1-cyanocyclopropyl)methylamino]phenyl]pyrimidin-2-yl]amino]pyrazol-1-yl]piperidine-1-carboxylate Chemical compound N#CC1(CNC(C=C2)=CC=C2C2=NC(NC3=CN(C(CC4)CCN4C(OCC4=CC=CC=C4)=O)N=C3)=NC=C2Cl)CC1 RSDFQNIAFZFPEH-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 229940125876 compound 15a Drugs 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 208000033679 diabetic kidney disease Diseases 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 206010028417 myasthenia gravis Diseases 0.000 description 3
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 208000008795 neuromyelitis optica Diseases 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229940068917 polyethylene glycols Drugs 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- DAAXYQZSKBPJOX-FQEVSTJZSA-N (2S)-2-amino-3-[4-[5-[3-(4-hydroxyphenyl)-4-methoxyphenyl]-1,2,4-oxadiazol-3-yl]phenyl]propanoic acid Chemical compound COC1=C(C=C(C=C1)C2=NC(=NO2)C3=CC=C(C=C3)C[C@@H](C(=O)O)N)C4=CC=C(C=C4)O DAAXYQZSKBPJOX-FQEVSTJZSA-N 0.000 description 2
- HPJGEESDHAUUQR-SKGSPYGFSA-N (2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(2s)-3-naphthalen-2-yl-2-(3-pyridin-3-ylpropanoylamino)propanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]buta Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)CCC=1C=NC=CC=1)CC1=CC=CC=C1 HPJGEESDHAUUQR-SKGSPYGFSA-N 0.000 description 2
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 2
- COIQUVGFTILYGA-UHFFFAOYSA-N (4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C=C1 COIQUVGFTILYGA-UHFFFAOYSA-N 0.000 description 2
- RXNPEQZHMGFNAY-GEALJGNFSA-N (5R)-4-[(1S,6R)-5-[(2S)-2-(4-chlorophenyl)-3-(propan-2-ylamino)propanoyl]-2,5-diazabicyclo[4.1.0]heptan-2-yl]-5-methyl-6,8-dihydro-5H-pyrido[2,3-d]pyrimidin-7-one Chemical compound C[C@@H]1CC(=O)NC2=C1C(=NC=N2)N3CCN([C@H]4[C@@H]3C4)C(=O)[C@H](CNC(C)C)C5=CC=C(C=C5)Cl RXNPEQZHMGFNAY-GEALJGNFSA-N 0.000 description 2
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 2
- 125000005869 (methoxyethoxy)methanyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])* 0.000 description 2
- 125000005867 (methoxymethoxy)ethanyl group Chemical group [H]C([H])([H])OC([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- 125000005868 (methoxymethoxy)methanyl group Chemical group [H]C([H])([H])OC([H])([H])OC([H])([H])* 0.000 description 2
- KWPIMEFDGBTQIL-UHFFFAOYSA-N 1,1,1-trifluoropropan-2-yl methanesulfonate Chemical compound FC(F)(F)C(C)OS(C)(=O)=O KWPIMEFDGBTQIL-UHFFFAOYSA-N 0.000 description 2
- XSXZKGLWPRJOMM-UHFFFAOYSA-N 1-(1-methylpiperidin-4-yl)pyrazol-4-amine Chemical compound C1CN(C)CCC1N1N=CC(N)=C1 XSXZKGLWPRJOMM-UHFFFAOYSA-N 0.000 description 2
- QMCQBAJOOAMKBX-UHFFFAOYSA-N 1-(hydroxymethyl)cyclopropane-1-carbonitrile Chemical compound OCC1(C#N)CC1 QMCQBAJOOAMKBX-UHFFFAOYSA-N 0.000 description 2
- DRDUMOIVYMSLAJ-UHFFFAOYSA-N 1-[(4-bromoanilino)methyl]cyclopropane-1-carbonitrile Chemical compound Brc1ccc(NCC2(CC2)C#N)cc1 DRDUMOIVYMSLAJ-UHFFFAOYSA-N 0.000 description 2
- ZBDUJLPJSXTFSP-UHFFFAOYSA-N 1-[4-(4-aminopyrazol-1-yl)piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1N1N=CC(N)=C1 ZBDUJLPJSXTFSP-UHFFFAOYSA-N 0.000 description 2
- ANXQOKIZDITIHE-UHFFFAOYSA-N 1-[4-(4-nitropyrazol-1-yl)piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1N1N=CC([N+]([O-])=O)=C1 ANXQOKIZDITIHE-UHFFFAOYSA-N 0.000 description 2
- NKIVMWSYPXQCPJ-UHFFFAOYSA-N 1-[[2,6-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]methyl]cyclopropane-1-carbonitrile Chemical compound FC1=C(OCC2(CC2)C#N)C(=CC(=C1)B1OC(C(O1)(C)C)(C)C)F NKIVMWSYPXQCPJ-UHFFFAOYSA-N 0.000 description 2
- WMWAYTGTONRTCA-UHFFFAOYSA-N 1-[[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]methyl]cyclopropane-1-carbonitrile Chemical compound FC1=C(OCC2(CC2)C#N)C=CC(=C1)B1OC(C(O1)(C)C)(C)C WMWAYTGTONRTCA-UHFFFAOYSA-N 0.000 description 2
- VDGUVWOCLJFMBG-UHFFFAOYSA-N 1-[[2-fluoro-N-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)anilino]methyl]cyclopropane-1-carbonitrile Chemical compound FC1=C(C=CC(=C1)B1OC(C(O1)(C)C)(C)C)N(C)CC1(CC1)C#N VDGUVWOCLJFMBG-UHFFFAOYSA-N 0.000 description 2
- GTDXPJJHRWOFDI-UHFFFAOYSA-N 1-methylcyclopropane-1-carbonyl chloride Chemical compound ClC(=O)C1(C)CC1 GTDXPJJHRWOFDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WGABOZPQOOZAOI-UHFFFAOYSA-N 2-[4-[[(3,5-dimethoxy-4-methylbenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]acetic acid Chemical compound COC1=C(C)C(OC)=CC(C(=O)N(CCCC=2C=CC=CC=2)CC=2C=CC(CC(O)=O)=CC=2)=C1 WGABOZPQOOZAOI-UHFFFAOYSA-N 0.000 description 2
- LESCKMSHIQQVMR-UHFFFAOYSA-N 3-(4-bromo-2-fluoroanilino)-2,2-dimethylpropanenitrile Chemical compound BrC1=CC(=C(C=C1)NCC(C#N)(C)C)F LESCKMSHIQQVMR-UHFFFAOYSA-N 0.000 description 2
- ZTTLPUZMPWUSPD-UHFFFAOYSA-N 3-(4-bromo-2-fluoroanilino)-2,2-dimethylpropanoic acid Chemical compound OC(=O)C(C)(C)CNC1=CC=C(Br)C=C1F ZTTLPUZMPWUSPD-UHFFFAOYSA-N 0.000 description 2
- RLPAAMGOHNSZRL-UHFFFAOYSA-N 3-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)anilino]-2,2-dimethylpropanenitrile Chemical compound FC1=C(C=CC(=C1)B1OC(C(O1)(C)C)(C)C)NCC(C#N)(C)C RLPAAMGOHNSZRL-UHFFFAOYSA-N 0.000 description 2
- AHKZVSJPLIMJAD-UHFFFAOYSA-N 3-[4-(2,5-dichloropyrimidin-4-yl)-2-fluoro-N-methylanilino]-2,2-dimethylpropanenitrile Chemical compound ClC1=NC=C(C(=N1)C1=CC(=C(C=C1)N(CC(C#N)(C)C)C)F)Cl AHKZVSJPLIMJAD-UHFFFAOYSA-N 0.000 description 2
- HCLQARMRCPEALF-DNQXCXABSA-N 3-[[(2r)-2-[(1r)-2-[[1-(1-benzothiophen-2-yl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]pyrrolidin-1-yl]methyl]benzonitrile Chemical compound C([C@@H]1[C@H](O)CNC(C)(CC=2SC3=CC=CC=C3C=2)C)CCN1CC1=CC=CC(C#N)=C1 HCLQARMRCPEALF-DNQXCXABSA-N 0.000 description 2
- WWXFHHXOVMQARV-UHFFFAOYSA-N 3-hydroxy-2,2-dimethylpropanenitrile Chemical compound OCC(C)(C)C#N WWXFHHXOVMQARV-UHFFFAOYSA-N 0.000 description 2
- BJRSYIQYWPPBHO-UHFFFAOYSA-N 4-(2,5-dichloropyrimidin-4-yl)phenol Chemical compound ClC1=NC=C(C(=N1)C1=CC=C(C=C1)O)Cl BJRSYIQYWPPBHO-UHFFFAOYSA-N 0.000 description 2
- IASYGOYEKKNAEQ-UHFFFAOYSA-N 4-(2-chloro-5-methylpyrimidin-4-yl)phenol Chemical compound ClC1=NC=C(C(=N1)C1=CC=C(C=C1)O)C IASYGOYEKKNAEQ-UHFFFAOYSA-N 0.000 description 2
- WPLZTPDEYQBXSG-UHFFFAOYSA-N 4-(4-nitropyrazol-1-yl)piperidine hydrochloride Chemical compound Cl.[O-][N+](=O)c1cnn(c1)C1CCNCC1 WPLZTPDEYQBXSG-UHFFFAOYSA-N 0.000 description 2
- HGNONAHZRMPHON-UHFFFAOYSA-N 4-bromo-2-fluoro-n-methylaniline Chemical compound CNC1=CC=C(Br)C=C1F HGNONAHZRMPHON-UHFFFAOYSA-N 0.000 description 2
- XORHNJQEWQGXCN-UHFFFAOYSA-N 4-nitro-1h-pyrazole Chemical compound [O-][N+](=O)C=1C=NNC=1 XORHNJQEWQGXCN-UHFFFAOYSA-N 0.000 description 2
- VEMHNHDZDRKTJR-UHFFFAOYSA-N 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-chromene-3-carbonitrile Chemical compound CC1(OB(OC1(C)C)C=1C=C2C=C(COC2=CC=1)C#N)C VEMHNHDZDRKTJR-UHFFFAOYSA-N 0.000 description 2
- SIAGUJHXCCKDQM-UHFFFAOYSA-N 6-bromo-2h-chromene-3-carbonitrile Chemical compound O1CC(C#N)=CC2=CC(Br)=CC=C21 SIAGUJHXCCKDQM-UHFFFAOYSA-N 0.000 description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000033237 Aicardi-Goutières syndrome Diseases 0.000 description 2
- 206010001766 Alopecia totalis Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- XSDOLPMTOWMPBP-UHFFFAOYSA-N BrC1=CC(=C(C=C1)N(C)CC1(CC1)C#N)F Chemical compound BrC1=CC(=C(C=C1)N(C)CC1(CC1)C#N)F XSDOLPMTOWMPBP-UHFFFAOYSA-N 0.000 description 2
- VTCAOVCXOALIIW-UHFFFAOYSA-N BrC1=CC(=C(C=C1)N(CC(C(=O)OC)(C)C)C)F Chemical compound BrC1=CC(=C(C=C1)N(CC(C(=O)OC)(C)C)C)F VTCAOVCXOALIIW-UHFFFAOYSA-N 0.000 description 2
- KXZHCYHENVVPKA-UHFFFAOYSA-N BrC1=CC(=C(C=C1)NCC(C(=O)N)(C)C)F Chemical compound BrC1=CC(=C(C=C1)NCC(C(=O)N)(C)C)F KXZHCYHENVVPKA-UHFFFAOYSA-N 0.000 description 2
- KDIXRZQCXGQDHU-UHFFFAOYSA-N BrC1=CC(=C(OCC(C#N)(C)C)C=C1)F Chemical compound BrC1=CC(=C(OCC(C#N)(C)C)C=C1)F KDIXRZQCXGQDHU-UHFFFAOYSA-N 0.000 description 2
- VESJACVVATTWRK-UHFFFAOYSA-N BrC1=CC(=C(OCC2(CC2)C#N)C(=C1)F)F Chemical compound BrC1=CC(=C(OCC2(CC2)C#N)C(=C1)F)F VESJACVVATTWRK-UHFFFAOYSA-N 0.000 description 2
- NKNDUWYITASYIX-UHFFFAOYSA-N BrC1=CC(=C(OCC2(CC2)C#N)C=C1)F Chemical compound BrC1=CC(=C(OCC2(CC2)C#N)C=C1)F NKNDUWYITASYIX-UHFFFAOYSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- HZYAKAXJXFOBIX-UHFFFAOYSA-N C1(CC1)C(=O)N1CCC(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(C=C1)O)F)C Chemical compound C1(CC1)C(=O)N1CCC(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(C=C1)O)F)C HZYAKAXJXFOBIX-UHFFFAOYSA-N 0.000 description 2
- AYTDNZBJDMKYJX-UHFFFAOYSA-N C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(C=C1)O)F)C Chemical compound C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC(=C(C=C1)O)F)C AYTDNZBJDMKYJX-UHFFFAOYSA-N 0.000 description 2
- JMQGZBQFKOSRKQ-UHFFFAOYSA-N C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC=C(C=C1)O)C Chemical compound C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C1=CC=C(C=C1)O)C JMQGZBQFKOSRKQ-UHFFFAOYSA-N 0.000 description 2
- KSQGMQCOWXPMNW-UHFFFAOYSA-N C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C=1C=C2C=C(COC2=CC=1)C#N)C Chemical compound C1(CC1)N1N=CC(=C1)NC1=NC=C(C(=N1)C=1C=C2C=C(COC2=CC=1)C#N)C KSQGMQCOWXPMNW-UHFFFAOYSA-N 0.000 description 2
- OYBAEJMLGQLEOP-UHFFFAOYSA-N CC(=O)N1CCC(n2cc(Nc3ncc(C)c(-c4ccc(OCC(C)(C)C#N)c(C)c4)n3)cn2)CC1 Chemical compound CC(=O)N1CCC(n2cc(Nc3ncc(C)c(-c4ccc(OCC(C)(C)C#N)c(C)c4)n3)cn2)CC1 OYBAEJMLGQLEOP-UHFFFAOYSA-N 0.000 description 2
- PLWPLAGZUKXHBW-UHFFFAOYSA-N CC1(CC1)C(=O)N1CCC(CC1)N1N=CC(=C1)[N+](=O)[O-] Chemical compound CC1(CC1)C(=O)N1CCC(CC1)N1N=CC(=C1)[N+](=O)[O-] PLWPLAGZUKXHBW-UHFFFAOYSA-N 0.000 description 2
- OJGLUKXUFGXCEC-UHFFFAOYSA-N CC=1C(=NC(=NC=1)NC=1C=NN(C=1)C)C1=CC=C(C=C1)O Chemical compound CC=1C(=NC(=NC=1)NC=1C=NN(C=1)C)C1=CC=C(C=C1)O OJGLUKXUFGXCEC-UHFFFAOYSA-N 0.000 description 2
- LABDKDPDMJQVAZ-UHFFFAOYSA-N CC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CCN(CC1)C)C1=CC=C(C=C1)O Chemical compound CC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CCN(CC1)C)C1=CC=C(C=C1)O LABDKDPDMJQVAZ-UHFFFAOYSA-N 0.000 description 2
- UGGCYEXWTDBQKC-UHFFFAOYSA-N CC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CCOCC1)C1=CC=C(C=C1)O Chemical compound CC=1C(=NC(=NC=1)NC=1C=NN(C=1)C1CCOCC1)C1=CC=C(C=C1)O UGGCYEXWTDBQKC-UHFFFAOYSA-N 0.000 description 2
- UYKYSWYYYRWROG-UHFFFAOYSA-N COCCn1cc(Nc2ncc(C)c(-c3ccc(OCC4(C#N)CC4)c(C)c3)n2)cn1 Chemical compound COCCn1cc(Nc2ncc(C)c(-c3ccc(OCC4(C#N)CC4)c(C)c3)n2)cn1 UYKYSWYYYRWROG-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- IZTOPEQRCJLUQL-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(C(C)C(C)(C)C)c3)ncc2C)ccc1OCC(C)(C)C#N Chemical compound Cc1cc(-c2nc(Nc3cnn(C(C)C(C)(C)C)c3)ncc2C)ccc1OCC(C)(C)C#N IZTOPEQRCJLUQL-UHFFFAOYSA-N 0.000 description 2
- YNQCNIPCJLNFIU-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(C(C)C(C)(C)C)c3)ncc2C)ccc1OCC1(C#N)CC1 Chemical compound Cc1cc(-c2nc(Nc3cnn(C(C)C(C)(C)C)c3)ncc2C)ccc1OCC1(C#N)CC1 YNQCNIPCJLNFIU-UHFFFAOYSA-N 0.000 description 2
- DOGKERKPIYTYRK-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(C4CC4)c3)ncc2C)ccc1N(C)CC1(C#N)CC1 Chemical compound Cc1cc(-c2nc(Nc3cnn(C4CC4)c3)ncc2C)ccc1N(C)CC1(C#N)CC1 DOGKERKPIYTYRK-UHFFFAOYSA-N 0.000 description 2
- AMZFHRYRJNXEIJ-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(C4CCN(C(=O)C5(C)CC5)CC4)c3)ncc2C)ccc1OCC1(C#N)CC1 Chemical compound Cc1cc(-c2nc(Nc3cnn(C4CCN(C(=O)C5(C)CC5)CC4)c3)ncc2C)ccc1OCC1(C#N)CC1 AMZFHRYRJNXEIJ-UHFFFAOYSA-N 0.000 description 2
- UXZJVNCZUFHUHQ-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(C4CCN(C(=O)C5CC5)CC4)c3)ncc2C)ccc1OCC1(C#N)CC1 Chemical compound Cc1cc(-c2nc(Nc3cnn(C4CCN(C(=O)C5CC5)CC4)c3)ncc2C)ccc1OCC1(C#N)CC1 UXZJVNCZUFHUHQ-UHFFFAOYSA-N 0.000 description 2
- JSAAAYKTFKMROM-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(C4CCN(C)CC4)c3)ncc2C)ccc1OCC(C)(C)C#N Chemical compound Cc1cc(-c2nc(Nc3cnn(C4CCN(C)CC4)c3)ncc2C)ccc1OCC(C)(C)C#N JSAAAYKTFKMROM-UHFFFAOYSA-N 0.000 description 2
- LQTYZAFUMPJUGS-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(C4CCNCC4)c3)ncc2C)ccc1OCC(C)(C)C#N Chemical compound Cc1cc(-c2nc(Nc3cnn(C4CCNCC4)c3)ncc2C)ccc1OCC(C)(C)C#N LQTYZAFUMPJUGS-UHFFFAOYSA-N 0.000 description 2
- MOAOAVQPRNCAEZ-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(CC#N)c3)ncc2C)ccc1OCC(C)(C)C#N Chemical compound Cc1cc(-c2nc(Nc3cnn(CC#N)c3)ncc2C)ccc1OCC(C)(C)C#N MOAOAVQPRNCAEZ-UHFFFAOYSA-N 0.000 description 2
- BYFYDXKHFXXHMX-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(CC#N)c3)ncc2C)ccc1OCC1(C#N)CC1 Chemical compound Cc1cc(-c2nc(Nc3cnn(CC#N)c3)ncc2C)ccc1OCC1(C#N)CC1 BYFYDXKHFXXHMX-UHFFFAOYSA-N 0.000 description 2
- UMEQJWSMKNOICG-UHFFFAOYSA-N Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1cc(C)c(OCC2(C#N)CC2)c(C)c1 Chemical compound Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1cc(C)c(OCC2(C#N)CC2)c(C)c1 UMEQJWSMKNOICG-UHFFFAOYSA-N 0.000 description 2
- ORYDTBMNAVSXIZ-UHFFFAOYSA-N Cc1cnc(Nc2cnn(C3CCNCC3)c2)nc1-c1ccc(NCC2(C#N)CC2)cc1 Chemical compound Cc1cnc(Nc2cnn(C3CCNCC3)c2)nc1-c1ccc(NCC2(C#N)CC2)cc1 ORYDTBMNAVSXIZ-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- BYECFUAXCICUAZ-UHFFFAOYSA-N ClC1=CC=C(C=N1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CC1 Chemical compound ClC1=CC=C(C=N1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CC1 BYECFUAXCICUAZ-UHFFFAOYSA-N 0.000 description 2
- BLPWICDUISOZPE-UHFFFAOYSA-N ClC1=CC=C(C=N1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCOCC1 Chemical compound ClC1=CC=C(C=N1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCOCC1 BLPWICDUISOZPE-UHFFFAOYSA-N 0.000 description 2
- CYDKCXXMMCMELE-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CC(=C(C=C1)O)F)C Chemical compound ClC1=NC=C(C(=N1)C1=CC(=C(C=C1)O)F)C CYDKCXXMMCMELE-UHFFFAOYSA-N 0.000 description 2
- ISXMZZIVLAWORU-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CC(=C(OCC(C#N)(C)C)C=C1)F)Cl Chemical compound ClC1=NC=C(C(=N1)C1=CC(=C(OCC(C#N)(C)C)C=C1)F)Cl ISXMZZIVLAWORU-UHFFFAOYSA-N 0.000 description 2
- RXYXSGKCIJNQDJ-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CC(=C(OCC(C#N)(C)C)C=C1)F)F Chemical compound ClC1=NC=C(C(=N1)C1=CC(=C(OCC(C#N)(C)C)C=C1)F)F RXYXSGKCIJNQDJ-UHFFFAOYSA-N 0.000 description 2
- BUIGFTBNTOLDOP-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CC(=C(OCC2(CC2)C#N)C=C1)F)Cl Chemical compound ClC1=NC=C(C(=N1)C1=CC(=C(OCC2(CC2)C#N)C=C1)F)Cl BUIGFTBNTOLDOP-UHFFFAOYSA-N 0.000 description 2
- FSTPNOYCERUBTN-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CC(=C(OCC2(CC2)C#N)C=C1)F)F Chemical compound ClC1=NC=C(C(=N1)C1=CC(=C(OCC2(CC2)C#N)C=C1)F)F FSTPNOYCERUBTN-UHFFFAOYSA-N 0.000 description 2
- NUQWLDYKCAOPRG-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C=1C=C2C=C(COC2=CC=1)C#N)C Chemical compound ClC1=NC=C(C(=N1)C=1C=C2C=C(COC2=CC=1)C#N)C NUQWLDYKCAOPRG-UHFFFAOYSA-N 0.000 description 2
- HXTJXFGNYUQLJU-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C=1C=NC(=CC=1)Cl)C Chemical compound ClC1=NC=C(C(=N1)C=1C=NC(=CC=1)Cl)C HXTJXFGNYUQLJU-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 208000021866 Dressler syndrome Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- ZGBOIJKFHRDNMC-UHFFFAOYSA-N FC1=C(C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C(C(F)(F)F)C)O Chemical compound FC1=C(C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C(C(F)(F)F)C)O ZGBOIJKFHRDNMC-UHFFFAOYSA-N 0.000 description 2
- UMJPSBBDYGDUSI-UHFFFAOYSA-N FC1=C(C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCN(CC1)C)O Chemical compound FC1=C(C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCN(CC1)C)O UMJPSBBDYGDUSI-UHFFFAOYSA-N 0.000 description 2
- PDVTXYUFMYQROI-UHFFFAOYSA-N FC1=C(C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCOCC1)O Chemical compound FC1=C(C=CC(=C1)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCOCC1)O PDVTXYUFMYQROI-UHFFFAOYSA-N 0.000 description 2
- PJUITTPZQFVHAR-UHFFFAOYSA-N FC1=C(OCC(C#N)(C)C)C=CC(=C1)B1OC(C(O1)(C)C)(C)C Chemical compound FC1=C(OCC(C#N)(C)C)C=CC(=C1)B1OC(C(O1)(C)C)(C)C PJUITTPZQFVHAR-UHFFFAOYSA-N 0.000 description 2
- QVQAOMMALLBERS-UHFFFAOYSA-N FC=1C=C(C=CC=1O)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCN(CC1)C(C)=O Chemical compound FC=1C=C(C=CC=1O)C1=NC(=NC=C1C)NC=1C=NN(C=1)C1CCN(CC1)C(C)=O QVQAOMMALLBERS-UHFFFAOYSA-N 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 description 2
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000012528 Juvenile dermatomyositis Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 2
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- DFVGZKFRAVAOPF-UHFFFAOYSA-N [4-(4-aminopyrazol-1-yl)piperidin-1-yl]-cyclopropylmethanone Chemical compound C1=C(N)C=NN1C1CCN(C(=O)C2CC2)CC1 DFVGZKFRAVAOPF-UHFFFAOYSA-N 0.000 description 2
- GIAJJPSMUVKDFZ-UHFFFAOYSA-N [N+](=O)([O-])C=1C=NN(C=1)C(C(F)(F)F)C Chemical compound [N+](=O)([O-])C=1C=NN(C=1)C(C(F)(F)F)C GIAJJPSMUVKDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- YGRLFZGDEFHWEY-UHFFFAOYSA-N benzyl 4-[4-[[4-(3-fluoro-4-hydroxyphenyl)-5-methylpyrimidin-2-yl]amino]pyrazol-1-yl]piperidine-1-carboxylate Chemical compound CC1=CN=C(NC2=CN(C(CC3)CCN3C(OCC3=CC=CC=C3)=O)N=C2)N=C1C(C=C1)=CC(F)=C1O YGRLFZGDEFHWEY-UHFFFAOYSA-N 0.000 description 2
- XWOTYORDEPGJSQ-UHFFFAOYSA-N benzyl 4-[4-[[4-[4-[(1-cyanocyclopropyl)methylamino]phenyl]-5-methylpyrimidin-2-yl]amino]pyrazol-1-yl]piperidine-1-carboxylate Chemical compound CC1=CN=C(NC2=CN(C(CC3)CCN3C(OCC3=CC=CC=C3)=O)N=C2)N=C1C(C=C1)=CC=C1NCC1(CC1)C#N XWOTYORDEPGJSQ-UHFFFAOYSA-N 0.000 description 2
- AMBWIRHJLQDRCN-UHFFFAOYSA-N benzyl 4-methylsulfonyloxypiperidine-1-carboxylate Chemical compound C1CC(OS(=O)(=O)C)CCN1C(=O)OCC1=CC=CC=C1 AMBWIRHJLQDRCN-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 201000010415 childhood type dermatomyositis Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 229940126212 compound 17a Drugs 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- MAGZRHACJSNECQ-UHFFFAOYSA-N cyclopropyl-[4-(4-nitropyrazol-1-yl)piperidin-1-yl]methanone Chemical compound C1(CC1)C(=O)N1CCC(CC1)N1N=CC(=C1)[N+](=O)[O-] MAGZRHACJSNECQ-UHFFFAOYSA-N 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- UAHIRBRNLQCYBV-UHFFFAOYSA-N methyl 3-(4-bromo-2-fluoroanilino)-2,2-dimethylpropanoate Chemical compound COC(=O)C(C)(C)CNC1=CC=C(Br)C=C1F UAHIRBRNLQCYBV-UHFFFAOYSA-N 0.000 description 2
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- AKXOKDIILNZEGQ-UHFFFAOYSA-N n-(benzotriazol-1-ylmethyl)-4-bromo-2-fluoroaniline Chemical compound FC1=CC(Br)=CC=C1NCN1C2=CC=CC=C2N=N1 AKXOKDIILNZEGQ-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 208000017502 proteosome-associated autoinflammatory syndrome Diseases 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- VJKGIRCOUCEJMQ-UHFFFAOYSA-N (1-cyanocyclobutyl)methyl methanesulfonate Chemical compound CS(=O)(=O)OCC1(C#N)CCC1 VJKGIRCOUCEJMQ-UHFFFAOYSA-N 0.000 description 1
- JNOGVQJEBGEKMG-UHFFFAOYSA-N (1-methoxy-2-methylprop-1-enoxy)-trimethylsilane Chemical compound COC(=C(C)C)O[Si](C)(C)C JNOGVQJEBGEKMG-UHFFFAOYSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- LAJAFFLJAJMYLK-CVOKMOJFSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[[(7s)-4-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5h-benzo[7]annulen-3-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N1([C@H]2CCC3=CC=C(C(=C3CC2)OC)NC=2N=C(C(=CN=2)Cl)N[C@H]2[C@H]([C@@]3([H])C[C@@]2(C=C3)[H])C(N)=O)CCOCC1 LAJAFFLJAJMYLK-CVOKMOJFSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- TWYYFYNJOJGNFP-CUXYNZQBSA-N (2s,4r,5s,6s)-2-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-2-carbamoyl-4-[[(e,4s,6s)-4,6-dimethyloct-2-enoyl]oxymethyl]-5-hydroxy-1,3-dioxane-4,5,6-tricarboxylic acid Chemical compound O1[C@H](C(O)=O)[C@](C(O)=O)(O)[C@](COC(=O)/C=C/[C@@H](C)C[C@@H](C)CC)(C(O)=O)O[C@]1(C(N)=O)CCC(=C)[C@@H](OC(C)=O)[C@H](C)CC1=CC=CC=C1 TWYYFYNJOJGNFP-CUXYNZQBSA-N 0.000 description 1
- DZOGRBQOXFVBEU-UHFFFAOYSA-N (3-cyanocyclobutyl) methanesulfonate Chemical compound CS(=O)(=O)OC1CC(C#N)C1 DZOGRBQOXFVBEU-UHFFFAOYSA-N 0.000 description 1
- OYNDLOJPYURCJG-UHFFFAOYSA-N (3-fluoro-4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C(F)=C1 OYNDLOJPYURCJG-UHFFFAOYSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- WRQNDLDUNQMTCL-UHFFFAOYSA-N (4-ethoxyphenyl)boronic acid Chemical compound CCOC1=CC=C(B(O)O)C=C1 WRQNDLDUNQMTCL-UHFFFAOYSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 description 1
- VICOOSNNZUPVHM-IGPZRPDBSA-M (e,3r,5s)-7-[2-(4-fluorophenyl)-4-(3-phenylpentan-3-yl)phenyl]-3,5-dihydroxyhept-6-enoate Chemical compound C=1C=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=CC=1C(CC)(CC)C1=CC=CC=C1 VICOOSNNZUPVHM-IGPZRPDBSA-M 0.000 description 1
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 1
- DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- GILIYJDBJZWGBG-UHFFFAOYSA-N 1,1,1-trifluoropropan-2-ol Chemical compound CC(O)C(F)(F)F GILIYJDBJZWGBG-UHFFFAOYSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- LURMHCWOXHNATM-UHFFFAOYSA-N 1-(2-methoxyethyl)pyrazol-4-amine Chemical compound COCCN1C=C(N)C=N1 LURMHCWOXHNATM-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
- DIZKLZKLNKQFGB-UHFFFAOYSA-N 1-methylcyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(C)CC1 DIZKLZKLNKQFGB-UHFFFAOYSA-N 0.000 description 1
- OEXNVHXUPNHOPP-UHFFFAOYSA-N 1-propan-2-ylpyrazol-4-amine Chemical compound CC(C)N1C=C(N)C=N1 OEXNVHXUPNHOPP-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- IEFBTHROULVUAH-UHFFFAOYSA-N 2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(Cl)N=C1 IEFBTHROULVUAH-UHFFFAOYSA-N 0.000 description 1
- BVGDEQPXPVCVQT-UHFFFAOYSA-N 2-cyanopropan-2-yl methanesulfonate Chemical compound N#CC(C)(C)OS(C)(=O)=O BVGDEQPXPVCVQT-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- UNSHMXUHOHBLIQ-UHFFFAOYSA-N 3-[4-chloro-3-(2-methylphenoxy)naphthalen-1-yl]-6-(trifluoromethyl)-1H-pyrimidine-2,4-dione Chemical compound ClC1=C(C=C(C2=CC=CC=C12)N1C(NC(=CC1=O)C(F)(F)F)=O)OC1=C(C=CC=C1)C UNSHMXUHOHBLIQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 1
- GZRMNMGWNKSANY-UHFFFAOYSA-N 4-bromo-2-fluoroaniline Chemical compound NC1=CC=C(Br)C=C1F GZRMNMGWNKSANY-UHFFFAOYSA-N 0.000 description 1
- RYVOZMPTISNBDB-UHFFFAOYSA-N 4-bromo-2-fluorophenol Chemical compound OC1=CC=C(Br)C=C1F RYVOZMPTISNBDB-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 1
- RRELDGDKULRRDM-UHFFFAOYSA-N 6-[2-chloro-4-nitro-5-(oxan-4-yloxy)anilino]-3,4-dihydro-1H-quinolin-2-one Chemical compound [O-][N+](=O)c1cc(Cl)c(Nc2ccc3NC(=O)CCc3c2)cc1OC1CCOCC1 RRELDGDKULRRDM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010071577 Autoimmune hyperlipidaemia Diseases 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- FDPOGALFPYRKEJ-UHFFFAOYSA-N B.C.C.C.CO.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(OCC(C)(C)C#N)cc1.[C-]#[N+]C(C)(C)C(=O)OC.[C-]#[N+]C(C)(C)CO.[C-]#[N+]C(C)(C)COS(C)(=O)=O.[NaH] Chemical compound B.C.C.C.CO.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(OCC(C)(C)C#N)cc1.[C-]#[N+]C(C)(C)C(=O)OC.[C-]#[N+]C(C)(C)CO.[C-]#[N+]C(C)(C)COS(C)(=O)=O.[NaH] FDPOGALFPYRKEJ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- GAVFDTHTLRBKJA-UHFFFAOYSA-N C.C.CC(C)C(F)(F)F.CC(O)C(F)(F)F.CC(n1cc(N)cn1)C(F)(F)F.CC(n1cc([N+](=O)[O-])cn1)C(F)(F)F.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C(C)C(F)(F)F)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C(C)C(F)(F)F)c2)nc1-c1ccc(OCC(C)(C)C#N)c(F)c1.O=[N+]([O-])c1cn[nH]c1.[C-]#[N+]C(C)(C)COS(C)(=O)=O.[HH] Chemical compound C.C.CC(C)C(F)(F)F.CC(O)C(F)(F)F.CC(n1cc(N)cn1)C(F)(F)F.CC(n1cc([N+](=O)[O-])cn1)C(F)(F)F.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C(C)C(F)(F)F)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C(C)C(F)(F)F)c2)nc1-c1ccc(OCC(C)(C)C#N)c(F)c1.O=[N+]([O-])c1cn[nH]c1.[C-]#[N+]C(C)(C)COS(C)(=O)=O.[HH] GAVFDTHTLRBKJA-UHFFFAOYSA-N 0.000 description 1
- FFQTUPRKKTXYPU-UHFFFAOYSA-N C.C.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CN(CC(C)(C)C#N)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1F.CN(CC(C)(C)C#N)c1ccc(Br)cc1F.CN(CC(C)(C)C(N)=O)c1ccc(Br)cc1F.Cc1cnc(Cl)nc1-c1ccc(N(C)CC(C)(C)C#N)c(F)c1.Cc1cnc(Cl)nc1Cl.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(N(C)CC(C)(C)C#N)c(F)c1.Nc1cnn(C2CC2)c1 Chemical compound C.C.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CN(CC(C)(C)C#N)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1F.CN(CC(C)(C)C#N)c1ccc(Br)cc1F.CN(CC(C)(C)C(N)=O)c1ccc(Br)cc1F.Cc1cnc(Cl)nc1-c1ccc(N(C)CC(C)(C)C#N)c(F)c1.Cc1cnc(Cl)nc1Cl.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(N(C)CC(C)(C)C#N)c(F)c1.Nc1cnn(C2CC2)c1 FFQTUPRKKTXYPU-UHFFFAOYSA-N 0.000 description 1
- LTYKYMDQCIEBNT-UHFFFAOYSA-N C.C.CC1CCN(C(=O)OCc2ccccc2)CC1.CCC(C)(C)C#N.CS(=O)(=O)Cl.Cc1cnc(Nc2cnn(C3CCN(C(=O)OCc4ccccc4)CC3)c2)nc1-c1ccc(O)c(F)c1.Cl.N.Nc1cnn(C2CCN(C(=O)OCc3ccccc3)CC2)c1.O=C(OCc1ccccc1)N1CCC(O)CC1.O=C(OCc1ccccc1)N1CCC(n2cc([N+](=O)[O-])cn2)CC1.O=[N+]([O-])c1cn[nH]c1.[Fe] Chemical compound C.C.CC1CCN(C(=O)OCc2ccccc2)CC1.CCC(C)(C)C#N.CS(=O)(=O)Cl.Cc1cnc(Nc2cnn(C3CCN(C(=O)OCc4ccccc4)CC3)c2)nc1-c1ccc(O)c(F)c1.Cl.N.Nc1cnn(C2CCN(C(=O)OCc3ccccc3)CC2)c1.O=C(OCc1ccccc1)N1CCC(O)CC1.O=C(OCc1ccccc1)N1CCC(n2cc([N+](=O)[O-])cn2)CC1.O=[N+]([O-])c1cn[nH]c1.[Fe] LTYKYMDQCIEBNT-UHFFFAOYSA-N 0.000 description 1
- WZHDCHRWNDGYAQ-UHFFFAOYSA-N C.CC(=O)N1CCC(n2cc(N)cn2)CC1.CC(=O)N1CCC(n2cc(Nc3ncc(C)c(-c4ccc(O)c(F)c4)n3)cn2)CC1.CC(=O)N1CCC(n2cc(Nc3ncc(C)c(-c4ccc(OCC5(C#N)CC5)c(F)c4)n3)cn2)CC1.CC(=O)N1CCC(n2cc([N+](=O)[O-])cn2)CC1.CC(=O)OC(C)=O.CO.CS(=O)(=O)OCC1(C#N)CC1.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.O=[N+]([O-])c1cnn(C2CCNCC2)c1 Chemical compound C.CC(=O)N1CCC(n2cc(N)cn2)CC1.CC(=O)N1CCC(n2cc(Nc3ncc(C)c(-c4ccc(O)c(F)c4)n3)cn2)CC1.CC(=O)N1CCC(n2cc(Nc3ncc(C)c(-c4ccc(OCC5(C#N)CC5)c(F)c4)n3)cn2)CC1.CC(=O)N1CCC(n2cc([N+](=O)[O-])cn2)CC1.CC(=O)OC(C)=O.CO.CS(=O)(=O)OCC1(C#N)CC1.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.O=[N+]([O-])c1cnn(C2CCNCC2)c1 WZHDCHRWNDGYAQ-UHFFFAOYSA-N 0.000 description 1
- RWQNDTJZZYSAAL-UHFFFAOYSA-N C.CC(C)(C#N)COS(C)(=O)=O.CN1CCC(n2cc(N)cn2)CC1.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCN(C)CC3)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCN(C)CC3)c2)nc1-c1ccc(OCC(C)(C)C#N)c(F)c1 Chemical compound C.CC(C)(C#N)COS(C)(=O)=O.CN1CCC(n2cc(N)cn2)CC1.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCN(C)CC3)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCN(C)CC3)c2)nc1-c1ccc(OCC(C)(C)C#N)c(F)c1 RWQNDTJZZYSAAL-UHFFFAOYSA-N 0.000 description 1
- XZUPMAKITKSZHY-UHFFFAOYSA-N C.CC(C)(C#N)COS(C)(=O)=O.COCCn1cc(N)cn1.COCCn1cc(Nc2ncc(C)c(-c3ccc(O)c(F)c3)n2)cn1.COCCn1cc(Nc2ncc(C)c(-c3ccc(OCC(C)(C)C#N)c(F)c3)n2)cn1.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1 Chemical compound C.CC(C)(C#N)COS(C)(=O)=O.COCCn1cc(N)cn1.COCCn1cc(Nc2ncc(C)c(-c3ccc(O)c(F)c3)n2)cn1.COCCn1cc(Nc2ncc(C)c(-c3ccc(OCC(C)(C)C#N)c(F)c3)n2)cn1.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1 XZUPMAKITKSZHY-UHFFFAOYSA-N 0.000 description 1
- NFXWMAVWFIVUMW-UHFFFAOYSA-N C.CC(C)(C)OC(=O)N1CCC(n2cc([N+](=O)[O-])cn2)CC1.CC1(C(=O)N2CCC(n3cc(N)cn3)CC2)CC1.CC1(C(=O)N2CCC(n3cc([N+](=O)[O-])cn3)CC2)CC1.CC1(C(=O)O)CC1.CO.CS(=O)(=O)OCC1(C#N)CC1.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCN(C(=O)C4(C)CC4)CC3)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCN(C(=O)C4(C)CC4)CC3)c2)nc1-c1ccc(OCC2(C#N)CC2)c(F)c1.Cl.O=[N+]([O-])c1cnn(C2CCNCC2)c1 Chemical compound C.CC(C)(C)OC(=O)N1CCC(n2cc([N+](=O)[O-])cn2)CC1.CC1(C(=O)N2CCC(n3cc(N)cn3)CC2)CC1.CC1(C(=O)N2CCC(n3cc([N+](=O)[O-])cn3)CC2)CC1.CC1(C(=O)O)CC1.CO.CS(=O)(=O)OCC1(C#N)CC1.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCN(C(=O)C4(C)CC4)CC3)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCN(C(=O)C4(C)CC4)CC3)c2)nc1-c1ccc(OCC2(C#N)CC2)c(F)c1.Cl.O=[N+]([O-])c1cnn(C2CCNCC2)c1 NFXWMAVWFIVUMW-UHFFFAOYSA-N 0.000 description 1
- AJPPHCFTFJPJHB-UHFFFAOYSA-N C.CC1CC(C#N)C1.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(OC2CC(C#N)C2)cc1 Chemical compound C.CC1CC(C#N)C1.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(OC2CC(C#N)C2)cc1 AJPPHCFTFJPJHB-UHFFFAOYSA-N 0.000 description 1
- DDFYVCBTOCYVNY-UHFFFAOYSA-N C.CO.CS(=O)(=O)OCC1(C#N)CC1.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCN(C(=O)C4CC4)CC3)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCN(C(=O)C4CC4)CC3)c2)nc1-c1ccc(OCC2(C#N)CC2)c(F)c1.Nc1cnn(C2CCN(C(=O)C3CC3)CC2)c1.O=C(C1CC1)N1CCC(n2cc([N+](=O)[O-])cn2)CC1.O=C(Cl)C1CC1.O=[N+]([O-])c1cnn(C2CCNCC2)c1 Chemical compound C.CO.CS(=O)(=O)OCC1(C#N)CC1.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCN(C(=O)C4CC4)CC3)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCN(C(=O)C4CC4)CC3)c2)nc1-c1ccc(OCC2(C#N)CC2)c(F)c1.Nc1cnn(C2CCN(C(=O)C3CC3)CC2)c1.O=C(C1CC1)N1CCC(n2cc([N+](=O)[O-])cn2)CC1.O=C(Cl)C1CC1.O=[N+]([O-])c1cnn(C2CCNCC2)c1 DDFYVCBTOCYVNY-UHFFFAOYSA-N 0.000 description 1
- WZBDEYBFWQGYNO-UHFFFAOYSA-N C.CS(=O)(=O)OCC1(C#N)CC1.Cc1cnc(Nc2cnn(C3CCN(C)CC3)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCN(C)CC3)c2)nc1-c1ccc(OCC(C)(C)C#N)c(F)c1 Chemical compound C.CS(=O)(=O)OCC1(C#N)CC1.Cc1cnc(Nc2cnn(C3CCN(C)CC3)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCN(C)CC3)c2)nc1-c1ccc(OCC(C)(C)C#N)c(F)c1 WZBDEYBFWQGYNO-UHFFFAOYSA-N 0.000 description 1
- SUKQVWBZBNAPFJ-UHFFFAOYSA-N C.CS(=O)(=O)OCC1(C#N)CCC1.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(OCC2(C#N)CCC2)cc1 Chemical compound C.CS(=O)(=O)OCC1(C#N)CCC1.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(OCC2(C#N)CCC2)cc1 SUKQVWBZBNAPFJ-UHFFFAOYSA-N 0.000 description 1
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- AVTKFXOEUGZGCB-UHFFFAOYSA-N C=CC#N.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CC1(C)OB(c2ccc3c(c2)C=C(C#N)CO3)OC1(C)C.Cc1cnc(Cl)nc1-c1ccc2c(c1)C=C(C#N)CO2.Cc1cnc(Cl)nc1Cl.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc2c(c1)C=C(C#N)CO2.N#CC1=Cc2cc(Br)ccc2OC1.Nc1cnn(C2CC2)c1.O=Cc1cc(Br)ccc1O Chemical compound C=CC#N.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CC1(C)OB(c2ccc3c(c2)C=C(C#N)CO3)OC1(C)C.Cc1cnc(Cl)nc1-c1ccc2c(c1)C=C(C#N)CO2.Cc1cnc(Cl)nc1Cl.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc2c(c1)C=C(C#N)CO2.N#CC1=Cc2cc(Br)ccc2OC1.Nc1cnn(C2CC2)c1.O=Cc1cc(Br)ccc1O AVTKFXOEUGZGCB-UHFFFAOYSA-N 0.000 description 1
- BKHXSWWHXNRDFJ-UHFFFAOYSA-M C=CC#N.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C)c2)nc1-c1ccc(OCCC#N)c(F)c1.Cn1cc(N)cn1.O=COO[Na].[NaH] Chemical compound C=CC#N.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C)c2)nc1-c1ccc(OCCC#N)c(F)c1.Cn1cc(N)cn1.O=COO[Na].[NaH] BKHXSWWHXNRDFJ-UHFFFAOYSA-M 0.000 description 1
- PXAXUCLHRQYNRT-UHFFFAOYSA-M C=CC#N.Cc1cnc(Nc2cnn(C)c2)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C)c2)nc1-c1ccc(OCCC#N)cc1.O=COO[K].[KH] Chemical compound C=CC#N.Cc1cnc(Nc2cnn(C)c2)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C)c2)nc1-c1ccc(OCCC#N)cc1.O=COO[K].[KH] PXAXUCLHRQYNRT-UHFFFAOYSA-M 0.000 description 1
- VHVDDOGQGZUHHZ-UHFFFAOYSA-N CC(=O)N1CCC(n2cc(Nc3ncc(C)c(-c4ccc(O)c(F)c4)n3)cn2)CC1.CC(=O)N1CCC(n2cc(Nc3ncc(C)c(-c4ccc(OCC(C)(C)C#N)c(F)c4)n3)cn2)CC1.CC(C)(C#N)COS(C)(=O)=O Chemical compound CC(=O)N1CCC(n2cc(Nc3ncc(C)c(-c4ccc(O)c(F)c4)n3)cn2)CC1.CC(=O)N1CCC(n2cc(Nc3ncc(C)c(-c4ccc(OCC(C)(C)C#N)c(F)c4)n3)cn2)CC1.CC(C)(C#N)COS(C)(=O)=O VHVDDOGQGZUHHZ-UHFFFAOYSA-N 0.000 description 1
- CEAYADJCOXLXKC-UHFFFAOYSA-N CC(C)(C#N)CNc1ccc(B2OC(C)(C)C(C)(C)O2)cc1F.Cc1cnc(Cl)nc1-c1ccc(NCC(C)(C)C#N)c(F)c1.Cc1cnc(Cl)nc1Cl.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(NCC(C)(C)C#N)c(F)c1.Nc1cnn(C2CC2)c1 Chemical compound CC(C)(C#N)CNc1ccc(B2OC(C)(C)C(C)(C)O2)cc1F.Cc1cnc(Cl)nc1-c1ccc(NCC(C)(C)C#N)c(F)c1.Cc1cnc(Cl)nc1Cl.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(NCC(C)(C)C#N)c(F)c1.Nc1cnn(C2CC2)c1 CEAYADJCOXLXKC-UHFFFAOYSA-N 0.000 description 1
- VYMLMBREARRKJL-UHFFFAOYSA-N CC(C)(C#N)CNc1ccc(Br)cc1F.CC(C)(CNc1ccc(Br)cc1F)C(=O)O.CC(C)(CNc1ccc(Br)cc1F)C(N)=O.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.COC(=O)C(C)(C)CNc1ccc(Br)cc1F Chemical compound CC(C)(C#N)CNc1ccc(Br)cc1F.CC(C)(CNc1ccc(Br)cc1F)C(=O)O.CC(C)(CNc1ccc(Br)cc1F)C(N)=O.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.COC(=O)C(C)(C)CNc1ccc(Br)cc1F VYMLMBREARRKJL-UHFFFAOYSA-N 0.000 description 1
- BJXYCAPOEIQENX-UHFFFAOYSA-N CC(C)(C#N)COS(C)(=O)=O.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(OCC(C)(C)C#N)c(F)c1 Chemical compound CC(C)(C#N)COS(C)(=O)=O.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(OCC(C)(C)C#N)c(F)c1 BJXYCAPOEIQENX-UHFFFAOYSA-N 0.000 description 1
- NDNPHBYEZQHZSC-UHFFFAOYSA-N CC(C)(C#N)COc1ccc(-c2nc(Cl)ncc2Cl)cc1F.CC(C)(C#N)COc1ccc(-c2nc(Nc3cnn(C4CCOCC4)c3)ncc2Cl)cc1F.CC(C)(C#N)COc1ccc(B2OC(C)(C)C(C)(C)O2)cc1F.Clc1ncc(Cl)c(Cl)n1.Nc1cnn(C2CCOCC2)c1 Chemical compound CC(C)(C#N)COc1ccc(-c2nc(Cl)ncc2Cl)cc1F.CC(C)(C#N)COc1ccc(-c2nc(Nc3cnn(C4CCOCC4)c3)ncc2Cl)cc1F.CC(C)(C#N)COc1ccc(B2OC(C)(C)C(C)(C)O2)cc1F.Clc1ncc(Cl)c(Cl)n1.Nc1cnn(C2CCOCC2)c1 NDNPHBYEZQHZSC-UHFFFAOYSA-N 0.000 description 1
- ZUOFIHSHQBWOOA-UHFFFAOYSA-N CC(C)(C#N)COc1ccc(-c2nc(Cl)ncc2F)cc1F.CC(C)(C#N)COc1ccc(B2OC(C)(C)C(C)(C)O2)cc1F.CC(C)(C#N)COc1ccc(Br)cc1F.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CCC(C)(C)C#N.Fc1cnc(Cl)nc1Cl.Nc1cnn(C2CCOCC2)c1.Oc1ccc(Br)cc1F Chemical compound CC(C)(C#N)COc1ccc(-c2nc(Cl)ncc2F)cc1F.CC(C)(C#N)COc1ccc(B2OC(C)(C)C(C)(C)O2)cc1F.CC(C)(C#N)COc1ccc(Br)cc1F.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CCC(C)(C)C#N.Fc1cnc(Cl)nc1Cl.Nc1cnn(C2CCOCC2)c1.Oc1ccc(Br)cc1F ZUOFIHSHQBWOOA-UHFFFAOYSA-N 0.000 description 1
- YXYOSOLJKAEGNO-UHFFFAOYSA-N CC(C)(C#N)COc1ccc(-c2nc(Nc3cnn(C4CC4)c3)ncc2Cl)cc1.Nc1cnn(C2CC2)c1.Oc1ccc(-c2nc(Cl)ncc2Cl)cc1.Oc1ccc(-c2nc(Nc3cnn(C4CC4)c3)ncc2Cl)cc1.[C-]#[N+]C(C)(C)COS(C)(=O)=O Chemical compound CC(C)(C#N)COc1ccc(-c2nc(Nc3cnn(C4CC4)c3)ncc2Cl)cc1.Nc1cnn(C2CC2)c1.Oc1ccc(-c2nc(Cl)ncc2Cl)cc1.Oc1ccc(-c2nc(Nc3cnn(C4CC4)c3)ncc2Cl)cc1.[C-]#[N+]C(C)(C)COS(C)(=O)=O YXYOSOLJKAEGNO-UHFFFAOYSA-N 0.000 description 1
- SNHZHBRYEBWVIK-UHFFFAOYSA-N CC(C)(C#N)OS(C)(=O)=O.CN1CCC(n2cc(N)cn2)CC1.Cc1cnc(Cl)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C3CCN(C)CC3)c2)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C3CCN(C)CC3)c2)nc1-c1ccc(OCC(C)(C)C#N)cc1 Chemical compound CC(C)(C#N)OS(C)(=O)=O.CN1CCC(n2cc(N)cn2)CC1.Cc1cnc(Cl)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C3CCN(C)CC3)c2)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C3CCN(C)CC3)c2)nc1-c1ccc(OCC(C)(C)C#N)cc1 SNHZHBRYEBWVIK-UHFFFAOYSA-N 0.000 description 1
- PBQZZTLQKXFPSJ-UHFFFAOYSA-N CC(C)(C)OC(=O)Nc1ccc(Br)cc1F.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CI.CN(C(=O)OC(C)(C)C)c1ccc(Br)cc1F.CN(CC1(C#N)CC1)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1F.CN(CC1(C#N)CC1)c1ccc(Br)cc1F.CNc1ccc(Br)cc1F.CS(=O)(=O)OCC1(C#N)CC1.Cc1cnc(Cl)nc1-c1ccc(N(C)CC2(C#N)CC2)c(F)c1.Cc1cnc(Cl)nc1Cl.Nc1cnn(C2CC2)c1 Chemical compound CC(C)(C)OC(=O)Nc1ccc(Br)cc1F.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CI.CN(C(=O)OC(C)(C)C)c1ccc(Br)cc1F.CN(CC1(C#N)CC1)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1F.CN(CC1(C#N)CC1)c1ccc(Br)cc1F.CNc1ccc(Br)cc1F.CS(=O)(=O)OCC1(C#N)CC1.Cc1cnc(Cl)nc1-c1ccc(N(C)CC2(C#N)CC2)c(F)c1.Cc1cnc(Cl)nc1Cl.Nc1cnn(C2CC2)c1 PBQZZTLQKXFPSJ-UHFFFAOYSA-N 0.000 description 1
- BGVKSVKBRWFAOC-UHFFFAOYSA-N CC(C)C(C)(C)C#N.CC(O)C(C)(C)C#N.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(OC(C)C(C)(C)C#N)cc1 Chemical compound CC(C)C(C)(C)C#N.CC(O)C(C)(C)C#N.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(OC(C)C(C)(C)C#N)cc1 BGVKSVKBRWFAOC-UHFFFAOYSA-N 0.000 description 1
- GMDQLBBPNYWFID-UHFFFAOYSA-M CC.CC(C)(C#N)COS(C)(=O)=O.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Cl)nc1Cl.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(OCC(C)(C)C#N)c(F)c1.Nc1cnn(C2CC2)c1.O=COO[Cs].OB(O)c1ccc(O)c(F)c1.[CsH] Chemical compound CC.CC(C)(C#N)COS(C)(=O)=O.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Cl)nc1Cl.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(OCC(C)(C)C#N)c(F)c1.Nc1cnn(C2CC2)c1.O=COO[Cs].OB(O)c1ccc(O)c(F)c1.[CsH] GMDQLBBPNYWFID-UHFFFAOYSA-M 0.000 description 1
- IAYKTUZQRFWIGH-UHFFFAOYSA-M CC.Cc1cnc(Cl)nc1-c1ccc(O)cc1.Cc1cnc(Cl)nc1Cl.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(O)cc1.Nc1cnn(C2CC2)c1.O=COO[Cs].OB(O)c1ccc(O)cc1.[CsH] Chemical compound CC.Cc1cnc(Cl)nc1-c1ccc(O)cc1.Cc1cnc(Cl)nc1Cl.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(O)cc1.Nc1cnn(C2CC2)c1.O=COO[Cs].OB(O)c1ccc(O)cc1.[CsH] IAYKTUZQRFWIGH-UHFFFAOYSA-M 0.000 description 1
- STPVACKPPALPSW-UHFFFAOYSA-N CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CC1(C)OB(c2cc(F)c(OCC3(C#N)CC3)c(F)c2)OC1(C)C.CCC1(C#N)CC1.Cc1cnc(Cl)nc1-c1cc(F)c(OCC2(C#N)CC2)c(F)c1.Cc1cnc(Cl)nc1Cl.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1cc(F)c(OCC2(C#N)CC2)c(F)c1.N#CC1(COc2c(F)cc(Br)cc2F)CC1.Nc1cnn(C2CC2)c1.Oc1c(F)cc(Br)cc1F Chemical compound CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CC1(C)OB(c2cc(F)c(OCC3(C#N)CC3)c(F)c2)OC1(C)C.CCC1(C#N)CC1.Cc1cnc(Cl)nc1-c1cc(F)c(OCC2(C#N)CC2)c(F)c1.Cc1cnc(Cl)nc1Cl.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1cc(F)c(OCC2(C#N)CC2)c(F)c1.N#CC1(COc2c(F)cc(Br)cc2F)CC1.Nc1cnn(C2CC2)c1.Oc1c(F)cc(Br)cc1F STPVACKPPALPSW-UHFFFAOYSA-N 0.000 description 1
- PNIHTNDQFQWUGQ-UHFFFAOYSA-N CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CC1(C)OB(c2ccc(NCC3(C#N)CC3)cc2)OC1(C)C.Cc1cnc(Cl)nc1-c1ccc(NCC2(C#N)CC2)cc1.Cc1cnc(Cl)nc1Cl.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(NCC2(C#N)CC2)cc1.N#CC1(CNc2ccc(Br)cc2)CC1.Nc1ccc(Br)cc1.Nc1cnn(C2CC2)c1.[C-]#[N+]C1(COS(C)(=O)=O)CC1 Chemical compound CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CC1(C)OB(c2ccc(NCC3(C#N)CC3)cc2)OC1(C)C.Cc1cnc(Cl)nc1-c1ccc(NCC2(C#N)CC2)cc1.Cc1cnc(Cl)nc1Cl.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(NCC2(C#N)CC2)cc1.N#CC1(CNc2ccc(Br)cc2)CC1.Nc1ccc(Br)cc1.Nc1cnn(C2CC2)c1.[C-]#[N+]C1(COS(C)(=O)=O)CC1 PNIHTNDQFQWUGQ-UHFFFAOYSA-N 0.000 description 1
- XQRURSASAVBNSO-UHFFFAOYSA-N CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CC1(C)OB(c2ccc(OCC3(C#N)CC3)c(F)c2)OC1(C)C.CCC1(C#N)CC1.Fc1cnc(Cl)nc1Cl.N#CC1(COc2ccc(-c3nc(Cl)ncc3F)cc2F)CC1.N#CC1(COc2ccc(Br)cc2F)CC1.Nc1cnn(C2CCOCC2)c1.Oc1ccc(Br)cc1F Chemical compound CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CC1(C)OB(c2ccc(OCC3(C#N)CC3)c(F)c2)OC1(C)C.CCC1(C#N)CC1.Fc1cnc(Cl)nc1Cl.N#CC1(COc2ccc(-c3nc(Cl)ncc3F)cc2F)CC1.N#CC1(COc2ccc(Br)cc2F)CC1.Nc1cnn(C2CCOCC2)c1.Oc1ccc(Br)cc1F XQRURSASAVBNSO-UHFFFAOYSA-N 0.000 description 1
- ZHSZVQGWLPFHJC-UHFFFAOYSA-N CC1(C)OB(c2ccc(Cl)nc2)OC1(C)C.Cc1cnc(Cl)nc1-c1ccc(Cl)nc1.Cc1cnc(Cl)nc1Cl.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(Cl)nc1.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(OCC2(C#N)CC2)nc1.N#CC1(CO)CC1.Nc1cnn(C2CC2)c1 Chemical compound CC1(C)OB(c2ccc(Cl)nc2)OC1(C)C.Cc1cnc(Cl)nc1-c1ccc(Cl)nc1.Cc1cnc(Cl)nc1Cl.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(Cl)nc1.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(OCC2(C#N)CC2)nc1.N#CC1(CO)CC1.Nc1cnn(C2CC2)c1 ZHSZVQGWLPFHJC-UHFFFAOYSA-N 0.000 description 1
- YHJUGLAMGKLZES-UHFFFAOYSA-N CC1(C)OB(c2ccc(NCC3(C#N)CC3)cc2)OC1(C)C.Clc1ncc(Cl)c(Cl)n1.N#CC1(CNc2ccc(-c3nc(Cl)ncc3Cl)cc2)CC1.N#CC1(CNc2ccc(-c3nc(Nc4cnn(C5CCN(C(=O)OCc6ccccc6)CC5)c4)ncc3Cl)cc2)CC1.N#CC1(CNc2ccc(-c3nc(Nc4cnn(C5CCNCC5)c4)ncc3Cl)cc2)CC1.Nc1cnn(C2CCN(C(=O)OCc3ccccc3)CC2)c1.[HH] Chemical compound CC1(C)OB(c2ccc(NCC3(C#N)CC3)cc2)OC1(C)C.Clc1ncc(Cl)c(Cl)n1.N#CC1(CNc2ccc(-c3nc(Cl)ncc3Cl)cc2)CC1.N#CC1(CNc2ccc(-c3nc(Nc4cnn(C5CCN(C(=O)OCc6ccccc6)CC5)c4)ncc3Cl)cc2)CC1.N#CC1(CNc2ccc(-c3nc(Nc4cnn(C5CCNCC5)c4)ncc3Cl)cc2)CC1.Nc1cnn(C2CCN(C(=O)OCc3ccccc3)CC2)c1.[HH] YHJUGLAMGKLZES-UHFFFAOYSA-N 0.000 description 1
- WPEFQQHYXGVLLG-UHFFFAOYSA-N CC1(C)OB(c2ccc(OCC3(C#N)CC3)c(F)c2)OC1(C)C.Clc1ncc(Cl)c(Cl)n1.N#CC1(COc2ccc(-c3nc(Cl)ncc3Cl)cc2F)CC1.N#CC1(COc2ccc(-c3nc(Nc4cnn(C5CCOCC5)c4)ncc3Cl)cc2F)CC1.Nc1cnn(C2CCOCC2)c1 Chemical compound CC1(C)OB(c2ccc(OCC3(C#N)CC3)c(F)c2)OC1(C)C.Clc1ncc(Cl)c(Cl)n1.N#CC1(COc2ccc(-c3nc(Cl)ncc3Cl)cc2F)CC1.N#CC1(COc2ccc(-c3nc(Nc4cnn(C5CCOCC5)c4)ncc3Cl)cc2F)CC1.Nc1cnn(C2CCOCC2)c1 WPEFQQHYXGVLLG-UHFFFAOYSA-N 0.000 description 1
- VWSQAUNWEUMEDA-UHFFFAOYSA-M CCC(C)(C)C#N.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(CC#N)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(CC#N)c2)nc1-c1ccc(OCC(C)(C)C#N)c(F)c1.N#CCn1cc(N)cn1.O=COO[K].[KH] Chemical compound CCC(C)(C)C#N.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(CC#N)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(CC#N)c2)nc1-c1ccc(OCC(C)(C)C#N)c(F)c1.N#CCn1cc(N)cn1.O=COO[K].[KH] VWSQAUNWEUMEDA-UHFFFAOYSA-M 0.000 description 1
- QDHWJFPKNQWEPL-UHFFFAOYSA-N CCC(C)(C)C#N.Cc1cnc(Cl)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C)c2)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C)c2)nc1-c1ccc(OCC(C)(C)C#N)cc1.Cn1cc(N)cn1 Chemical compound CCC(C)(C)C#N.Cc1cnc(Cl)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C)c2)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C)c2)nc1-c1ccc(OCC(C)(C)C#N)cc1.Cn1cc(N)cn1 QDHWJFPKNQWEPL-UHFFFAOYSA-N 0.000 description 1
- IWEJQGODLOIABN-UHFFFAOYSA-N CCC(C)(C)C#N.Clc1ncc(Cl)c(Cl)n1.Cn1cc(N)cn1.Cn1cc(Nc2ncc(Cl)c(-c3ccc(O)cc3)n2)cn1.Cn1cc(Nc2ncc(Cl)c(-c3ccc(OCC(C)(C)C#N)cc3)n2)cn1.OB(O)c1ccc(O)cc1.Oc1ccc(-c2nc(Cl)ncc2Cl)cc1 Chemical compound CCC(C)(C)C#N.Clc1ncc(Cl)c(Cl)n1.Cn1cc(N)cn1.Cn1cc(Nc2ncc(Cl)c(-c3ccc(O)cc3)n2)cn1.Cn1cc(Nc2ncc(Cl)c(-c3ccc(OCC(C)(C)C#N)cc3)n2)cn1.OB(O)c1ccc(O)cc1.Oc1ccc(-c2nc(Cl)ncc2Cl)cc1 IWEJQGODLOIABN-UHFFFAOYSA-N 0.000 description 1
- SFEZHUUZTHPNII-UHFFFAOYSA-M CCC1(C#N)CC1.Cc1cnc(Nc2cnn(CC#N)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(CC#N)c2)nc1-c1ccc(OCC2(C#N)CC2)c(F)c1.O=COO[K].[KH] Chemical compound CCC1(C#N)CC1.Cc1cnc(Nc2cnn(CC#N)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(CC#N)c2)nc1-c1ccc(OCC2(C#N)CC2)c(F)c1.O=COO[K].[KH] SFEZHUUZTHPNII-UHFFFAOYSA-M 0.000 description 1
- CRWAFTKYRSVMBV-UHFFFAOYSA-N CCCOc1ccc(-c2nc(Nc3cnn(C)c3)ncc2C)cc1C Chemical compound CCCOc1ccc(-c2nc(Nc3cnn(C)c3)ncc2C)cc1C CRWAFTKYRSVMBV-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- OGXJOFPTKJHBBL-UHFFFAOYSA-N CCOc1ccc(-c2nc(Cl)ncc2C)cc1.CCOc1ccc(-c2nc(Nc3cnn(C)c3)ncc2C)cc1.CCOc1ccc(B(O)O)cc1.Cc1cnc(Cl)nc1Cl.Cn1cc(N)cn1 Chemical compound CCOc1ccc(-c2nc(Cl)ncc2C)cc1.CCOc1ccc(-c2nc(Nc3cnn(C)c3)ncc2C)cc1.CCOc1ccc(B(O)O)cc1.Cc1cnc(Cl)nc1Cl.Cn1cc(N)cn1 OGXJOFPTKJHBBL-UHFFFAOYSA-N 0.000 description 1
- NZTSAHQEAMRBEM-UHFFFAOYSA-N CCOc1ccc(-c2nc(Nc3cnn(C(C)C)c3)ncc2C)cc1C Chemical compound CCOc1ccc(-c2nc(Nc3cnn(C(C)C)c3)ncc2C)cc1C NZTSAHQEAMRBEM-UHFFFAOYSA-N 0.000 description 1
- NEOLLOLMXVXXJU-UHFFFAOYSA-N CCOc1ccc(-c2nc(Nc3cnn(C)c3)ncc2C)cc1C Chemical compound CCOc1ccc(-c2nc(Nc3cnn(C)c3)ncc2C)cc1C NEOLLOLMXVXXJU-UHFFFAOYSA-N 0.000 description 1
- OAVLRTWLPLACPU-UHFFFAOYSA-N CI.COc1ccc(-c2nc(Nc3cnn(C)c3)ncc2C)cc1F.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C)c2)nc1-c1ccc(O)c(F)c1.Cn1cc(N)cn1 Chemical compound CI.COc1ccc(-c2nc(Nc3cnn(C)c3)ncc2C)cc1F.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C)c2)nc1-c1ccc(O)c(F)c1.Cn1cc(N)cn1 OAVLRTWLPLACPU-UHFFFAOYSA-N 0.000 description 1
- BMCOVIFQRCAECA-UHFFFAOYSA-N CN(CC(C)(C)C#N)c1ccc(-c2nc(Cl)ncc2Cl)cc1F.CN(CC(C)(C)C#N)c1ccc(-c2nc(Nc3cnn(C4CC4)c3)ncc2Cl)cc1F.CN(CC(C)(C)C#N)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1F.Clc1ncc(Cl)c(Cl)n1.Nc1cnn(C2CC2)c1 Chemical compound CN(CC(C)(C)C#N)c1ccc(-c2nc(Cl)ncc2Cl)cc1F.CN(CC(C)(C)C#N)c1ccc(-c2nc(Nc3cnn(C4CC4)c3)ncc2Cl)cc1F.CN(CC(C)(C)C#N)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1F.Clc1ncc(Cl)c(Cl)n1.Nc1cnn(C2CC2)c1 BMCOVIFQRCAECA-UHFFFAOYSA-N 0.000 description 1
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 1
- WPCSZDSQPYQNBZ-UHFFFAOYSA-N COCCn1cc(Nc2ncc(C)c(-c3ccc(O)c(F)c3)n2)cn1.COCCn1cc(Nc2ncc(C)c(-c3ccc(OCC4(C#N)CC4)c(F)c3)n2)cn1.CS(=O)(=O)OCC1(C#N)CC1 Chemical compound COCCn1cc(Nc2ncc(C)c(-c3ccc(O)c(F)c3)n2)cn1.COCCn1cc(Nc2ncc(C)c(-c3ccc(OCC4(C#N)CC4)c(F)c3)n2)cn1.CS(=O)(=O)OCC1(C#N)CC1 WPCSZDSQPYQNBZ-UHFFFAOYSA-N 0.000 description 1
- WYCZBKWEQZDFDQ-UHFFFAOYSA-N COc1ccc(-c2nc(Nc3cnn(C)c3)ncc2C)cc1C Chemical compound COc1ccc(-c2nc(Nc3cnn(C)c3)ncc2C)cc1C WYCZBKWEQZDFDQ-UHFFFAOYSA-N 0.000 description 1
- DPCPBKJMIFBVKP-UHFFFAOYSA-N CS(=O)(=O)OCC1(C#N)CC1.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(OCC2(C#N)CC2)c(F)c1.Nc1cnn(C2CCOCC2)c1 Chemical compound CS(=O)(=O)OCC1(C#N)CC1.Cc1cnc(Cl)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(OCC2(C#N)CC2)c(F)c1.Nc1cnn(C2CCOCC2)c1 DPCPBKJMIFBVKP-UHFFFAOYSA-N 0.000 description 1
- WLBDVMQHBZFAPM-UHFFFAOYSA-N CS(=O)(=O)OCC1(C#N)CC1.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(OCC2(C#N)CC2)c(F)c1 Chemical compound CS(=O)(=O)OCC1(C#N)CC1.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(O)c(F)c1.Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(OCC2(C#N)CC2)c(F)c1 WLBDVMQHBZFAPM-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- OOJKTVFZVCFURE-UHFFFAOYSA-N Cc1cc(-c2nc(Nc3cnn(C)c3)ncc2C)ccc1OC(C)C Chemical compound Cc1cc(-c2nc(Nc3cnn(C)c3)ncc2C)ccc1OC(C)C OOJKTVFZVCFURE-UHFFFAOYSA-N 0.000 description 1
- KWUCJFQBUCDXIQ-UHFFFAOYSA-N Cc1cnc(Cl)nc1-c1ccc(Cl)nc1.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(Cl)nc1.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(OCC2(C#N)CC2)nc1.N#CC1(CO)CC1.Nc1cnn(C2CCOCC2)c1 Chemical compound Cc1cnc(Cl)nc1-c1ccc(Cl)nc1.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(Cl)nc1.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(OCC2(C#N)CC2)nc1.N#CC1(CO)CC1.Nc1cnn(C2CCOCC2)c1 KWUCJFQBUCDXIQ-UHFFFAOYSA-N 0.000 description 1
- CSKSKZWOLMPKSS-UHFFFAOYSA-N Cc1cnc(Cl)nc1-c1ccc(NCC2(C#N)CC2)cc1.Cc1cnc(Nc2cnn(C3CCN(C(=O)OCc4ccccc4)CC3)c2)nc1-c1ccc(NCC2(C#N)CC2)cc1.Cc1cnc(Nc2cnn(C3CCN(C)CC3)c2)nc1-c1ccc(NCC2(C#N)CC2)cc1.Nc1cnn(C2CCN(C(=O)OCc3ccccc3)CC2)c1 Chemical compound Cc1cnc(Cl)nc1-c1ccc(NCC2(C#N)CC2)cc1.Cc1cnc(Nc2cnn(C3CCN(C(=O)OCc4ccccc4)CC3)c2)nc1-c1ccc(NCC2(C#N)CC2)cc1.Cc1cnc(Nc2cnn(C3CCN(C)CC3)c2)nc1-c1ccc(NCC2(C#N)CC2)cc1.Nc1cnn(C2CCN(C(=O)OCc3ccccc3)CC2)c1 CSKSKZWOLMPKSS-UHFFFAOYSA-N 0.000 description 1
- MBYLBOBJDDGPOX-UHFFFAOYSA-N Cc1cnc(Cl)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(OCC(C)(C)C#N)cc1.Nc1cnn(C2CCOCC2)c1.[C-]#[N+]C(C)(C)COS(C)(=O)=O Chemical compound Cc1cnc(Cl)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(O)cc1.Cc1cnc(Nc2cnn(C3CCOCC3)c2)nc1-c1ccc(OCC(C)(C)C#N)cc1.Nc1cnn(C2CCOCC2)c1.[C-]#[N+]C(C)(C)COS(C)(=O)=O MBYLBOBJDDGPOX-UHFFFAOYSA-N 0.000 description 1
- UWWQMLKAHGRHPU-UHFFFAOYSA-N Cc1cnc(Nc2cnn(C3CCN(C(=O)OCc4ccccc4)CC3)c2)nc1-c1ccc(OCC(C)(C)C#N)c(F)c1.Cc1cnc(Nc2cnn(C3CCNCC3)c2)nc1-c1ccc(OCC(C)(C)C#N)c(F)c1.[HH] Chemical compound Cc1cnc(Nc2cnn(C3CCN(C(=O)OCc4ccccc4)CC3)c2)nc1-c1ccc(OCC(C)(C)C#N)c(F)c1.Cc1cnc(Nc2cnn(C3CCNCC3)c2)nc1-c1ccc(OCC(C)(C)C#N)c(F)c1.[HH] UWWQMLKAHGRHPU-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HCMCXNXEZPWQHZ-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CC(=C(C=C1)N(CC(C#N)(C)C)C)F)C Chemical compound ClC1=NC=C(C(=N1)C1=CC(=C(C=C1)N(CC(C#N)(C)C)C)F)C HCMCXNXEZPWQHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011258 Coxsackie myocarditis Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000003084 Graves Ophthalmopathy Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019263 Heart block congenital Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 206010019939 Herpes gestationis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 208000021330 IgG4-related disease Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000031781 Immunoglobulin G4 related sclerosing disease Diseases 0.000 description 1
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 102000008986 Janus Human genes 0.000 description 1
- 108050000950 Janus Proteins 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- 208000012309 Linear IgA disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 208000024599 Mooren ulcer Diseases 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010073137 Myxoid liposarcoma Diseases 0.000 description 1
- VFWFBPADRVIITP-UHFFFAOYSA-N N#CC1(COc2ccc(-c3nc(Cl)ncc3Cl)cc2F)CC1.N#CC1(COc2ccc(-c3nc(Nc4cnn(C5CC5)c4)ncc3Cl)cc2F)CC1.Nc1cnn(C2CC2)c1 Chemical compound N#CC1(COc2ccc(-c3nc(Cl)ncc3Cl)cc2F)CC1.N#CC1(COc2ccc(-c3nc(Nc4cnn(C5CC5)c4)ncc3Cl)cc2F)CC1.Nc1cnn(C2CC2)c1 VFWFBPADRVIITP-UHFFFAOYSA-N 0.000 description 1
- YHRZOXCDWCLVHW-UHFFFAOYSA-M N#CC1(COc2ccc(-c3nc(Cl)ncc3F)cc2F)CC1.N#CC1(COc2ccc(-c3nc(Nc4cnn(C5CC5)c4)ncc3F)cc2F)CC1.Nc1cnn(C2CC2)c1.O=COO[Cs].[CsH] Chemical compound N#CC1(COc2ccc(-c3nc(Cl)ncc3F)cc2F)CC1.N#CC1(COc2ccc(-c3nc(Nc4cnn(C5CC5)c4)ncc3F)cc2F)CC1.Nc1cnn(C2CC2)c1.O=COO[Cs].[CsH] YHRZOXCDWCLVHW-UHFFFAOYSA-M 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010071579 Neuronal neuropathy Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 208000004788 Pars Planitis Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- 208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 208000004347 Postpericardiotomy Syndrome Diseases 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 206010073139 Round cell liposarcoma Diseases 0.000 description 1
- 208000027066 STING-associated vasculopathy with onset in infancy Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010042276 Subacute endocarditis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000002286 Susac Syndrome Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 208000004732 Systemic Vasculitis Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010071574 Testicular autoimmunity Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 108700036309 Type I Plasminogen Deficiency Proteins 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 1
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- NPUXORBZRBIOMQ-RUZDIDTESA-N [(2R)-1-[[4-[[3-(benzenesulfonylmethyl)-5-methylphenoxy]methyl]phenyl]methyl]-2-pyrrolidinyl]methanol Chemical compound C=1C(OCC=2C=CC(CN3[C@H](CCC3)CO)=CC=2)=CC(C)=CC=1CS(=O)(=O)C1=CC=CC=C1 NPUXORBZRBIOMQ-RUZDIDTESA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 208000027625 autoimmune inner ear disease Diseases 0.000 description 1
- 208000006424 autoimmune oophoritis Diseases 0.000 description 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
- 206010071578 autoimmune retinopathy Diseases 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 208000029407 autoimmune urticaria Diseases 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 206010003882 axonal neuropathy Diseases 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000005875 benzo[b][1,4]dioxepinyl group Chemical group 0.000 description 1
- 125000005876 benzo[b][1,4]oxazinyl group Chemical group 0.000 description 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- JKIUUDJOCYHIGY-UHFFFAOYSA-N benzyl 4-hydroxypiperidine-1-carboxylate Chemical compound C1CC(O)CCN1C(=O)OCC1=CC=CC=C1 JKIUUDJOCYHIGY-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- AJRQIXBBIDPNGK-BVSLBCMMSA-N benzyl n-[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](C[C@H]1C(NCC1)=O)C(=O)C=1SC2=CC=CC=C2N=1)C(=O)OCC1=CC=CC=C1 AJRQIXBBIDPNGK-BVSLBCMMSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 201000010882 cellular myxoid liposarcoma Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000009614 chemical analysis method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 201000004395 congenital heart block Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 208000019479 dysautonomia Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 150000002170 ethers Chemical group 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 208000002980 facial hemiatrophy Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000018090 giant cell myocarditis Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 208000024312 invasive carcinoma Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 206010071570 ligneous conjunctivitis Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000005866 methoxyethanyl group Chemical group 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- SKEAGJWUKCNICJ-LSDHHAIUSA-N n-[(4-fluoro-3-methoxyphenyl)methyl]-6-[2-[[(2s,5r)-5-(hydroxymethyl)-1,4-dioxan-2-yl]methyl]tetrazol-5-yl]-2-methylpyrimidine-4-carboxamide Chemical compound C1=C(F)C(OC)=CC(CNC(=O)C=2N=C(C)N=C(C=2)C2=NN(C[C@@H]3OC[C@@H](CO)OC3)N=N2)=C1 SKEAGJWUKCNICJ-LSDHHAIUSA-N 0.000 description 1
- MUJNAWXXOJRNGK-UHFFFAOYSA-N n-[3-(6-methyl-1,2,3,4-tetrahydrocarbazol-9-yl)propyl]cyclohexanamine Chemical compound C1=2CCCCC=2C2=CC(C)=CC=C2N1CCCNC1CCCCC1 MUJNAWXXOJRNGK-UHFFFAOYSA-N 0.000 description 1
- YRCHYHRCBXNYNU-UHFFFAOYSA-N n-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=S)NC(=O)CC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 YRCHYHRCBXNYNU-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- ASOADIZOVZTJSR-UHFFFAOYSA-N opicapone Chemical compound CC1=C(Cl)C(C)=[N+]([O-])C(Cl)=C1C1=NOC(C=2C=C(C(O)=C(O)C=2)[N+]([O-])=O)=N1 ASOADIZOVZTJSR-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 201000005580 palindromic rheumatism Diseases 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000001828 phenalenyl group Chemical group C1(C=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 208000018290 primary dysautonomia Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000009169 relapsing polychondritis Diseases 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JYRWUSXRTGACLY-UHFFFAOYSA-N tert-butyl 4-[[3-(4-methylsulfonylphenyl)-[1,2]oxazolo[4,5-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC=NC2=C1ON=C2C1=CC=C(S(C)(=O)=O)C=C1 JYRWUSXRTGACLY-UHFFFAOYSA-N 0.000 description 1
- FRACPXUHUTXLCX-BELIEFIBSA-N tert-butyl N-{1-[(1S)-1-{[(1R,2S)-1-(benzylcarbamoyl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}-2-cyclopropylethyl]-2-oxopyridin-3-yl}carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CN(C1=O)[C@@H](CC2CC2)C(=O)N[C@@H](C[C@@H]3CCNC3=O)[C@H](C(=O)NCC4=CC=CC=C4)O FRACPXUHUTXLCX-BELIEFIBSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- AHZJKOKFZJYCLG-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+) Chemical compound [Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F AHZJKOKFZJYCLG-UHFFFAOYSA-K 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000003156 vasculitic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Definitions
- the invention generally relates to novel compounds and methods for their therapeutic use. More particularly, the invention relates to a novel class of therapeutics that are safe and effective JAK inhibitors. The invention also relates to pharmaceutical compositions of these compounds and methods of preparation and use thereof against various diseases and disorders.
- Janus kinase is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the Janus kinase—Signal Transduction Activators of Transcription (JAK-STAT) pathway.
- JAK1, JAK2, JAK3 and TYK2 There are four members in the JAK family of enzymes in humans, i.e., JAK1, JAK2, JAK3 and TYK2.
- the family is defined by the presence of two adjacent kinase domains, JH1 and JH2, of which JH1 performs the phosphorylation involved in pathway activation whereas JH2 regulates JH1 function. (Thomas, et al., 2015 British Journal of Cancer 113, 365-371.)
- cytoplasmic tyrosine kinases are associated with membrane cytokine receptors such as common gamma-chain receptors and the glycoprotein 130 (gp130) transmembrane proteins.
- membrane cytokine receptors such as common gamma-chain receptors and the glycoprotein 130 (gp130) transmembrane proteins.
- gp130 glycoprotein 130
- the JAK-STAT signaling pathway plays a major role in many fundamental biological processes, such as apoptosis and inflammation via communication of chemical signals outside of a cell to the cell nucleus, resulting in the activation of genes through transcription.
- a dysfunctional JAK-STAT pathway may lead to a number of diseases, such as cancer and diseases affecting the immune system.
- JAK inhibitors As medication to inhibit the activity of one or more members of the JAK family, thereby interfering with the JAK-STAT signaling pathway.
- Some JAK inhibitors have been shown to have therapeutic benefits in treating cancer or inflammatory diseases such as rheumatoid arthritis.
- JAK inhibitors for the treatment of cancer with low susceptibility to drug resistance remains challenging but necessary for improving the long-term effectiveness of this class of drugs.
- the invention provides novel, selective and potent compounds that are orally and/or topically available and/or suitable for gastrointestinal (GI) tract restricted and/or topical administration. These therapeutic agents are safe and effective JAK inhibitors and may exhibit fewer and/or lesser side effects than currently available drugs.
- GI gastrointestinal
- the invention also provides pharmaceutical compositions of these compounds and methods of their preparation and use.
- JAK inhibitors that were specifically designed to fit in the profiles that are potentially suitable for either (I) oral administrations or (II) GI and/or skin topical uses.
- compounds designed for oral administration they are potent for JAK2 with an array of selectivity against other JAK kinases and with good overall drug profiles.
- the compounds that are potentially suitable for GI restricted or skin topical uses they are designed to show strong pan JAK activities including JAK1 and/or TYK2.
- these compounds are designed to show minimum oral absorption to limit systemic exposure but high exposure at site of action, in particular in the gastric intestine.
- This new class of inhibitors exhibits exceptional potency profiles with JAK2 IC 50 values in the low nanomolar range at Km ATP concentration. Some of these compounds also showed exceptional potency against JAK1 and/or TYK2.
- the invention generally relates to a compound having the structural formula (I):
- L is O or NR 4′ ;
- X is N or CR x , wherein R x is R′, halogen (e.g., Cl, F), CN or OR′;
- Y is N or CR Y , wherein R Y is R′, halogen (e.g., Cl, F), CN or OR′;
- each of Z 1 and Z 2 is independently selected from N and CR′, provided that one of Z 1 and Z 2 is N and the other is CR′;
- R 1 is hydrogen, halogen, CN, C 1 -C 6 (e.g., C 1 -C 3 ) unsubstituted or substituted alkyl or OR′;
- R 2 is a C 1 -C 16 (e.g., C 1 -C 6 , C 7 -C 16 ) aliphatic group optionally comprising one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with one or more of halogen, OR′, NRR′, CN, CONRR′, NRCOR′ and C 1 -C 6 (e.g., C 1 -C 3 ) alkyl, which is in turn optionally substituted with F (e.g., CH 2 F, CHF 2 , or CF 3 ), OR′ or NRR′;
- F e.g., CH 2 F, CHF 2 , or CF 3
- R 3 is R′ or halogen
- each of R 4 and R 4′ when L is NR 4′ , is selected from hydrogen and C 1 -C 16 (e.g., C 1 -C 6 , C 7 -C 16 ) aliphatic groups optionally comprising one or more heteroatoms selected from N, O, S and P, and R 4 and R 4′ together may form a 3- to 7-membered ring, having 0 to 3 heteroatoms selected from O, N and S, and wherein each of R 4 and R 4′ is optionally substituted with CN, CF 3 or OR′; provided that if one of R 4 and R 4′ is hydrogen, the other is not hydrogen; and
- each R and R′ is independently hydrogen or a C 1 -C 12 unsubstituted or substituted alkyl group
- the invention generally relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound disclosed herein, effective to treat or reduce one or more diseases or disorders, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- the invention generally relates to a pharmaceutical composition
- a pharmaceutical composition comprising an amount of a compound having the structural formula (I):
- L is O or NR 4′ ;
- X is N or CR x , wherein R x is R′, halogen (e.g., Cl, F), CN or OR′;
- Y is N or CR Y , wherein R Y is R′, halogen (e.g., Cl, F), CN or OR′;
- each of Z 1 and Z 2 is independently selected from N and CR′, provided that one of Z 1 and Z 2 is N and the other is CR′;
- R 1 is hydrogen, halogen, CN, C 1 -C 6 (e.g., C 1 -C 3 ) unsubstituted or substituted alkyl or OR′;
- R 2 is a C 1 -C 16 (e.g., C 1 -C 6 , C 7 -C 16 ) aliphatic group optionally comprising one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with one or more of halogen, OR′, NRR′, CN, CONRR′, NRCOR′ and C 1 -C 6 (e.g., C 1 -C 3 ) alkyl, which is in turn optionally substituted with F (e.g., CH 2 F, CHF 2 , or CF 3 ), OR′ or NRR′;
- F e.g., CH 2 F, CHF 2 , or CF 3
- R 3 is R′ or halogen
- each of R 4 and R 4′ when L is NR 4′ , is selected from hydrogen and C 1 -C 16 (e.g., C 1 -C 6 , C 7 -C 16 ) aliphatic groups optionally comprising one or more heteroatoms selected from N, O, S and P, and R 4 and R 4′ together may form a 3- to 7-membered ring, having 0 to 3 heteroatoms selected from O, N and S, and wherein each of R 4 and R 4′ is optionally substituted with CN, CF 3 or OR′; provided that if one of R 4 and R 4′ is hydrogen, the other is not hydrogen; and
- each R and R′ is independently hydrogen or a C 1 -C 12 unsubstituted or substituted alkyl group
- a pharmaceutically acceptable form or an isotope derivative thereof effective to treat, or reduce one or more diseases or disorders, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- the invention generally relates to a unit dosage form comprising a pharmaceutical composition disclosed herein.
- the invention generally relates to a method for treating or reducing a disease or disorder.
- the method includes administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula (I):
- L is O or NR 4′ ;
- X is N or CR x , wherein R x is R′, halogen (e.g., Cl, F), CN or OR′;
- Y is N or CR Y , wherein R Y is R′, halogen (e.g., Cl, F), CN or OR′;
- each of Z 1 and Z 2 is independently selected from N and CR′, provided that one of Z 1 and Z 2 is N and the other is CR′;
- R 1 is hydrogen, halogen, CN, C 1 -C 6 (e.g., C 1 -C 3 ) unsubstituted or substituted alkyl or OR′;
- R 2 is a C 1 -C 16 (e.g., C 1 -C 6 , C 7 -C 16 ) aliphatic group optionally comprising one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with one or more of halogen, OR′, NRR′, CN, CONRR′, NRCOR′ and C 1 -C 6 (e.g., C 1 -C 3 ) alkyl, which is in turn optionally substituted with F (e.g., CH 2 F, CHF 2 , or CF 3 ), OR′ or NRR′;
- F e.g., CH 2 F, CHF 2 , or CF 3
- R 3 is R′ or halogen
- each of R 4 and R 4′ when L is NR 4′ , is selected from hydrogen and C 1 -C 16 (e.g., C 1 -C 6 , C 7 -C 16 ) aliphatic groups optionally comprising one or more heteroatoms selected from N, O, S and P, and R 4 and R 4′ together may form a 3- to 7-membered ring, having 0 to 3 heteroatoms selected from O, N and S, and wherein each of R 4 and R 4′ is optionally substituted with CN, CF 3 or OR′; provided that if one of R 4 and R 4′ is hydrogen, the other is not hydrogen; and
- each R and R′ is independently hydrogen or a C 1 -C 12 unsubstituted or substituted alkyl group
- a pharmaceutically acceptable form or an isotope derivative thereof effective to treat, prevent, or reduce one or more of inflammatory diseases, immune-mediated diseases, cancer, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent
- the invention generally relates to a method for treating or reducing a disease or disorder.
- the method includes administering to a subject in need thereof a pharmaceutical composition comprising a compound disclosed herein, wherein the disease or disorder is one or more of inflammatory diseases, immune-mediated diseases and cancer, or a related disease or disorder.
- the invention generally relates to use of a compound disclosed herein, and a pharmaceutically acceptable excipient, carrier, or diluent, in preparation of a medicament for treating a disease or disorder.
- Ranges provided herein are understood to be shorthand for all of the values within the range.
- a range of 1 to 16 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16.
- compositions or methods disclosed herein can be combined with one or more of any of the other compositions and methods provided herein.
- compositions and methods when used to define compositions and methods, is intended to mean that the compositions and methods include the recited elements, but do not exclude other elements.
- “consisting essentially of” refers to administration of the pharmacologically active agents expressly recited and excludes pharmacologically active agents not expressly recited.
- the term consisting essentially of does not exclude pharmacologically inactive or inert agents, e.g., pharmaceutically acceptable excipients, carriers or diluents.
- Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms.
- the present invention contemplates all such compounds, including cis- and trans-isomers, atropisomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention.
- Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
- Isomeric mixtures containing any of a variety of isomer ratios may be utilized in accordance with the present invention. For example, where only two isomers are combined, mixtures containing 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0 isomer ratios are contemplated by the present invention. Those of ordinary skill in the art will readily appreciate that analogous ratios are contemplated for more complex isomer mixtures.
- a particular enantiomer of a compound of the present invention may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers.
- the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic methods well known in the art, and subsequent recovery of the pure enantiomers.
- Solvates and polymorphs of the compounds of the invention are also contemplated herein.
- Solvates of the compounds of the present invention include, for example, hydrates.
- C 1-6 alkyl is intended to encompass, C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-4 , C 3-5 , C 3-4 , C 4-6 , C 4-5 , and C 5-6 alkyl.
- substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., —C( ⁇ O)—O— is equivalent to —O—C( ⁇ O)—.
- Structures of compounds of the invention are limited by principles of chemical bonding known to those skilled in the art. Accordingly, where a group may be substituted by one or more of a number of substituents, such substitutions are selected so as to comply with principles of chemical bonding and to give compounds that are not inherently unstable and/or would be known to one of ordinary skill in the art as likely to be unstable under ambient conditions (e.g., aqueous, neutral, and several known physiological conditions).
- alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to ten carbon atoms (e.g., C 1-10 alkyl).
- a numerical range such as “1 to 10” refers to each integer in the given range; e.g., “1 to 10 carbon atoms” means that the alkyl group can consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated.
- alkyl can be a C 1-6 alkyl group. In some embodiments, alkyl groups have 1 to 10, 1 to 8, 1 to 6, or 1 to 3 carbon atoms.
- Representative saturated straight chain alkyls include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, and -n-hexyl; while saturated branched alkyls include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, 2-methylbutyl, 3-methylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, and the like.
- alkyl is attached to the parent molecule by a single bond.
- an alkyl group is optionally substituted by one or more of substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfona
- a substituted alkyl can be selected from fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 3-fluoropropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, benzyl, and phenethyl.
- alkoxy refers to the group —O-alkyl, including from 1 to 10 carbon atoms (C 1-10 ) of a straight, branched, saturated cyclic configuration and combinations thereof, attached to the parent molecular structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy, cyclopropyloxy, cyclohexyloxy and the like. “Lower alkoxy” refers to alkoxy groups containing one to six carbons. In some embodiments, C 1-3 alkoxy is an alkoxy group that encompasses both straight and branched chain alkyls of from 1 to 3 carbon atoms.
- an alkoxy group can be optionally substituted by one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfonate
- aromatic refers to a radical with 6 to 14 ring atoms (e.g., C 6-14 aromatic or C 6-14 aryl) that has at least one ring having a conjugated pi electron system which is carbocyclic (e.g., phenyl, fluorenyl, and naphthyl).
- the aryl is a C 6-10 aryl group.
- bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals.
- bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in “-yl” by removal of one hydrogen atom from the carbon atom with the free valence are named by adding “-idene” to the name of the corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene.
- a numerical range such as “6 to 14 aryl” refers to each integer in the given range; e.g., “6 to 14 ring atoms” means that the aryl group can consist of 6 ring atoms, 7 ring atoms, etc., up to and including 14 ring atoms.
- the term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups.
- Polycyclic aryl groups include bicycles, tricycles, tetracycles, and the like. In a multi-ring group, only one ring is required to be aromatic, so groups such as indanyl are encompassed by the aryl definition.
- Non-limiting examples of aryl groups include phenyl, phenalenyl, naphthalenyl, tetrahydronaphthyl, phenanthrenyl, anthracenyl, fluorenyl, indolyl, indanyl, and the like.
- an aryl moiety can be optionally substituted by one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfon
- cycloalkyl and “carbocyclyl” each refers to a monocyclic or polycyclic radical that contains only carbon and hydrogen, and can be saturated or partially unsaturated.
- Partially unsaturated cycloalkyl groups can be termed “cycloalkenyl” if the carbocycle contains at least one double bond, or “cycloalkynyl” if the carbocycle contains at least one triple bond.
- Cycloalkyl groups include groups having from 3 to 13 ring atoms (i.e., C 3-13 cycloalkyl).
- a numerical range such as “3 to 10” refers to each integer in the given range; e.g., “3 to 13 carbon atoms” means that the cycloalkyl group can consist of 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, etc., up to and including 13 carbon atoms.
- the term “cycloalkyl” also includes bridged and spiro-fused cyclic structures containing no heteroatoms.
- the term also includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups.
- Polycyclic aryl groups include bicycles, tricycles, tetracycles, and the like.
- cycloalkyl can be a C 3-8 cycloalkyl radical. In some embodiments, “cycloalkyl” can be a C 3-5 cycloalkyl radical.
- Illustrative examples of cycloalkyl groups include, but are not limited to the following moieties: C 3-6 carbocyclyl groups include, without limitation, cyclopropyl (C 3 ), cyclobutyl (C 4 ), cyclopentyl (C 5 ), cyclopentenyl (C 5 ), cyclohexyl (C 6 ), cyclohexenyl (C 6 ), cyclohexadienyl (C 6 ) and the like.
- C 3-7 carbocyclyl groups include norbornyl (C 7 ).
- Examples of C 3-8 carbocyclyl groups include the aforementioned C 3-7 carbocyclyl groups as well as cycloheptyl (C 7 ), cycloheptadienyl (C 7 ), cycloheptatrienyl (C 7 ), cyclooctyl (C 8 ), bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, and the like.
- C 3-13 carbocyclyl groups include the aforementioned C 3-8 carbocyclyl groups as well as octahydro-1H indenyl, decahydronaphthalenyl, spiro[4.5]decanyl and the like.
- a cycloalkyl group can be optionally substituted by one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, s
- cycloalkenyl and cycloalkynyl mirror the above description of “cycloalkyl” wherein the prefix “alk” is replaced with “alken” or “alkyn” respectively, and the parent “alkenyl” or “alkynyl” terms are as described herein.
- a cycloalkenyl group can have 3 to 13 ring atoms, such as 5 to 8 ring atoms.
- a cycloalkynyl group can have 5 to 13 ring atoms.
- halogen refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).
- halide or “halo”, means fluoro, chloro, bromo or iodo.
- haloalkyl haloalkenyl
- fluoroalkyl and fluoroalkoxy include haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine, such as, but not limited to, trifluoromethyl, difluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, and the like.
- halo is fluorine, such as, but not limited to, trifluoromethyl, difluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, and the like.
- alkyl, alkenyl, alkynyl and alkoxy groups are as defined herein and can be optionally further substituted as defined herein.
- heteroatom refers to oxygen (O), nitrogen (N), sulfur (S), and phosphorus (P).
- heteroalkyl refers to an alkyl radical, which have one or more skeletal chain atoms selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof.
- a numerical range can be given, e.g., C 1-4 heteroalkyl, which refers to the chain length in total, which in this example is 4 atoms long.
- a —CH 2 OCH 2 CH 3 radical is referred to as a “C 4 ” heteroalkyl, which includes the heteroatom center in the atom chain length description.
- Connection to the parent molecular structure can be through either a heteroatom or a carbon in the heteroalkyl chain.
- an N-containing heteroalkyl moiety refers to a group in which at least one of the skeletal atoms is a nitrogen atom.
- One or more heteroatom(s) in the heteroalkyl radical can be optionally oxidized.
- One or more nitrogen atoms, if present, can also be optionally quaternized.
- heteroalkyl also includes skeletal chains substituted with one or more nitrogen oxide (—O—) substituents.
- heteroalkyl groups include, without limitation, ethers such as methoxyethanyl (—CH 2 CH 2 OCH 3 ), ethoxymethanyl (—CH 2 OCH 2 CH 3 ), (methoxymethoxy)ethanyl (—CH 2 CH 2 OCH 2 OCH 3 ), (methoxymethoxy) methanyl (—CH 2 OCH 2 OCH 3 ) and (methoxyethoxy)methanyl (—CH 2 OCH 2 CH 2 OCH 3 ) and the like; amines such as (—CH 2 CH 2 NHCH 3 , —CH 2 CH 2 N(CH 3 ) 2 , —CH 2 NHCH 2 CH 3 , —CH 2 N(CH 2 CH 3 )(CH 3 )) and the like.
- ethers such as methoxyethanyl (—CH 2 CH 2 OCH 3 ), ethoxymethanyl (—CH 2 OCH 2 CH 3 ), (methoxymethoxy)ethany
- heteroaryl or, alternatively, “heteroaromatic” refers to a refers to a radical of a 5-18 membered monocyclic or polycyclic (e.g., bicyclic, tricyclic, tetracyclic and the like) aromatic ring system (e.g., having 6, 10 or 14 ⁇ electrons shared in a cyclic array) having ring carbon atoms and 1-6 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous and sulfur (“5-18 membered heteroaryl”).
- Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings.
- a numerical range such as “5 to 18” refers to each integer in the given range; e.g., “5 to 18 ring atoms” means that the heteroaryl group can consist of 5 ring atoms, 6 ring atoms, etc., up to and including 18 ring atoms. In some instances, a heteroaryl can have 5 to 14 ring atoms.
- the heteroaryl has, for example, bivalent radicals derived from univalent heteroaryl radicals whose names end in “-yl” by removal of one hydrogen atom from the atom with the free valence are named by adding “-ene” to the name of the corresponding univalent radical, e.g., a pyridyl group with two points of attachment is a pyridylene.
- an N-containing “heteroaromatic” or “heteroaryl” moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom.
- One or more heteroatom(s) in the heteroaryl radical can be optionally oxidized.
- One or more nitrogen atoms, if present, can also be optionally quaternized.
- Heteroaryl also includes ring systems substituted with one or more nitrogen oxide (—O—) substituents, such as pyridinyl N-oxides. The heteroaryl is attached to the parent molecular structure through any atom of the ring(s).
- Heteroaryl also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment to the parent molecular structure is either on the aryl or on the heteroaryl ring, or wherein the heteroaryl ring, as defined above, is fused with one or more cycloalkyl or heterocycyl groups wherein the point of attachment to the parent molecular structure is on the heteroaryl ring.
- a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur (“5-10 membered heteroaryl”).
- a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur (“5-8 membered heteroaryl”).
- a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur (“5-6 membered heteroaryl”).
- the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, phosphorous, and sulfur.
- the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, phosphorous, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, phosphorous, and sulfur.
- heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, benzo[b][1,4] oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzoxazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzopyranonyl, benzofurazanyl, benzothiazolyl, benzothienyl (benzothiophenyl), benzothieno[3,2-d]pyrimidinyl,
- a heteroaryl moiety can be optionally substituted by one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulf
- administering refers to oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intracranial, inhalation, intraocular, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject.
- a slow-release device e.g., a mini-osmotic pump
- Administration may be by any suitable route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal).
- Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial.
- Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc.
- composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies.
- the compound of the invention can be administered alone or can be co-administered to the patient.
- Co-administration is meant to include simultaneous or sequential administration of the compound individually or in combination (more than one compound or agent).
- the preparations can also be combined, when desired, with other active substances (e.g., to reduce metabolic degradation).
- compositions of the present invention can be delivered transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
- Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient
- Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
- Liquid form preparations include solutions, suspensions, and emulsions, gels, for example, water or water/propylene glycol solutions.
- compositions of the present invention may additionally include components to provide sustained release and/or comfort.
- Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes.
- the compositions of the present invention can also be delivered as microspheres for slow release in the body.
- microspheres can be administered via intradermal injection of drug-containing microspheres, which slowly release subcutaneously (see Rao, 1995 J. Biomater Sci. Polym . Ed.
- the terms “disease,” “condition,” and “disorder” are used interchangeably herein and refer to a state of being or health status of a patient or subject capable of being treated with a compound, pharmaceutical composition, or method provided herein.
- the term “effective amount” of an active agent refers to an amount sufficient to elicit the desired biological response.
- the effective amount of a compound of the invention may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the patient.
- the terms “inhibition,” “inhibit” and “inhibiting” and the like in reference to a biological target (e.g., JAKs) inhibitor interaction refers to negatively affecting (e.g., decreasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the inhibitor.
- inhibition means negatively affecting (e.g. decreasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the inhibitor.
- inhibition refers to reduction of a disease or symptoms of disease.
- inhibition refers to a reduction in the activity of a particular protein target.
- Inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein.
- inhibition refers to a reduction of activity of a target protein resulting from a direct interaction (e.g., an inhibitor binds to the target protein).
- inhibition refers to a reduction of activity of a target protein from an indirect interaction (e.g., an inhibitor binds to a protein that activates the target protein, thereby preventing target protein activation).
- isolated or “purified” refer to a material that is substantially or essentially free from components that normally accompany it in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high-performance liquid chromatography.
- a “pharmaceutically acceptable form” of a disclosed compound includes, but is not limited to, pharmaceutically acceptable salts, esters, hydrates, solvates, isomers, prodrugs, and isotopically labeled derivatives thereof.
- a “pharmaceutically acceptable form” includes, but is not limited to, pharmaceutically acceptable salts, esters, prodrugs and isotopically labeled derivatives thereof.
- a “pharmaceutically acceptable form” includes, but is not limited to, pharmaceutically acceptable isomers and stereoisomers, prodrugs and isotopically labeled derivatives thereof.
- the pharmaceutically acceptable form is a pharmaceutically acceptable salt.
- pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of subjects without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
- Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66:1-19.
- Pharmaceutically acceptable salts of the compounds provided herein include those derived from suitable inorganic and organic acids and bases.
- Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchlorate acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
- inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchlorate acid
- organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
- salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, besylate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate,
- organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, lactic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
- the salts can be prepared in situ during the isolation and purification of the disclosed compounds, or separately, such as by reacting the free base or free acid of a parent compound with a suitable base or acid, respectively.
- Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4 salts.
- Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like.
- compositions include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.
- Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
- the pharmaceutically acceptable base addition salt can be chosen from ammonium, potassium, sodium, calcium, and magnesium salts.
- the pharmaceutically acceptable form is a “solvate” (e.g., a hydrate).
- solvate refers to compounds that further include a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces.
- the solvate can be of a disclosed compound or a pharmaceutically acceptable salt thereof. Where the solvent is water, the solvate is a “hydrate.”
- Pharmaceutically acceptable solvates and hydrates are complexes that, for example, can include 1 to about 100, or 1 to about 10, or 1 to about 2, about 3 or about 4, solvent or water molecules. It will be understood that the term “compound”” as used herein encompasses the compound and solvates of the compound, as well as mixtures thereof.
- the pharmaceutically acceptable form is a prodrug.
- prodrug refers to compounds that are transformed in vivo to yield a disclosed compound or a pharmaceutically acceptable form of the compound.
- a prodrug can be inactive when administered to a subject, but is converted in vivo to an active compound, for example, by hydrolysis (e.g., hydrolysis in blood).
- hydrolysis e.g., hydrolysis in blood
- a prodrug has improved physical and/or delivery properties over the parent compound.
- Prodrugs can increase the bioavailability of the compound when administered to a subject (e.g., by permitting enhanced absorption into the blood following oral administration) or which enhance delivery to a biological compartment of interest (e.g., the brain or lymphatic system) relative to the parent compound.
- exemplary prodrugs include derivatives of a disclosed compound with enhanced aqueous solubility or active transport through the gut membrane, relative to the parent compound.
- the prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam).
- a discussion of prodrugs is provided in Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” A.C.S. Symposium Series , Vol. 14, and in Bioreversible Carriers in Drug Design , ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated in full by reference herein.
- Prodrug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism.
- Prodrugs commonly known in the art include well-known acid derivatives, such as, for example, esters prepared by reaction of the parent acids with a suitable alcohol, amides prepared by reaction of the parent acid compound with an amine, basic groups reacted to form an acylated base derivative, etc.
- acid derivatives such as, for example, esters prepared by reaction of the parent acids with a suitable alcohol, amides prepared by reaction of the parent acid compound with an amine, basic groups reacted to form an acylated base derivative, etc.
- Other prodrug derivatives may be combined with other features disclosed herein to enhance bioavailability.
- Prodrugs include compounds having a carbonate, carbamate, amide or alkyl ester moiety covalently bonded to any of the above substituents disclosed herein.
- Exemplary advantages of a prodrug can include, but are not limited to, its physical properties, such as enhanced water solubility for parenteral administration at physiological pH compared to the parent compound, or it can enhance absorption from the digestive tract, or it can enhance drug stability for long-term storage.
- the term “pharmaceutically acceptable” excipient, carrier, or diluent refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient
- materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide
- wetting agents such as sodium lauryl sulfate, magnesium stearate, and polyethylene oxide-polypropylene oxide copolymer as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- the term “subject” refers to any animal (e.g., a mammal), including, but not limited to humans, non-human primates, rodents, and the like, which is to be the recipient of a particular treatment.
- a subject to which administration is contemplated includes, but is not limited to, humans (e.g., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and/or other non-human animals, for example, non-human mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs), rodents (e.g., rats and/or mice), etc.
- humans e.g., a male or female of any age group, e
- the non-human animal is a mammal.
- the non-human animal may be a male or female at any stage of development
- a non-human animal may be a transgenic animal.
- the terms “subject” and “patient” are used interchangeably herein in reference to a human subject.
- treatment refers to a method of reducing, delaying or ameliorating such a condition before or after it has occurred. Treatment may be directed at one or more effects or symptoms of a disease and/or the underlying pathology.
- the treatment can be any reduction and can be, but is not limited to, the complete ablation of the disease or the symptoms of the disease.
- Treating or treatment thus refers to any indicia of success in the therapy or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being.
- the treatment or amelioration of symptoms can be based on objective or subjective parameters, for example, the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation. As compared with an equivalent untreated control, such reduction or degree of amelioration may be at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, or 100% as measured by any standard technique.
- Treatment methods include administering to a subject a therapeutically effective amount of a compound described herein.
- the administering step may be a single administration or may include a series of administrations.
- the length of the treatment period depends on a variety of factors, such as the severity of the condition, the patient's age, the concentration of the compound, the activity of the compositions used in the treatment, or a combination thereof.
- the effective dosage of an agent used for the treatment may increase or decrease over the course of a particular treatment regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some instances, chronic administration may be required.
- the compositions are administered to the subject in an amount and for a duration sufficient to treat the patient
- the invention is based on an unexpected discovery of novel, selective and potent compounds that are orally and/or topically available and/or suitable for gastrointestinal (GI) tract restricted administration.
- a series of novel JAK inhibitors are disclosed herein that have been designed to be potentially suitable for either (I) oral administrations or (II) GI and/or skin topical uses.
- compounds designed for oral administration they are potent for JAK2 with an array of selectivity against other JAK kinases and with good overall drug profiles.
- the compounds that are potentially suitable for GI restricted or skin topical uses they are designed to show strong pan JAK activities including JAK1 and/or TYK2. In particular, these compounds are designed to show minimum oral absorption to limit systemic exposure but high exposure at site of action, in particular in the gastric intestine.
- JAK2 is a driver of the cancer
- JAK2 selective inhibitors preserve immune function which is not dependent on JAK2 signaling.
- Select compounds of the invention are suitable for oral administrations against cancers. These compounds are designed to show good potency against JAK2 with good oral absorption and good in vivo stability. Additionally, compounds may possess selectivity against other JAK kinases (e.g., JAK1).
- Select compounds of the invention are suitable for treating GI diseases with limited systemic exposure after oral administration. These compounds possess good potency against JAK kinases (e.g., JAK1, TYK2 and JAK2) and through limited absorption demonstrate higher exposure at the site of action.
- JAK kinases e.g., JAK1, TYK2 and JAK2
- Select compounds of the invention are suitable for the topical skin administration. These compounds show good potency against JAK kinases (e.g., JAK1, TYK2 and JAK2) with limited systemic exposure and higher exposure in the dermis/epidermis and thus at the site of action in the skin.
- JAK kinases e.g., JAK1, TYK2 and JAK2
- the invention also provides pharmaceutical compositions of these compounds and methods of preparation and use thereof.
- the JAK inhibitors disclosed herein exhibited exceptional potency profiles while enjoying favorable pharmacokinetic profiles and drug properties that are suitable for target indications.
- the invention generally relates to a compound having the structural formula (I):
- L is O or NR 4′ ;
- X is N or CR x , wherein R x is R′, halogen (e.g., Cl, F), CN or OR′;
- Y is N or CR Y , wherein R Y is R′, halogen (e.g., Cl, F), CN or OR′;
- each of Z 1 and Z 2 is independently selected from N and CR′, provided that one of Z 1 and Z 2 is N and the other is CR′;
- R 1 is hydrogen, halogen, CN, C 1 -C 6 (e.g., C 1 -C 3 ) unsubstituted or substituted alkyl or OR′;
- R 2 is a C 1 -C 16 (e.g., C 1 -C 6 , C 7 -C 16 ) aliphatic group optionally comprising one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with one or more of halogen, OR′, NRR′, CN, CONRR′, NRCOR′ and C 1 -C 6 (e.g., C 1 -C 3 ) alkyl, which is in turn optionally substituted with F (e.g., CH 2 F, CHF 2 , or CF 3 ), OR′ or NRR′;
- F e.g., CH 2 F, CHF 2 , or CF 3
- R 3 is R′ or halogen
- each of R 4 and R 4′ when L is NR 4′ , is selected from hydrogen and C 1 -C 16 (e.g., C 1 -C 6 , C 7 -C 16 ) aliphatic groups optionally comprising one or more heteroatoms selected from N, O, S and P, and R 4 and R 4′ together may form a 3- to 7-membered ring, having 0 to 3 heteroatoms selected from O, N and S, and wherein each of R 4 and R 4′ is optionally substituted with CN, CF 3 or OR′; provided that if one of R 4 and R 4′ is hydrogen, the other is not hydrogen; and
- each R and R′ is independently hydrogen or a C 1 -C 12 unsubstituted or substituted alkyl group
- L is O having the structural formula:
- L is NR 4′ having the structural formula:
- X is CR x , wherein R x is H, halogen, C 1 -C 6 (e.g., C 1 -C 3 ) unsubstituted or substituted alkyl or alkoxy.
- X is CH.
- X is N.
- Y is CR Y , wherein R is H, halogen, C 1 -C 6 (e.g., C 1 -C 3 ) unsubstituted or substituted alkyl or alkoxy.
- Y is CH.
- Y is N.
- Z 1 is CH and Z 2 is N.
- Z 1 is N and Z 2 is CH.
- R 4 comprises a linear, branched or cyclic C 1 -C 12 (e.g., C 1 -C 6 ) unsubstituted or substituted alkyl group.
- R 4 comprises a 3- to 7-membered (e.g., 3-, 4- or 5-membered) ring having 0 to 3 (e.g., 0, 1, 2, 3) heteroatoms selected from O, N and S. In certain embodiments of (I), R 4 comprises a 3- to 7-membered ring having 0 heteroatoms
- R 4 comprises a cyclopropyl ring.
- R 4 comprises a 4-membered ring.
- R 4 comprises a 5-membered ring.
- R 4 is a group that comprises a CN group. In certain embodiments, wherein the CN group is bonded to a carbon atom at 0 position to L
- the CN group is attached to a secondary carbon atom.
- the CN group is attached to a tertiary carbon atom.
- R 4 is a C 3 alkyl group substituted with CN.
- R 4 is a C 4 alkyl group substituted with CN.
- R 4 is a C 5 alkyl group substituted with CN.
- R 4′ is a C 1 -C 3 alkyl (e.g., methyl, ethyl, propyl). In certain embodiments, wherein R 4′ is methyl.
- R 4′ is methyl
- L is O
- X is CR x
- Y is CH
- Z 1 is CH
- Z 2 is N, having the structural formula (II):
- L is NR 4′ , X is CR x , Y is CH, Z 1 is CH and Z 2 is N, having the structural formula (III):
- R 1 is F.
- R 1 is Cl.
- R 1 is a C 1 -C 3 alkyl (e.g., methyl, ethyl, propyl). In certain embodiments, R 1 is methyl.
- R 2 is a C 1 -C 6 (e.g., C 1 -C 3 ) aliphatic group with 0 to 2 (e.g., 0, 1 or 2) carbon atoms replaced by one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with a CN or CF 3 group.
- C 1 -C 6 e.g., C 1 -C 3
- aliphatic group with 0 to 2 (e.g., 0, 1 or 2) carbon atoms replaced by one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with a CN or CF 3 group.
- R 2 is a C 7 -C 16 (e.g., C 7 -C 10 ) aliphatic group with 0 to 3 (e.g., 0, 1, 2 or 3) carbon atoms replaced by one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with a CN or CF 3 group.
- C 7 -C 16 e.g., C 7 -C 10
- aliphatic group with 0 to 3 (e.g., 0, 1, 2 or 3) carbon atoms replaced by one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with a CN or CF 3 group.
- R 2 comprises a C 3 -C 16 (e.g., C 3 -C 10 ) cyclic alkyl with 0 to 8 (e.g., 0, 1, 2, 3, 4, 5, 6, 7 or 8) carbon atoms replaced by one or more heteroatoms selected from N, O, S and P, optionally substituted with a CN or CF 3 group.
- C 3 -C 16 e.g., C 3 -C 10
- 0 to 8 e.g., 0, 1, 2, 3, 4, 5, 6, 7 or 8
- carbon atoms replaced by one or more heteroatoms selected from N, O, S and P, optionally substituted with a CN or CF 3 group.
- the cyclic alkyl is a C 3 -C 6 cyclic alkyl.
- the cyclic alkyl is a C 3 cyclic alkyl.
- R 2 is a group that comprises CN.
- R 2 comprises CH 2 —CN.
- R 2 does not comprise CN.
- R 2 is:
- Z 3 is N, CH or O, wherein when Z 3 is O, R 5 is absent;
- each of m and n is independently 0, 1, 2, 3 or 4; provided that m and n are not both 0 at the same time, and
- R 5 is a C 1 -C 6 (e.g., C 1 -C 3 ) alkyl, CN, halogen or C(O)R 6 , wherein R 6 is a C 1 -C 6 (e.g., C 1 -C 3 ) alkyl; provided that when Z 3 is N, R 5 is not CN or halo.
- each of m and n is 2.
- Z 3 is N.
- Z 3 is O.
- R 5 is a C 1 -C 6 (e.g., C 1 -C 3 ) alkyl. In certain embodiments, R 5 is methyl.
- R 5 is C(O)R 6 and R 6 is a C 1 -C 6 alkyl, provided at least one of m and n is not 0.
- R 2 is a substituted or unsubstituted piperidine.
- R 2 is a substituted or unsubstituted cyclopropyl.
- R 2 is methyl
- R 3 is H.
- R 3 is CH 3 .
- R 3 is F or Cl.
- Table 1 A list of non-limiting examples of the compounds of the invention is provided in Table 1. Certain exemplary data of select compounds are provided in Table 2. Tables 3A and 3B show certain literature compounds and exemplary testing data.
- a compound of the invention is selected from:
- a compound of the invention is selected from:
- isotope derivative compounds having one or more hydrogen atoms e.g., 1, 2, 4, 5, 6, 7, 8, 9, 10, etc.
- isotope derivative compounds of the invention have one hydrogen atom replaced with a deuterium atom.
- the invention generally relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound disclosed herein, effective to treat or reduce one or more diseases or disorders, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent
- the invention generally relates to a pharmaceutical composition
- a pharmaceutical composition comprising an amount of a compound having the structural formula (I):
- L is O or NR 4′ ;
- X is N or CR x , wherein R x is R′, halogen (e.g., Cl, F), CN or OR′;
- Y is N or CR Y , wherein R Y is R′, halogen (e.g., Cl, F), CN or OR′;
- each of Z 1 and Z 2 is independently selected from N and CR′, provided that one of Z 1 and Z 2 is N and the other is CR′;
- R 1 is hydrogen, halogen, CN, C 1 -C 6 (e.g., C 1 -C 3 ) unsubstituted or substituted alkyl or OR′;
- R 2 is a C 1 -C 16 (e.g., C 1 -C 6 , C 7 -C 16 ) aliphatic group optionally comprising one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with one or more of halogen, OR′, NRR′, CN, CONRR′, NRCOR′ and C 1 -C 6 (e.g., C 1 -C 3 ) alkyl, which is in turn optionally substituted with F (e.g., CH 2 F, CHF 2 , or CF 3 ), OR′ or NRR′;
- F e.g., CH 2 F, CHF 2 , or CF 3
- R 3 is R′ or halogen
- each of R 4 and R 4′ when L is NR 4′ , is selected from hydrogen and C 1 -C 16 (e.g., C 1 -C 6 , C 7 -C 16 ) aliphatic groups optionally comprising one or more heteroatoms selected from N, O, S and P, and R 4 and R 4′ together may form a 3- to 7-membered ring, having 0 to 3 heteroatoms selected from O, N and S, and wherein each of R 4 and R 4′ is optionally substituted with CN, CF 3 or OR′; provided that if one of R 4 and R 4′ is hydrogen, the other is not hydrogen; and
- each R and R′ is independently hydrogen or a C 1 -C 12 unsubstituted or substituted alkyl group
- a pharmaceutically acceptable form or an isotope derivative thereof effective to treat, or reduce one or more diseases or disorders, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- L is O
- X is CR x
- Y is CH
- Z 1 is CH and Z 2 is N
- the compound has the structural formula (II):
- L is NR 4′
- X is CR x
- Y is CH
- Z 1 is CH
- Z 2 is N
- the compound has the structural formula (III):
- R 4 comprises a linear, branched or cyclic C 1 -C 12 (e.g., C 1 -C 6 , C 7 -C 12 ) unsubstituted or substituted alkyl group.
- R 4 comprises a 3- to 7-membered (e.g., 3-, 4- or 5-membered) ring having 0 to 3 (e.g., 0, 1, 2, 3) heteroatoms selected from O, N and S. In certain embodiments of the pharmaceutical compositions, R 4 comprises a 3-to 7-membered (e.g., 3-, 4- or 5-membered) ring having 0 heteroatoms.
- the pharmaceutical composition of the invention is suitable for oral administration.
- the pharmaceutical composition of the invention is suitable for topical administration.
- the pharmaceutical composition of the invention is suitable for GI-restricted administration.
- the pharmaceutical composition of the invention is useful to treat or reduce one or more of inflammatory diseases, immune-mediated diseases and cancers, or a related disease or disorder.
- the pharmaceutical composition of the invention is useful for treating or reducing an inflammatory disease, or a related disease or disorder.
- the pharmaceutical composition of the invention is useful for treating or reducing an immune-mediated disease, or a related disease or disorder.
- the pharmaceutical composition of the invention is useful for treating or reducing cancer, or a related disease or disorder.
- the pharmaceutical composition of the invention is useful for treating or reducing a disease or disorder selected from: inflammatory bowel disease, psoriasis, vitiligo, alopecia areata, alopecia totalis, atopic dermatitis, systemic lupus erythematosus, asthma, diabetic nephropathy, chronic myelogenous leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), breast cancer and ovarian cancer.
- a disease or disorder selected from: inflammatory bowel disease, psoriasis, vitiligo, alopecia areata, alopecia totalis, atopic dermatitis, systemic lupus erythematosus, asthma, diabetic nephropathy, chronic myelogenous leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), my
- the invention generally relates to a unit dosage form comprising a pharmaceutical composition disclosed herein.
- the unit dosage form is a solid dosage form, for example, in the forms of capsules, tablets, pills, powders or granules.
- the unit dosage form is a capsule.
- the unit dosage form is a tablet.
- the unit dosage form is a liquid dosage form, for example, in the forms of emulsions, solutions, suspensions, syrups or elixirs.
- the invention generally relates to a method for treating or reducing a disease or disorder.
- the method includes administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula (I):
- L is O or NR 4′ ;
- X is N or CR x , wherein R x is R′, halogen (e.g., Cl, F), CN or OR′;
- Y is N or CR Y , wherein R Y is R′, halogen (e.g., Cl, F), CN or OR′;
- each of Z 1 and Z 2 is independently selected from N and CR′, provided that one of Z 1 and Z 2 is N and the other is CR′;
- R 1 is hydrogen, halogen, CN, C 1 -C 6 (e.g., C 1 -C 3 ) unsubstituted or substituted alkyl or OR′;
- R 2 is a C 1 -C 16 (e.g., C 1 -C 6 , C 7 -C 16 ) aliphatic group optionally comprising one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with one or more of halogen, OR′, NRR′, CN, CONRR′, NRCOR′ and C 1 -C 6 (e.g., C 1 -C 3 ) alkyl, which is in turn optionally substituted with F (e.g., CH 2 F, CHF 2 , or CF 3 ), OR′ or NRR′;
- F e.g., CH 2 F, CHF 2 , or CF 3
- R 3 is R′ or halogen
- each of R 4 and R 4′ when L is NR 4′ , is selected from hydrogen and C 1 -C 16 (e.g., C 1 -C 6 , C 7 -C 16 ) aliphatic groups optionally comprising one or more heteroatoms selected from N, O, S and P, and R 4 and R 4′ together may form a 3- to 7-membered ring, having 0 to 3 heteroatoms selected from O, N and S, and wherein each of R 4 and R 4′ is optionally substituted with CN, CF 3 or OR′; provided that if one of R 4 and R 4′ is hydrogen, the other is not hydrogen; and
- each R and R′ is independently hydrogen or a C 1 -C 12 unsubstituted or substituted alkyl group
- a pharmaceutically acceptable form or an isotope derivative thereof effective to treat, prevent, or reduce one or more of inflammatory diseases, immune-mediated diseases, cancer, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent
- L is O
- X is CR x
- Y is CH
- Z 1 is CH and Z 2 is N
- the compound has the structural formula (II):
- L is NR 4′
- X is CR x
- Y is CH
- Z 1 is CH
- Z 2 is N
- the compound has the structural formula (III):
- R 4 comprises a linear, branched or cyclic C 1 -C 12 (e.g., C 1 -C 6 , C 7 -C 12 ) unsubstituted or substituted alkyl group.
- R 4 comprises a 3- to 7-membered (e.g., 3-, 4- or 5-membered) ring having 0 to 3 (e.g., 0, 1, 2, 3) heteroatoms selected from O, N and S.
- R 4 comprises a 3- to 7-membered (e.g., 3-, 4- or 5-membered) ring having 0 heteroatoms.
- the invention generally relates to a method for treating or reducing a disease or disorder.
- the method includes administering to a subject in need thereof a pharmaceutical composition comprising a compound disclosed herein, wherein the disease or disorder is one or more of inflammatory diseases, immune-mediated diseases and cancer, or a related disease or disorder.
- the disease or disorder is an inflammatory disease.
- the disease or disorder is an immune-mediated disease.
- the disease or disorder is cancer.
- the disease or disorder is selected from: inflammatory bowel disease, psoriasis, vitiligo, atopic dermatitis, systemic lupus erythematosus, asthma, diabetic nephropathy, chronic myelogenous leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), breast cancer and ovarian cancer.
- CML chronic myelogenous leukemia
- ET essential thrombocythemia
- PV polycythemia vera
- MF myelofibrosis
- the administration is via oral administration.
- the administration is via topical administration.
- the administration is via GI-restricted administration.
- the invention generally relates to use of a compound disclosed herein, and a pharmaceutically acceptable excipient, carrier, or diluent, in preparation of a medicament for treating a disease or disorder.
- the disease or disorder is one or more of inflammatory diseases, immune-mediated diseases and cancer.
- the disease or disorder is an autoimmune disease.
- the disease or disorder is an immune-mediated disease.
- the disease or disorder is cancer.
- the medicament is for oral administration.
- the medicament is for topical administration.
- the medicament is for GI restriction administration.
- inflammatory disease refers to a disease or condition characterized by aberrant inflammation, e.g. an increased level of inflammation compared to a control such as a healthy person not suffering from a disease.
- inflammatory diseases include autoimmune diseases, traumatic brain injury, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Sjogren's syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid,
- inflammatory-related diseases, disorders and conditions which may, for example, be caused by inflammatory cytokines, include, arthritis, kidney failure, lupus, asthma, psoriasis, colitis, pancreatitis, allergies, fibrosis, surgical complications (e.g., where inflammatory cytokines prevent healing), anemia, and fibromyalgia.
- diseases and disorders which may be associated with chronic inflammation include Alzheimer's disease, congestive heart failure, stroke, aortic valve stenosis, arteriosclerosis, osteoporosis, Parkinson's disease, infections, inflammatory bowel disease (IBD), allergic contact dermatitis and other eczemas, systemic sclerosis, transplantation and multiple sclerosis.
- IBD inflammatory bowel disease
- autoimmune disease refers to a disease or condition in which a subject's immune system has an aberrant immune response against a substance that does not normally elicit an immune response in a healthy subject.
- autoimmune diseases that may be treated with a compound, pharmaceutical composition, or method described herein include acne vulgaris, acute disseminated encephalomyelitis, acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, Aicardi-Goutines syndrome (AGS), alopecia areata, alopecia totalis, amyloidosis, ankylosing spondylitis, anti-GBM/anti-TBM nephritis, antiphospholipid syndrome, autoimmune angioedema, autoimmune aplastic anemia, autoimmune dysautonomia, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease, autoimmune myocarditis, autoimmune oopho
- Immune-mediated disease refers to chronic inflammatory diseases perpetuated by antibodies and cellular immunity.
- Immune-mediated diseases include, for example, but not limited to, asthma, allergies, arthritis (e.g., rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis), juvenile arthritis, inflammatory bowel diseases (e.g., ulcerative colitis and Crohn's disease), endocrinopathies (e.g., type 1 diabetes and Graves' disease), neurodegenerative diseases (e.g., multiple sclerosis (MS)), autistic spectrum disorder, depression, Alzheimer's disease, Guillain-Barre syndrome, obsessive-compulsive disorder, optic neuritis, retinal degeneration, dry eye syndrome DES, Sjogren's syndrome, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Huntington's Disease, Guillain-Barre syndrome, myasthenia gravis, and chronic idiopathic demyelinating
- Hashimoto's thyroiditis pernicious anemia, Cushing's disease, Addison's disease, chronic active hepatitis, polycystic ovary syndrome (PCOS), celiac disease, pemphigus, transplant rejection (allograft transplant rejection), graft-versus-host disease (GVDH).
- PCOS polycystic ovary syndrome
- celiac disease pernicious anemia
- pemphigus polycystic ovary syndrome
- transplant rejection allograft transplant rejection
- GVDH graft-versus-host disease
- cancer refers to all types of cancer, neoplasm or malignant tumors found in mammals, e.g., humans, including hematological cancers leukemia, and lymphomas, T-ALL, large B-cell lymphoma, solid cancers such as carcinomas and sarcomas.
- Exemplary cancers include blood cancer, brain cancer, glioma, glioblastoma, neuroblastoma, prostate cancer, colorectal cancer, pancreatic cancer, cervical cancer, gastric cancer, ovarian cancer, lung cancer, and cancer of the head.
- Exemplary cancers include cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus, medulloblastoma, colorectal cancer, pancreatic cancer.
- Additional examples include penile, skin—non-melanoma, anal, hepatobiliary, esophagogastric, uterine sarcoma, gastrointestinal stromal tumor, salivary gland, peripheral nervous system, soft tissue sarcoma, bone, renal, myeloproliferative neoplasms, thyroid carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, skin cutaneous melanoma, colon adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, breast invasive carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhab
- the disease or disorder is selected from: inflammatory bowel disease, psoriasis, vitiligo, atopic dermatitis, systemic lupus erythematosus, asthma, diabetic nephropathy, chronic myelogenous leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), breast cancer and ovarian cancer.
- CML chronic myelogenous leukemia
- ET essential thrombocythemia
- PV polycythemia vera
- MF myelofibrosis
- Isotopically-labeled compounds are also within the scope of the present disclosure.
- an “isotopically-labeled compound” refers to a presently disclosed compound including pharmaceutical salts and prodrugs thereof, each as described herein, in which one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes that can be incorporated into compounds presently disclosed include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, and 36 Cl, respectively.
- the compounds may be useful in drug and/or substrate tissue distribution assays.
- Tritiated ( 3 H) and carbon-14 ( 14 C) labeled compounds are particularly preferred for their ease of preparation and detectability.
- substitution with heavier isotopes such as deuterium ( 2 H) can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances.
- Isotopically labeled compounds presently disclosed, including pharmaceutical salts, esters, and prodrugs thereof, can be prepared by any means known in the art.
- Stereoisomers e.g., cis and trans isomers
- optical isomers of a presently disclosed compound e.g., R and S enantiomers
- racemic, diastereomeric and other mixtures of such isomers are within the scope of the present disclosure.
- Compounds of the present invention are, subsequent to their preparation, preferably isolated and purified to obtain a composition containing an amount by weight equal to or greater than 95% (“substantially pure”), which is then used or formulated as described herein. In certain embodiments, the compounds of the present invention are more than 99% pure. Solvates and polymorphs of the compounds of the invention are also contemplated herein. Solvates of the compounds of the present invention include, for example, hydrates.
- Any appropriate route of administration can be employed, for example, parenteral, intravenous, subcutaneous, intramuscular, intraventricular, intracorporeal, intraperitoneal, rectal, or oral administration. Most suitable means of administration for a particular patient will depend on the nature and severity of the disease or condition being treated or the nature of the therapy being used and on the nature of the active compound.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the compounds described herein or derivatives thereof are admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or
- fillers or extenders as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid
- binders as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia
- humectants as for example, glycerol
- disintegrating agents as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate
- solution retarders as for example, paraffin
- absorption accelerators as for example, quaternary
- the dosage forms may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethyleneglycols, and the like.
- Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others known in the art.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers, such as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, and fatty acid esters of sorbitan, or mixtures of these substances, and the like.
- the composition can also include additional agents,
- Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms.
- the present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention.
- Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
- Isomeric mixtures containing any of a variety of isomer ratios may be utilized in accordance with the present invention. For example, where only two isomers are combined, mixtures containing 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0 isomer ratios are contemplated by the present invention. Those of ordinary skill in the art will readily appreciate that analogous ratios are contemplated for more complex isomer mixtures.
- a particular enantiomer of a compound of the present invention may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers.
- the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic methods well known in the art, and subsequent recovery of the pure enantiomers.
- Method 1 Analysis was performed on an Agilent 1260 series HPLC-6120MS. UHPLC Long Gradient Equivalent 5% to 95% acetonitrile (containing 0.02% NH 4 OAc) in water run time of 6.5 minutes with a flow rate of 1.5 mL/min. A XBridge C18 column (5 ⁇ m, 4.6*50 mm; PN 186003113) was used at a temperature of 40° C.
- Method 2 Analysis was performed on an Agilent 1200 series HPLC-6120MS. UHPLC Long Gradient Equivalent 5% to 95% acetonitrile (containing 0.1% trifluoroacetic acid) in water run time of 6.5 minutes with a flow rate of 1.5 mL/min. A XBridge C18 column (5 ⁇ m, 4.6*50 mm; PN 186003113) was used at a temperature of 40° C.
- Method 3 Analysis was performed on an Agilent 1260 series HPLC-6120MS. UHPLC Long Gradient Equivalent 5% to 95% acetonitrile (containing 0.02% NH 4 OAc) in water run time of 6.5 minutes with a flow rate of 2 mL/min. A Diamonsil Plus C18 column (5 ⁇ m, 4.6*30 mm Cat #99436) was used at a temperature of 40° C.
- Compound 22c (crude) was synthesized by utilizing a similar preparative procedure to the second step of Example 10 with compound 22b (440 mg, 1.63 mmol) and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (455 mg, 1.79 mmol) as starting materials. The crude product was used for next step without further purification.
- Example 51 Testing for Biological Activities
- JAK activity was determined in the reaction buffer 50 mM HEPES, 0.01% Brij35, 10 mM MgCl2, 2 mM DTT by a microfluidic assay.
- the phosphorylation of a FAM labeled peptide substrate was monitored in the Caliper EZ Reader II (Perkin Elmer).
- the assay condition for each batch of enzyme was optimized to obtain 10% conversion rate of peptide substrate.
- test compounds were dissolved in DMSO to a stock concentration of 10 mM. 3-fold serially diluted compounds with top concentration of 5 ⁇ M were pre-incubated with JAK1, JAK2, JAK2V617F or TYK2 for 10 min at ambient temperature. The final DMSO concentration of assay mixture was 1%. FAM labeled peptide substrate (final concentration 3 ⁇ M) and ATP (1 mM concentration) were sequentially added to initiate the kinase reaction at 28° C. The reaction was stopped by adding 50 mM EDTA. The reaction time for JAK1, JAK2, JAK2V617F and TYK2 was 120 min, 20 min, 30 min and 10 min, respectively.
- the well in the test plate without enzyme was defined as 100% inhibition.
- the well without compound but with equivalent DMSO was defined as no inhibition.
- the percent inhibition was calculated by the following formula.
- the dose-response (percent inhibition) curve was plotted and IC50 values were determined by GraphPad software.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Provided is a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. Also provided is pharmaceutical composition of these compounds and methods of their preparation and use thereof.
Description
- This application claims the benefit of priority to PCT International application No. PCT/CN2019/081742, filed on Apr. 8, 2019, the entire content of which is incorporated herein by reference for all purposes.
- The invention generally relates to novel compounds and methods for their therapeutic use. More particularly, the invention relates to a novel class of therapeutics that are safe and effective JAK inhibitors. The invention also relates to pharmaceutical compositions of these compounds and methods of preparation and use thereof against various diseases and disorders.
- Janus kinase (JAK) is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the Janus kinase—Signal Transduction Activators of Transcription (JAK-STAT) pathway. There are four members in the JAK family of enzymes in humans, i.e., JAK1, JAK2, JAK3 and TYK2. The family is defined by the presence of two adjacent kinase domains, JH1 and JH2, of which JH1 performs the phosphorylation involved in pathway activation whereas JH2 regulates JH1 function. (Thomas, et al., 2015 British Journal of Cancer 113, 365-371.)
- These cytoplasmic tyrosine kinases are associated with membrane cytokine receptors such as common gamma-chain receptors and the glycoprotein 130 (gp130) transmembrane proteins. (Murray, et al. 2007 Immunol. 178(5):2623-2629.) About 40 cytokine receptors signal through combinations of these four JAKs and their 7 downstream substrates: the STAT family members. (Ghoreschi et al. 2009 Immunol Rev. 228(1):273-287.)
- The JAK-STAT signaling pathway plays a major role in many fundamental biological processes, such as apoptosis and inflammation via communication of chemical signals outside of a cell to the cell nucleus, resulting in the activation of genes through transcription. A dysfunctional JAK-STAT pathway may lead to a number of diseases, such as cancer and diseases affecting the immune system.
- There has been a growing interest in JAK inhibitors as medication to inhibit the activity of one or more members of the JAK family, thereby interfering with the JAK-STAT signaling pathway. Some JAK inhibitors have been shown to have therapeutic benefits in treating cancer or inflammatory diseases such as rheumatoid arthritis. (Kontzias, et al. 2012 Current Opinion in Pharmacology 12 (4): 464-70; Pesu, et al. 2008 Immunological Reviews 223: 132-42; Norman 2014 Expert Opinion on Investigational Drugs 23 (8): 1067-77; Forster, et al. 2017 Bioorganic & Medicinal Chemistry Letters 27 (18): 4229-4237.)
- Development of JAK inhibitors for the treatment of cancer with low susceptibility to drug resistance remains challenging but necessary for improving the long-term effectiveness of this class of drugs. An urgent need exists across broad therapeutic areas for JAK inhibitors with improved potency and minimal side effects that are also less susceptible to or can overcome drug resistance than existing therapeutics.
- The invention provides novel, selective and potent compounds that are orally and/or topically available and/or suitable for gastrointestinal (GI) tract restricted and/or topical administration. These therapeutic agents are safe and effective JAK inhibitors and may exhibit fewer and/or lesser side effects than currently available drugs. The invention also provides pharmaceutical compositions of these compounds and methods of their preparation and use.
- Disclosed herein are a series of novel JAK inhibitors that were specifically designed to fit in the profiles that are potentially suitable for either (I) oral administrations or (II) GI and/or skin topical uses. For compounds designed for oral administration, they are potent for JAK2 with an array of selectivity against other JAK kinases and with good overall drug profiles. For the compounds that are potentially suitable for GI restricted or skin topical uses, they are designed to show strong pan JAK activities including JAK1 and/or TYK2. In particular, these compounds are designed to show minimum oral absorption to limit systemic exposure but high exposure at site of action, in particular in the gastric intestine.
- This new class of inhibitors exhibits exceptional potency profiles with JAK2 IC50 values in the low nanomolar range at Km ATP concentration. Some of these compounds also showed exceptional potency against JAK1 and/or TYK2.
- In one aspect, the invention generally relates to a compound having the structural formula (I):
- wherein
- L is O or NR4′;
- X is N or CRx, wherein Rx is R′, halogen (e.g., Cl, F), CN or OR′;
- Y is N or CRY, wherein RY is R′, halogen (e.g., Cl, F), CN or OR′;
- each of Z1 and Z2 is independently selected from N and CR′, provided that one of Z1 and Z2 is N and the other is CR′;
- R1 is hydrogen, halogen, CN, C1-C6 (e.g., C1-C3) unsubstituted or substituted alkyl or OR′;
- R2 is a C1-C16 (e.g., C1-C6, C7-C16) aliphatic group optionally comprising one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with one or more of halogen, OR′, NRR′, CN, CONRR′, NRCOR′ and C1-C6 (e.g., C1-C3) alkyl, which is in turn optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR′ or NRR′;
- R3 is R′ or halogen;
- each of R4 and R4′, when L is NR4′, is selected from hydrogen and C1-C16 (e.g., C1-C6, C7-C16) aliphatic groups optionally comprising one or more heteroatoms selected from N, O, S and P, and R4 and R4′ together may form a 3- to 7-membered ring, having 0 to 3 heteroatoms selected from O, N and S, and wherein each of R4 and R4′ is optionally substituted with CN, CF3 or OR′; provided that if one of R4 and R4′ is hydrogen, the other is not hydrogen; and
- each R and R′ is independently hydrogen or a C1-C12 unsubstituted or substituted alkyl group,
- or a pharmaceutically acceptable form or an isotope derivative thereof.
- In another aspect, the invention generally relates to a pharmaceutical composition comprising a compound disclosed herein, effective to treat or reduce one or more diseases or disorders, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- In yet another aspect, the invention generally relates to a pharmaceutical composition comprising an amount of a compound having the structural formula (I):
- wherein
- L is O or NR4′;
- X is N or CRx, wherein Rx is R′, halogen (e.g., Cl, F), CN or OR′;
- Y is N or CRY, wherein RY is R′, halogen (e.g., Cl, F), CN or OR′;
- each of Z1 and Z2 is independently selected from N and CR′, provided that one of Z1 and Z2 is N and the other is CR′;
- R1 is hydrogen, halogen, CN, C1-C6 (e.g., C1-C3) unsubstituted or substituted alkyl or OR′;
- R2 is a C1-C16 (e.g., C1-C6, C7-C16) aliphatic group optionally comprising one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with one or more of halogen, OR′, NRR′, CN, CONRR′, NRCOR′ and C1-C6 (e.g., C1-C3) alkyl, which is in turn optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR′ or NRR′;
- R3 is R′ or halogen;
- each of R4 and R4′, when L is NR4′, is selected from hydrogen and C1-C16 (e.g., C1-C6, C7-C16) aliphatic groups optionally comprising one or more heteroatoms selected from N, O, S and P, and R4 and R4′ together may form a 3- to 7-membered ring, having 0 to 3 heteroatoms selected from O, N and S, and wherein each of R4 and R4′ is optionally substituted with CN, CF3 or OR′; provided that if one of R4 and R4′ is hydrogen, the other is not hydrogen; and
- each R and R′ is independently hydrogen or a C1-C12 unsubstituted or substituted alkyl group,
- or a pharmaceutically acceptable form or an isotope derivative thereof, effective to treat, or reduce one or more diseases or disorders, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- In yet another aspect, the invention generally relates to a unit dosage form comprising a pharmaceutical composition disclosed herein.
- In yet another aspect, the invention generally relates to a method for treating or reducing a disease or disorder. The method includes administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula (I):
- wherein
- L is O or NR4′;
- X is N or CRx, wherein Rx is R′, halogen (e.g., Cl, F), CN or OR′;
- Y is N or CRY, wherein RY is R′, halogen (e.g., Cl, F), CN or OR′;
- each of Z1 and Z2 is independently selected from N and CR′, provided that one of Z1 and Z2 is N and the other is CR′;
- R1 is hydrogen, halogen, CN, C1-C6 (e.g., C1-C3) unsubstituted or substituted alkyl or OR′;
- R2 is a C1-C16 (e.g., C1-C6, C7-C16) aliphatic group optionally comprising one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with one or more of halogen, OR′, NRR′, CN, CONRR′, NRCOR′ and C1-C6 (e.g., C1-C3) alkyl, which is in turn optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR′ or NRR′;
- R3 is R′ or halogen;
- each of R4 and R4′, when L is NR4′, is selected from hydrogen and C1-C16 (e.g., C1-C6, C7-C16) aliphatic groups optionally comprising one or more heteroatoms selected from N, O, S and P, and R4 and R4′ together may form a 3- to 7-membered ring, having 0 to 3 heteroatoms selected from O, N and S, and wherein each of R4 and R4′ is optionally substituted with CN, CF3 or OR′; provided that if one of R4 and R4′ is hydrogen, the other is not hydrogen; and
- each R and R′ is independently hydrogen or a C1-C12 unsubstituted or substituted alkyl group,
- or a pharmaceutically acceptable form or an isotope derivative thereof, effective to treat, prevent, or reduce one or more of inflammatory diseases, immune-mediated diseases, cancer, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent
- In yet another aspect, the invention generally relates to a method for treating or reducing a disease or disorder. The method includes administering to a subject in need thereof a pharmaceutical composition comprising a compound disclosed herein, wherein the disease or disorder is one or more of inflammatory diseases, immune-mediated diseases and cancer, or a related disease or disorder.
- In yet another aspect, the invention generally relates to use of a compound disclosed herein, and a pharmaceutically acceptable excipient, carrier, or diluent, in preparation of a medicament for treating a disease or disorder.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. General principles of organic chemistry, as well as specific functional moieties and reactivity, are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 2006.
- The following terms, unless indicated otherwise according to the context wherein the terms are found, are intended to have the following meanings.
- Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 16 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16.
- As used herein, “at least” a specific value is understood to be that value and all values greater than that value.
- Any compositions or methods disclosed herein can be combined with one or more of any of the other compositions and methods provided herein.
- The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.
- The term “comprising”, when used to define compositions and methods, is intended to mean that the compositions and methods include the recited elements, but do not exclude other elements. The term “consisting essentially of”, when used to define compositions and methods, shall mean that the compositions and methods include the recited elements and exclude other elements of any essential significance to the compositions and methods. For example, “consisting essentially of” refers to administration of the pharmacologically active agents expressly recited and excludes pharmacologically active agents not expressly recited. The term consisting essentially of does not exclude pharmacologically inactive or inert agents, e.g., pharmaceutically acceptable excipients, carriers or diluents. The term “consisting of”, when used to define compositions and methods, shall mean excluding trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention.
- Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, atropisomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
- Isomeric mixtures containing any of a variety of isomer ratios may be utilized in accordance with the present invention. For example, where only two isomers are combined, mixtures containing 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0 isomer ratios are contemplated by the present invention. Those of ordinary skill in the art will readily appreciate that analogous ratios are contemplated for more complex isomer mixtures.
- If, for instance, a particular enantiomer of a compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic methods well known in the art, and subsequent recovery of the pure enantiomers.
- Solvates and polymorphs of the compounds of the invention are also contemplated herein. Solvates of the compounds of the present invention include, for example, hydrates.
- Definitions of specific functional groups and chemical terms are described in more detail below. When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example, “C1-6 alkyl” is intended to encompass, C1, C2, C3, C4, C5, C6, C1-6, C1-5, C1-4, C1-3, C1-2, C2-6, C2-5, C2-4, C2-3, C3-4, C3-5, C3-4, C4-6, C4-5, and C5-6 alkyl.
- Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., —C(═O)—O— is equivalent to —O—C(═O)—.
- Structures of compounds of the invention are limited by principles of chemical bonding known to those skilled in the art. Accordingly, where a group may be substituted by one or more of a number of substituents, such substitutions are selected so as to comply with principles of chemical bonding and to give compounds that are not inherently unstable and/or would be known to one of ordinary skill in the art as likely to be unstable under ambient conditions (e.g., aqueous, neutral, and several known physiological conditions).
- As used herein, the term “alkyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to ten carbon atoms (e.g., C1-10 alkyl). Whenever it appears herein, a numerical range such as “1 to 10” refers to each integer in the given range; e.g., “1 to 10 carbon atoms” means that the alkyl group can consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated. In some embodiments, “alkyl” can be a C1-6 alkyl group. In some embodiments, alkyl groups have 1 to 10, 1 to 8, 1 to 6, or 1 to 3 carbon atoms. Representative saturated straight chain alkyls include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, and -n-hexyl; while saturated branched alkyls include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, 2-methylbutyl, 3-methylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, and the like. The alkyl is attached to the parent molecule by a single bond. Unless stated otherwise in the specification, an alkyl group is optionally substituted by one or more of substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfonate, urea, —Si(Ra)3, —ORa, —SRa, —OC(O)—Ra, —N(Ra)2, —C(O)Ra, —C(O)ORa, —OC(O)N(Ra)2, —C(O)N(Ra)2, —N(Ra)C(O)ORa, —N(Ra)C(O)Ra, —N(Ra)C(O)N(Ra)2, —N(Ra)C(NRa)N(Ra)2, —N(Ra)S(O)tN(Ra)2 (where t is 1 or 2), —P(═O)(Ra)(Ra), or —O—P(═O)(ORa)2 where each Ra is independently hydrogen, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, and each of these moieties can be optionally substituted as defined herein. In a non-limiting embodiment, a substituted alkyl can be selected from fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 3-fluoropropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, benzyl, and phenethyl.
- As used herein, the term “alkoxy” refers to the group —O-alkyl, including from 1 to 10 carbon atoms (C1-10) of a straight, branched, saturated cyclic configuration and combinations thereof, attached to the parent molecular structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy, cyclopropyloxy, cyclohexyloxy and the like. “Lower alkoxy” refers to alkoxy groups containing one to six carbons. In some embodiments, C1-3 alkoxy is an alkoxy group that encompasses both straight and branched chain alkyls of from 1 to 3 carbon atoms. Unless stated otherwise in the specification, an alkoxy group can be optionally substituted by one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfonate, urea, —Si(Ra)3, —ORa, —SRa, —OC(O)—Ra, —N(Ra)2, —C(O)Ra, —C(O)ORa, —OC(O)N(Ra)2, —C(O)N(Ra)2, —N(Ra)C(O)ORa, —N(Ra)C(O)Ra, —N(Ra)C(O)N(Ra)2, —N(Ra)C(NRa)N(Ra)2, —N(Ra)S(O)tN(Ra)2 (where t is 1 or 2), —P(═O)(Ra)(Ra), or —O—P(═O)(ORa)2 where each Ra is independently hydrogen, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, and each of these moieties can be optionally substituted as defined herein.
- As used herein, the terms “aromatic” or “aryl” refer to a radical with 6 to 14 ring atoms (e.g., C6-14 aromatic or C6-14 aryl) that has at least one ring having a conjugated pi electron system which is carbocyclic (e.g., phenyl, fluorenyl, and naphthyl). In some embodiments, the aryl is a C6-10 aryl group. For example, bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals. In other embodiments, bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in “-yl” by removal of one hydrogen atom from the carbon atom with the free valence are named by adding “-idene” to the name of the corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene. Whenever it appears herein, a numerical range such as “6 to 14 aryl” refers to each integer in the given range; e.g., “6 to 14 ring atoms” means that the aryl group can consist of 6 ring atoms, 7 ring atoms, etc., up to and including 14 ring atoms. The term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups. Polycyclic aryl groups include bicycles, tricycles, tetracycles, and the like. In a multi-ring group, only one ring is required to be aromatic, so groups such as indanyl are encompassed by the aryl definition. Non-limiting examples of aryl groups include phenyl, phenalenyl, naphthalenyl, tetrahydronaphthyl, phenanthrenyl, anthracenyl, fluorenyl, indolyl, indanyl, and the like. Unless stated otherwise in the specification, an aryl moiety can be optionally substituted by one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfonate, urea, —Si(Ra)3, —ORa, —SRa, —OC(O)—Ra, —N(Ra)2, —C(O)Ra, —C(O)ORa, —OC(O)N(Ra)2, —C(O)N(Ra)2, —N(Ra)C(O)ORa, —N(Ra)C(O)Ra, —N(Ra)C(O)N(Ra)2, —N(Ra)C(NRa)N(Ra)2, —N(Ra)S(O)tN(Ra)2 (where t is 1 or 2), —P(═O)(Ra)(Ra), or —O—P(═O)(ORa)2 where each Ra is independently hydrogen, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, and each of these moieties can be optionally substituted as defined herein.
- As used herein, the terms “cycloalkyl” and “carbocyclyl” each refers to a monocyclic or polycyclic radical that contains only carbon and hydrogen, and can be saturated or partially unsaturated. Partially unsaturated cycloalkyl groups can be termed “cycloalkenyl” if the carbocycle contains at least one double bond, or “cycloalkynyl” if the carbocycle contains at least one triple bond. Cycloalkyl groups include groups having from 3 to 13 ring atoms (i.e., C3-13 cycloalkyl). Whenever it appears herein, a numerical range such as “3 to 10” refers to each integer in the given range; e.g., “3 to 13 carbon atoms” means that the cycloalkyl group can consist of 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, etc., up to and including 13 carbon atoms. The term “cycloalkyl” also includes bridged and spiro-fused cyclic structures containing no heteroatoms. The term also includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups. Polycyclic aryl groups include bicycles, tricycles, tetracycles, and the like. In some embodiments, “cycloalkyl” can be a C3-8 cycloalkyl radical. In some embodiments, “cycloalkyl” can be a C3-5 cycloalkyl radical. Illustrative examples of cycloalkyl groups include, but are not limited to the following moieties: C3-6 carbocyclyl groups include, without limitation, cyclopropyl (C3), cyclobutyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6) and the like. Examples of C3-7 carbocyclyl groups include norbornyl (C7). Examples of C3-8 carbocyclyl groups include the aforementioned C3-7 carbocyclyl groups as well as cycloheptyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, and the like. Examples of C3-13 carbocyclyl groups include the aforementioned C3-8 carbocyclyl groups as well as octahydro-1H indenyl, decahydronaphthalenyl, spiro[4.5]decanyl and the like. Unless stated otherwise in the specification, a cycloalkyl group can be optionally substituted by one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfonate, urea, —Si(Ra)3, —ORa, —SRa, —OC(O)—Ra, —N(Ra)2, —C(O)Ra, —C(O)ORa, —OC(O)N(Ra)2, —C(O)N(Ra)2, —N(Ra)C(O)ORa, —N(Ra)C(O)Ra, —N(Ra)C(O)N(Ra)2, —N(Ra)C(NRa)N(Ra)2, —N(Ra)S(O)tN(Ra)2 (where t is 1 or 2), —P(═O)(Ra)(Ra), or —O—P(═O)(ORa)2 where each Ra is independently hydrogen, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, and each of these moieties can be optionally substituted as defined herein. The terms “cycloalkenyl” and “cycloalkynyl” mirror the above description of “cycloalkyl” wherein the prefix “alk” is replaced with “alken” or “alkyn” respectively, and the parent “alkenyl” or “alkynyl” terms are as described herein. For example, a cycloalkenyl group can have 3 to 13 ring atoms, such as 5 to 8 ring atoms. In some embodiments, a cycloalkynyl group can have 5 to 13 ring atoms.
- As used herein, the term “halogen” refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I). As used herein, the term “halide” or “halo”, means fluoro, chloro, bromo or iodo. The terms “haloalkyl,” “haloalkenyl,” “haloalkynyl” and “haloalkoxy” include alkyl, alkenyl, alkynyl and alkoxy structures that are substituted with one or more halo groups or with combinations thereof. For example, the terms “fluoroalkyl” and “fluoroalkoxy” include haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine, such as, but not limited to, trifluoromethyl, difluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, and the like. Each of the alkyl, alkenyl, alkynyl and alkoxy groups are as defined herein and can be optionally further substituted as defined herein.
- As used herein, the term “heteroatom” refers to oxygen (O), nitrogen (N), sulfur (S), and phosphorus (P).
- As used herein, the term “heteroalkyl” refers to an alkyl radical, which have one or more skeletal chain atoms selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof. A numerical range can be given, e.g., C1-4 heteroalkyl, which refers to the chain length in total, which in this example is 4 atoms long. For example, a —CH2OCH2CH3 radical is referred to as a “C4” heteroalkyl, which includes the heteroatom center in the atom chain length description. Connection to the parent molecular structure can be through either a heteroatom or a carbon in the heteroalkyl chain. For example, an N-containing heteroalkyl moiety refers to a group in which at least one of the skeletal atoms is a nitrogen atom. One or more heteroatom(s) in the heteroalkyl radical can be optionally oxidized. One or more nitrogen atoms, if present, can also be optionally quaternized. For example, heteroalkyl also includes skeletal chains substituted with one or more nitrogen oxide (—O—) substituents. Exemplary heteroalkyl groups include, without limitation, ethers such as methoxyethanyl (—CH2CH2OCH3), ethoxymethanyl (—CH2OCH2CH3), (methoxymethoxy)ethanyl (—CH2CH2OCH2OCH3), (methoxymethoxy) methanyl (—CH2OCH2OCH3) and (methoxyethoxy)methanyl (—CH2OCH2CH2OCH3) and the like; amines such as (—CH2CH2NHCH3, —CH2CH2N(CH3)2, —CH2NHCH2CH3, —CH2N(CH2CH3)(CH3)) and the like.
- As used herein, the term “heteroaryl” or, alternatively, “heteroaromatic” refers to a refers to a radical of a 5-18 membered monocyclic or polycyclic (e.g., bicyclic, tricyclic, tetracyclic and the like) aromatic ring system (e.g., having 6, 10 or 14 π electrons shared in a cyclic array) having ring carbon atoms and 1-6 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous and sulfur (“5-18 membered heteroaryl”). Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings. Whenever it appears herein, a numerical range such as “5 to 18” refers to each integer in the given range; e.g., “5 to 18 ring atoms” means that the heteroaryl group can consist of 5 ring atoms, 6 ring atoms, etc., up to and including 18 ring atoms. In some instances, a heteroaryl can have 5 to 14 ring atoms. In some embodiments, the heteroaryl has, for example, bivalent radicals derived from univalent heteroaryl radicals whose names end in “-yl” by removal of one hydrogen atom from the atom with the free valence are named by adding “-ene” to the name of the corresponding univalent radical, e.g., a pyridyl group with two points of attachment is a pyridylene.
- For example, an N-containing “heteroaromatic” or “heteroaryl” moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom. One or more heteroatom(s) in the heteroaryl radical can be optionally oxidized. One or more nitrogen atoms, if present, can also be optionally quaternized. Heteroaryl also includes ring systems substituted with one or more nitrogen oxide (—O—) substituents, such as pyridinyl N-oxides. The heteroaryl is attached to the parent molecular structure through any atom of the ring(s).
- “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment to the parent molecular structure is either on the aryl or on the heteroaryl ring, or wherein the heteroaryl ring, as defined above, is fused with one or more cycloalkyl or heterocycyl groups wherein the point of attachment to the parent molecular structure is on the heteroaryl ring. For polycyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl and the like), the point of attachment to the parent molecular structure can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl). In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur (“5-10 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur (“5-8 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur (“5-6 membered heteroaryl”). In some embodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, phosphorous, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, phosphorous, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, phosphorous, and sulfur.
- Examples of heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, benzo[b][1,4] oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzoxazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzopyranonyl, benzofurazanyl, benzothiazolyl, benzothienyl (benzothiophenyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno [2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl, 6,7-dihydro-5H benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furazanyl, furanonyl, furo [3,2-c]pyridinyl, 5,6,7,8,9,10-hexahydrocycloocta[d] pyrimidinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, 5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl, 5,6,7,8-tetrahydrobenzo [4,5] thieno [2,3-d]pyrimdinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno [2,3-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, thiapyranyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno [2,3-c]pridinyl, and thiophenyl (i.e., thienyl). Unless stated otherwise in the specification, a heteroaryl moiety can be optionally substituted by one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfonate, urea, —Si(Ra)3, —ORa, —SRa, —OC(O)—Ra, —N(Ra)2, —C(O)Ra, —C(O)ORa, —OC(O)N(Ra)2, —C(O)N(Ra)2, —N(Ra)C(O)ORa, —N(Ra)C(O)Ra, —N(Ra)C(O)N(Ra)2, —N(Ra)C(NRa)N(Ra)2, —N(Ra)S(O)tN(Ra)2 (where t is 1 or 2), —P(═O)(Ra)(Ra), or —O—P(═O)(ORa)2 where each Ra is independently hydrogen, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, and each of these moieties can be optionally substituted as defined herein.
- As used herein, the term “administering” refers to oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intracranial, inhalation, intraocular, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject. Suitable routes of administration for a particular patient will depend on the nature and severity of the disease or condition being treated or the nature of the therapy being used and on the nature of the active compound.
- Administration may be by any suitable route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc.
- By “co-administer” it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies.
- The compound of the invention can be administered alone or can be co-administered to the patient. Co-administration is meant to include simultaneous or sequential administration of the compound individually or in combination (more than one compound or agent). Thus, the preparations can also be combined, when desired, with other active substances (e.g., to reduce metabolic degradation).
- The compositions of the present invention can be delivered transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols. Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. Liquid form preparations include solutions, suspensions, and emulsions, gels, for example, water or water/propylene glycol solutions.
- The compositions of the present invention may additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes. The compositions of the present invention can also be delivered as microspheres for slow release in the body. For example, microspheres can be administered via intradermal injection of drug-containing microspheres, which slowly release subcutaneously (see Rao, 1995 J. Biomater Sci. Polym. Ed. 7:623-645; as biodegradable and injectable gel formulations (see, e.g., Gao 1995 Pharm. Res. 12:857-863); or, as microspheres for oral administration (see, e.g., Eyles 1997 J. Pharm. Pharmacol. 49:669-674).
- As used herein, the terms “disease,” “condition,” and “disorder” are used interchangeably herein and refer to a state of being or health status of a patient or subject capable of being treated with a compound, pharmaceutical composition, or method provided herein.
- As used herein, the term “effective amount” of an active agent refers to an amount sufficient to elicit the desired biological response. As will be appreciated by those of ordinary skill in this art, the effective amount of a compound of the invention may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the patient.
- As used herein, the terms “inhibition,” “inhibit” and “inhibiting” and the like in reference to a biological target (e.g., JAKs) inhibitor interaction refers to negatively affecting (e.g., decreasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the inhibitor. In embodiments, inhibition means negatively affecting (e.g. decreasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the inhibitor. In embodiments, inhibition refers to reduction of a disease or symptoms of disease. In embodiments, inhibition refers to a reduction in the activity of a particular protein target. Inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein. In embodiments, inhibition refers to a reduction of activity of a target protein resulting from a direct interaction (e.g., an inhibitor binds to the target protein). In embodiments, inhibition refers to a reduction of activity of a target protein from an indirect interaction (e.g., an inhibitor binds to a protein that activates the target protein, thereby preventing target protein activation).
- As used herein, the terms “isolated” or “purified” refer to a material that is substantially or essentially free from components that normally accompany it in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high-performance liquid chromatography.
- As used herein, a “pharmaceutically acceptable form” of a disclosed compound includes, but is not limited to, pharmaceutically acceptable salts, esters, hydrates, solvates, isomers, prodrugs, and isotopically labeled derivatives thereof. In one embodiment, a “pharmaceutically acceptable form” includes, but is not limited to, pharmaceutically acceptable salts, esters, prodrugs and isotopically labeled derivatives thereof. In some embodiments, a “pharmaceutically acceptable form” includes, but is not limited to, pharmaceutically acceptable isomers and stereoisomers, prodrugs and isotopically labeled derivatives thereof.
- In certain embodiments, the pharmaceutically acceptable form is a pharmaceutically acceptable salt. As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of subjects without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66:1-19. Pharmaceutically acceptable salts of the compounds provided herein include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchlorate acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, besylate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, p-toluenesulfonate, undecanoate, valerate salts, and the like. In some embodiments, organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, lactic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
- The salts can be prepared in situ during the isolation and purification of the disclosed compounds, or separately, such as by reacting the free base or free acid of a parent compound with a suitable base or acid, respectively. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1-4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. In some embodiments, the pharmaceutically acceptable base addition salt can be chosen from ammonium, potassium, sodium, calcium, and magnesium salts.
- In certain embodiments, the pharmaceutically acceptable form is a “solvate” (e.g., a hydrate). As used herein, the term “solvate” refers to compounds that further include a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. The solvate can be of a disclosed compound or a pharmaceutically acceptable salt thereof. Where the solvent is water, the solvate is a “hydrate.” Pharmaceutically acceptable solvates and hydrates are complexes that, for example, can include 1 to about 100, or 1 to about 10, or 1 to about 2, about 3 or about 4, solvent or water molecules. It will be understood that the term “compound”” as used herein encompasses the compound and solvates of the compound, as well as mixtures thereof.
- In certain embodiments, the pharmaceutically acceptable form is a prodrug. As used herein, the term “prodrug” (or “pro-drug”) refers to compounds that are transformed in vivo to yield a disclosed compound or a pharmaceutically acceptable form of the compound. A prodrug can be inactive when administered to a subject, but is converted in vivo to an active compound, for example, by hydrolysis (e.g., hydrolysis in blood). In certain cases, a prodrug has improved physical and/or delivery properties over the parent compound. Prodrugs can increase the bioavailability of the compound when administered to a subject (e.g., by permitting enhanced absorption into the blood following oral administration) or which enhance delivery to a biological compartment of interest (e.g., the brain or lymphatic system) relative to the parent compound. Exemplary prodrugs include derivatives of a disclosed compound with enhanced aqueous solubility or active transport through the gut membrane, relative to the parent compound.
- The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam). A discussion of prodrugs is provided in Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated in full by reference herein.
- Prodrug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism. (See, Bundgard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985 and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego, Calif., 1992.) Prodrugs commonly known in the art include well-known acid derivatives, such as, for example, esters prepared by reaction of the parent acids with a suitable alcohol, amides prepared by reaction of the parent acid compound with an amine, basic groups reacted to form an acylated base derivative, etc. Other prodrug derivatives may be combined with other features disclosed herein to enhance bioavailability. As such, those of skill in the art will appreciate that certain of the presently disclosed compounds having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds having a carbonate, carbamate, amide or alkyl ester moiety covalently bonded to any of the above substituents disclosed herein.
- Exemplary advantages of a prodrug can include, but are not limited to, its physical properties, such as enhanced water solubility for parenteral administration at physiological pH compared to the parent compound, or it can enhance absorption from the digestive tract, or it can enhance drug stability for long-term storage.
- As used herein, the term “pharmaceutically acceptable” excipient, carrier, or diluent refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient Some examples of materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate, magnesium stearate, and polyethylene oxide-polypropylene oxide copolymer as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- As used herein, the term “subject” refers to any animal (e.g., a mammal), including, but not limited to humans, non-human primates, rodents, and the like, which is to be the recipient of a particular treatment. A subject to which administration is contemplated includes, but is not limited to, humans (e.g., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and/or other non-human animals, for example, non-human mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs), rodents (e.g., rats and/or mice), etc. In certain embodiments, the non-human animal is a mammal. The non-human animal may be a male or female at any stage of development A non-human animal may be a transgenic animal. Typically, the terms “subject” and “patient” are used interchangeably herein in reference to a human subject.
- As used herein, the terms “treatment” or “treating” a disease or disorder refers to a method of reducing, delaying or ameliorating such a condition before or after it has occurred. Treatment may be directed at one or more effects or symptoms of a disease and/or the underlying pathology. The treatment can be any reduction and can be, but is not limited to, the complete ablation of the disease or the symptoms of the disease. Treating or treatment thus refers to any indicia of success in the therapy or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters, for example, the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation. As compared with an equivalent untreated control, such reduction or degree of amelioration may be at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, or 100% as measured by any standard technique.
- Treatment methods include administering to a subject a therapeutically effective amount of a compound described herein. The administering step may be a single administration or may include a series of administrations. The length of the treatment period depends on a variety of factors, such as the severity of the condition, the patient's age, the concentration of the compound, the activity of the compositions used in the treatment, or a combination thereof. It will also be appreciated that the effective dosage of an agent used for the treatment may increase or decrease over the course of a particular treatment regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some instances, chronic administration may be required. For example, the compositions are administered to the subject in an amount and for a duration sufficient to treat the patient
- The invention is based on an unexpected discovery of novel, selective and potent compounds that are orally and/or topically available and/or suitable for gastrointestinal (GI) tract restricted administration. A series of novel JAK inhibitors are disclosed herein that have been designed to be potentially suitable for either (I) oral administrations or (II) GI and/or skin topical uses. For compounds designed for oral administration, they are potent for JAK2 with an array of selectivity against other JAK kinases and with good overall drug profiles. For the compounds that are potentially suitable for GI restricted or skin topical uses, they are designed to show strong pan JAK activities including JAK1 and/or TYK2. In particular, these compounds are designed to show minimum oral absorption to limit systemic exposure but high exposure at site of action, in particular in the gastric intestine.
- Inhibition of Janus kinases will inevitably inhibit immune function and potentially increase the risk for infections both bacterial and viral. By restricting JAK inhibition to the GI tract, for GI restricted compounds or topically for compounds designed for external use on the skin, the systemic exposure of the compounds is greatly reduced or eliminated thereby preserving immune function. In oncology indications where JAK2 is a driver of the cancer, and inhibition of JAK2 is an appropriate treatment, JAK2 selective inhibitors preserve immune function which is not dependent on JAK2 signaling.
- Select compounds of the invention are suitable for oral administrations against cancers. These compounds are designed to show good potency against JAK2 with good oral absorption and good in vivo stability. Additionally, compounds may possess selectivity against other JAK kinases (e.g., JAK1).
- Select compounds of the invention are suitable for treating GI diseases with limited systemic exposure after oral administration. These compounds possess good potency against JAK kinases (e.g., JAK1, TYK2 and JAK2) and through limited absorption demonstrate higher exposure at the site of action.
- Select compounds of the invention are suitable for the topical skin administration. These compounds show good potency against JAK kinases (e.g., JAK1, TYK2 and JAK2) with limited systemic exposure and higher exposure in the dermis/epidermis and thus at the site of action in the skin.
- The invention also provides pharmaceutical compositions of these compounds and methods of preparation and use thereof. The JAK inhibitors disclosed herein exhibited exceptional potency profiles while enjoying favorable pharmacokinetic profiles and drug properties that are suitable for target indications.
- In one aspect, the invention generally relates to a compound having the structural formula (I):
- wherein
- L is O or NR4′;
- X is N or CRx, wherein Rx is R′, halogen (e.g., Cl, F), CN or OR′;
- Y is N or CRY, wherein RY is R′, halogen (e.g., Cl, F), CN or OR′;
- each of Z1 and Z2 is independently selected from N and CR′, provided that one of Z1 and Z2 is N and the other is CR′;
- R1 is hydrogen, halogen, CN, C1-C6 (e.g., C1-C3) unsubstituted or substituted alkyl or OR′;
- R2 is a C1-C16 (e.g., C1-C6, C7-C16) aliphatic group optionally comprising one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with one or more of halogen, OR′, NRR′, CN, CONRR′, NRCOR′ and C1-C6 (e.g., C1-C3) alkyl, which is in turn optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR′ or NRR′;
- R3 is R′ or halogen;
- each of R4 and R4′, when L is NR4′, is selected from hydrogen and C1-C16 (e.g., C1-C6, C7-C16) aliphatic groups optionally comprising one or more heteroatoms selected from N, O, S and P, and R4 and R4′ together may form a 3- to 7-membered ring, having 0 to 3 heteroatoms selected from O, N and S, and wherein each of R4 and R4′ is optionally substituted with CN, CF3 or OR′; provided that if one of R4 and R4′ is hydrogen, the other is not hydrogen; and
- each R and R′ is independently hydrogen or a C1-C12 unsubstituted or substituted alkyl group,
- or a pharmaceutically acceptable form or an isotope derivative thereof.
- In certain embodiments of (I), L is O having the structural formula:
- In certain embodiments of (I), L is NR4′ having the structural formula:
- In certain embodiments of (I), X is CRx, wherein Rx is H, halogen, C1-C6 (e.g., C1-C3) unsubstituted or substituted alkyl or alkoxy.
- In certain embodiments of (I), X is CH.
- In certain embodiments of (I), X is N.
- In certain embodiments of (I), Y is CRY, wherein R is H, halogen, C1-C6 (e.g., C1-C3) unsubstituted or substituted alkyl or alkoxy.
- In certain embodiments of (I), Y is CH.
- In certain embodiments of (I), Y is N.
- In certain embodiments of (I), Z1 is CH and Z2 is N.
- In certain embodiments of (I), Z1 is N and Z2 is CH.
- In certain embodiments of (I), R4 comprises a linear, branched or cyclic C1-C12 (e.g., C1-C6) unsubstituted or substituted alkyl group.
- In certain embodiments of (I), R4 comprises a 3- to 7-membered (e.g., 3-, 4- or 5-membered) ring having 0 to 3 (e.g., 0, 1, 2, 3) heteroatoms selected from O, N and S. In certain embodiments of (I), R4 comprises a 3- to 7-membered ring having 0 heteroatoms
- In certain embodiments of (I), R4 comprises a cyclopropyl ring.
- In certain embodiments of (I), R4 comprises a 4-membered ring.
- In certain embodiments of (I), R4 comprises a 5-membered ring.
- In certain embodiments of (I), R4 is a group that comprises a CN group. In certain embodiments, wherein the CN group is bonded to a carbon atom at 0 position to L
- In certain embodiments of (I), the CN group is attached to a secondary carbon atom.
- In certain embodiments of (I), the CN group is attached to a tertiary carbon atom.
- In certain embodiments of (I), R4 is a C3 alkyl group substituted with CN.
- In certain embodiments of (I), R4 is a C4 alkyl group substituted with CN.
- In certain embodiments of (I), R4 is a C5 alkyl group substituted with CN.
- In certain embodiments of (I), wherein R4′ is H.
- In certain embodiments of (I), wherein R4′ is a C1-C3 alkyl (e.g., methyl, ethyl, propyl). In certain embodiments, wherein R4′ is methyl.
- In certain embodiments of (I), R4′ is methyl.
- In certain embodiments of (I), L is O, X is CRx, Y is CH, Z1 is CH and Z2 is N, having the structural formula (II):
- In certain embodiments of (I), L is NR4′, X is CRx, Y is CH, Z1 is CH and Z2 is N, having the structural formula (III):
- In certain embodiments of (I), (I) or (III), R1 is F.
- In certain embodiments of (I), (II) or (III), R1 is Cl.
- In certain embodiments of (I), (II) or (III), R1 is a C1-C3 alkyl (e.g., methyl, ethyl, propyl). In certain embodiments, R1 is methyl.
- In certain embodiments of (I), (II) or (III), R2 is a C1-C6 (e.g., C1-C3) aliphatic group with 0 to 2 (e.g., 0, 1 or 2) carbon atoms replaced by one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with a CN or CF3 group.
- In certain embodiments of (I), (II) or (III), R2 is a C7-C16 (e.g., C7-C10) aliphatic group with 0 to 3 (e.g., 0, 1, 2 or 3) carbon atoms replaced by one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with a CN or CF3 group.
- In certain embodiments of (I), (II) or (III), R2 comprises a C3-C16 (e.g., C3-C10) cyclic alkyl with 0 to 8 (e.g., 0, 1, 2, 3, 4, 5, 6, 7 or 8) carbon atoms replaced by one or more heteroatoms selected from N, O, S and P, optionally substituted with a CN or CF3 group.
- In certain embodiments, the cyclic alkyl is a C3-C6 cyclic alkyl.
- In certain embodiments, the cyclic alkyl is a C3 cyclic alkyl.
- In certain embodiments of (I), (II) or (III), R2 is a group that comprises CN.
- In certain embodiments, R2 comprises CH2—CN.
- In certain embodiments of (I), (II) or (III), R2 does not comprise CN.
- In certain embodiments of (I), (II) or (III), R2 is:
- wherein
- Z3 is N, CH or O, wherein when Z3 is O, R5 is absent;
- each of m and n is independently 0, 1, 2, 3 or 4; provided that m and n are not both 0 at the same time, and
- R5 is a C1-C6 (e.g., C1-C3) alkyl, CN, halogen or C(O)R6, wherein R6 is a C1-C6 (e.g., C1-C3) alkyl; provided that when Z3 is N, R5 is not CN or halo.
- In certain embodiments, each of m and n is 2.
- In certain embodiments, Z3 is N.
- In certain embodiments, Z3 is O.
- In certain embodiments, R5 is a C1-C6 (e.g., C1-C3) alkyl. In certain embodiments, R5 is methyl.
- In certain embodiments, R5 is C(O)R6 and R6 is a C1-C6 alkyl, provided at least one of m and n is not 0.
- In certain embodiments of (I), (II) or (III), R2 is a substituted or unsubstituted piperidine.
- In certain embodiments of (I), (II) or (III), R2 is a substituted or unsubstituted cyclopropyl.
- In certain embodiments of (I), (II) or (III), R2 is methyl.
- In certain embodiments of (I), (II) or (III), R3 is H.
- In certain embodiments of (I), (II) or (III), R3 is CH3.
- In certain embodiments of (I), (II) or (III), R3 is F or Cl.
- A list of non-limiting examples of the compounds of the invention is provided in Table 1. Certain exemplary data of select compounds are provided in Table 2. Tables 3A and 3B show certain literature compounds and exemplary testing data.
- In certain embodiments, a compound of the invention is selected from:
-
1 3-(4-(2-((1-cyclopropyl-1H-pyrazol-4- yl)amino)-5-methylpyrimidin-4- yl)phenoxy)-2,2- dimethylpropanenitrile 3 1-((4-(2-((1-cyclopropyl-1H-pyrazol-4- yl)amino)-5-methylpyrimidin-4- yl)phenoxy)methyl)cyclobutane- carbonitrile 12 3-(2-fluoro-4-(5-methyl-2-((1-methyl- 1H-pyrazol-4-yl)amino)pyrimidin-4- yl)phenoxy)propanenitrile 29 3-(4-(5-chloro-2-((1-methyl-1H- pyrazol-4-yl)amino)pyrimidin-4- yl)phenoxy)-2,2- dimethylpropanenitrile 38 2,2-dimethyl-3-(4-(5-methyl-2-((1- methyl-1H-pyrazol-4- yl)amino)pyrimidin-4- yl)phenoxy)propanenitrile 41 3-(4-(5-methyl-2-((1-methyl-1H- pyrazol-4-yl)amino)pyrimidin-4- yl)phenoxy)propanenitrile 42 1-(((4-(2-((1-cyclopropyl-1H-pyrazol- 4-yl)amino)-5-methylpyrimidin-4- yl)phenyl)amino)methyl)cyclopropane- 1-carbonitrile - In certain embodiments, a compound of the invention is selected from:
-
Example Structure IUPAC name 4 3-(4-(2-((1-cyclopropyl-1H-pyrazol-4- yl)amino)-5-methylpyrimidin-4-yl)-2- fluorophenoxy)-2,2- dimethylpropanenitrile 5 1-((4-(2-((1-cyclopropyl-1H-pyrazol-4- yl)amino)-5-methylpyrimidin-4-yl)-2- fluorophenoxy)methyl)cyclopropane- carbonitrile 6 1-((2-fluoro-4-(5-methyl-2-((1- (tetrahydro-2H-pyran-4-yl)-1H- pyrazol-4-yl)amino)pyrimidin-4- yl)phenoxy)methyl)cyclopropane- carbonitrile 7 3-(2-fluoro-4-(5-methyl-2-((1- (tetrahydro-2H-pyran-4-yl)-1H- pyrazol-4-yl)amino)pyrimidin-4- yl)phenoxy)-2,2- dimethylpropanenitrile 13 1-((4-(2-((1-(1-acetylpiperidin-4-yl)- 1H-pyrazol-4-yl)amino)-5- methylpyrimidin-4-yl)-2- fluorophenoxy)methyl)cyclopropane- carbonitrile 17 2,2-dimethyl-3-(4-(5-methyl-2-((1-(1- methylpiperidin-4-yl)-1H-pyrazol-4- yl)amino)pyrimidin-4- yl)phenoxy)propanenitrile 19 3-(2-fluoro-4-(2-((1-(2-methoxyethyl)- 1H-pyrazol-4-yl)amino)-5- methylpyrimidin-4-yl)phenoxy)-2,2- dimethylpropanenitrile 20 1-((2-fluoro-4-(5-methyl-2-((1-(1- methylpiperidin-4-yl)-1H-pyrazol-4- yl)amino)pyrimidin-4- yl)phenoxy)methyl)cyclopropane- carbonitrile 40 3-(2-fluoro-4-(5-methyl-2-((1-(1,1,1- trifluoropropan-2-yl)-1H-pyrazol-4- yl)amino)pyrimidin-4-yl)phenoxy)-2,2- dimethylpropanenitrile - As discussed herein, isotope derivative compounds having one or more hydrogen atoms (e.g., 1, 2, 4, 5, 6, 7, 8, 9, 10, etc.) replaced with deuterium atoms are contemplated in the presented invention. In certain embodiments, isotope derivative compounds of the invention have one hydrogen atom replaced with a deuterium atom.
- In another aspect, the invention generally relates to a pharmaceutical composition comprising a compound disclosed herein, effective to treat or reduce one or more diseases or disorders, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent
- In yet another aspect, the invention generally relates to a pharmaceutical composition comprising an amount of a compound having the structural formula (I):
- wherein
- L is O or NR4′;
- X is N or CRx, wherein Rx is R′, halogen (e.g., Cl, F), CN or OR′;
- Y is N or CRY, wherein RY is R′, halogen (e.g., Cl, F), CN or OR′;
- each of Z1 and Z2 is independently selected from N and CR′, provided that one of Z1 and Z2 is N and the other is CR′;
- R1 is hydrogen, halogen, CN, C1-C6 (e.g., C1-C3) unsubstituted or substituted alkyl or OR′;
- R2 is a C1-C16 (e.g., C1-C6, C7-C16) aliphatic group optionally comprising one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with one or more of halogen, OR′, NRR′, CN, CONRR′, NRCOR′ and C1-C6 (e.g., C1-C3) alkyl, which is in turn optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR′ or NRR′;
- R3 is R′ or halogen;
- each of R4 and R4′, when L is NR4′, is selected from hydrogen and C1-C16 (e.g., C1-C6, C7-C16) aliphatic groups optionally comprising one or more heteroatoms selected from N, O, S and P, and R4 and R4′ together may form a 3- to 7-membered ring, having 0 to 3 heteroatoms selected from O, N and S, and wherein each of R4 and R4′ is optionally substituted with CN, CF3 or OR′; provided that if one of R4 and R4′ is hydrogen, the other is not hydrogen; and
- each R and R′ is independently hydrogen or a C1-C12 unsubstituted or substituted alkyl group,
- or a pharmaceutically acceptable form or an isotope derivative thereof, effective to treat, or reduce one or more diseases or disorders, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- In certain embodiments of the pharmaceutical compositions, L is O, X is CRx, Y is CH, Z1 is CH and Z2 is N, and the compound has the structural formula (II):
- In certain embodiments of the pharmaceutical compositions, L is NR4′, X is CRx, Y is CH, Z1 is CH and Z2 is N, and the compound has the structural formula (III):
- In certain embodiments of the pharmaceutical compositions, R4 comprises a linear, branched or cyclic C1-C12 (e.g., C1-C6, C7-C12) unsubstituted or substituted alkyl group.
- In certain embodiments of the pharmaceutical compositions, R4 comprises a 3- to 7-membered (e.g., 3-, 4- or 5-membered) ring having 0 to 3 (e.g., 0, 1, 2, 3) heteroatoms selected from O, N and S. In certain embodiments of the pharmaceutical compositions, R4 comprises a 3-to 7-membered (e.g., 3-, 4- or 5-membered) ring having 0 heteroatoms.
- In certain embodiments, the pharmaceutical composition of the invention is suitable for oral administration.
- In certain embodiments, the pharmaceutical composition of the invention is suitable for topical administration.
- In certain embodiments, the pharmaceutical composition of the invention is suitable for GI-restricted administration.
- In certain embodiments, the pharmaceutical composition of the invention is useful to treat or reduce one or more of inflammatory diseases, immune-mediated diseases and cancers, or a related disease or disorder.
- In certain embodiments, the pharmaceutical composition of the invention is useful for treating or reducing an inflammatory disease, or a related disease or disorder.
- In certain embodiments, the pharmaceutical composition of the invention is useful for treating or reducing an immune-mediated disease, or a related disease or disorder.
- In certain embodiments, the pharmaceutical composition of the invention is useful for treating or reducing cancer, or a related disease or disorder.
- In certain embodiments, the pharmaceutical composition of the invention is useful for treating or reducing a disease or disorder selected from: inflammatory bowel disease, psoriasis, vitiligo, alopecia areata, alopecia totalis, atopic dermatitis, systemic lupus erythematosus, asthma, diabetic nephropathy, chronic myelogenous leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), breast cancer and ovarian cancer.
- In yet another aspect, the invention generally relates to a unit dosage form comprising a pharmaceutical composition disclosed herein.
- In certain embodiments, the unit dosage form is a solid dosage form, for example, in the forms of capsules, tablets, pills, powders or granules. In certain embodiments, the unit dosage form is a capsule. In certain embodiments, the unit dosage form is a tablet.
- In certain embodiments, the unit dosage form is a liquid dosage form, for example, in the forms of emulsions, solutions, suspensions, syrups or elixirs.
- In yet another aspect, the invention generally relates to a method for treating or reducing a disease or disorder. The method includes administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula (I):
- wherein
- L is O or NR4′;
- X is N or CRx, wherein Rx is R′, halogen (e.g., Cl, F), CN or OR′;
- Y is N or CRY, wherein RY is R′, halogen (e.g., Cl, F), CN or OR′;
- each of Z1 and Z2 is independently selected from N and CR′, provided that one of Z1 and Z2 is N and the other is CR′;
- R1 is hydrogen, halogen, CN, C1-C6 (e.g., C1-C3) unsubstituted or substituted alkyl or OR′;
- R2 is a C1-C16 (e.g., C1-C6, C7-C16) aliphatic group optionally comprising one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with one or more of halogen, OR′, NRR′, CN, CONRR′, NRCOR′ and C1-C6 (e.g., C1-C3) alkyl, which is in turn optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR′ or NRR′;
- R3 is R′ or halogen;
- each of R4 and R4′, when L is NR4′, is selected from hydrogen and C1-C16 (e.g., C1-C6, C7-C16) aliphatic groups optionally comprising one or more heteroatoms selected from N, O, S and P, and R4 and R4′ together may form a 3- to 7-membered ring, having 0 to 3 heteroatoms selected from O, N and S, and wherein each of R4 and R4′ is optionally substituted with CN, CF3 or OR′; provided that if one of R4 and R4′ is hydrogen, the other is not hydrogen; and
- each R and R′ is independently hydrogen or a C1-C12 unsubstituted or substituted alkyl group,
- or a pharmaceutically acceptable form or an isotope derivative thereof, effective to treat, prevent,
or reduce one or more of inflammatory diseases, immune-mediated diseases, cancer, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent - In certain embodiments of the method, L is O, X is CRx, Y is CH, Z1 is CH and Z2 is N, and the compound has the structural formula (II):
- In certain embodiments of the method, L is NR4′, X is CRx, Y is CH, Z1 is CH and Z2 is N, and the compound has the structural formula (III):
- In certain embodiments of the method, R4 comprises a linear, branched or cyclic C1-C12 (e.g., C1-C6, C7-C12) unsubstituted or substituted alkyl group.
- In certain embodiments of the method, R4 comprises a 3- to 7-membered (e.g., 3-, 4- or 5-membered) ring having 0 to 3 (e.g., 0, 1, 2, 3) heteroatoms selected from O, N and S. In certain embodiments of the pharmaceutical compositions, R4 comprises a 3- to 7-membered (e.g., 3-, 4- or 5-membered) ring having 0 heteroatoms.
- In yet another aspect, the invention generally relates to a method for treating or reducing a disease or disorder. The method includes administering to a subject in need thereof a pharmaceutical composition comprising a compound disclosed herein, wherein the disease or disorder is one or more of inflammatory diseases, immune-mediated diseases and cancer, or a related disease or disorder.
- In certain embodiments of the method, the disease or disorder is an inflammatory disease.
- In certain embodiments of the method, the disease or disorder is an immune-mediated disease.
- In certain embodiments of the method, the disease or disorder is cancer.
- In certain embodiments of the method, the disease or disorder is selected from: inflammatory bowel disease, psoriasis, vitiligo, atopic dermatitis, systemic lupus erythematosus, asthma, diabetic nephropathy, chronic myelogenous leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), breast cancer and ovarian cancer.
- In certain embodiments of the method, the administration is via oral administration.
- In certain embodiments of the method, the administration is via topical administration.
- In certain embodiments of the method, the administration is via GI-restricted administration.
- In yet another aspect, the invention generally relates to use of a compound disclosed herein, and a pharmaceutically acceptable excipient, carrier, or diluent, in preparation of a medicament for treating a disease or disorder.
- In certain embodiments of the use, the disease or disorder is one or more of inflammatory diseases, immune-mediated diseases and cancer.
- In certain embodiments of the use, the disease or disorder is an autoimmune disease.
- In certain embodiments of the use, the disease or disorder is an immune-mediated disease.
- In certain embodiments of the use, the disease or disorder is cancer.
- In certain embodiments of the use, the medicament is for oral administration.
- In certain embodiments of the use, the medicament is for topical administration.
- In certain embodiments of the use, the medicament is for GI restriction administration.
- The term “inflammatory disease” refers to a disease or condition characterized by aberrant inflammation, e.g. an increased level of inflammation compared to a control such as a healthy person not suffering from a disease. Examples of inflammatory diseases that may be treated with a compound, pharmaceutical composition, or method described herein include autoimmune diseases, traumatic brain injury, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Sjogren's syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves ophthalmopathy, inflammatory bowel disease, Addison's disease, vitiligo, asthma, allergic asthma, acne vulgaris, celiac disease, chronic prostatitis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, ischemia reperfusion injury, stroke, sarcoidosis, transplant rejection, interstitial cystitis, atherosclerosis, scleroderma, and atopic dermatitis. Such conditions are frequently inextricably intertwined with other diseases, disorders and conditions. A non-limiting list of inflammatory-related diseases, disorders and conditions which may, for example, be caused by inflammatory cytokines, include, arthritis, kidney failure, lupus, asthma, psoriasis, colitis, pancreatitis, allergies, fibrosis, surgical complications (e.g., where inflammatory cytokines prevent healing), anemia, and fibromyalgia. Other diseases and disorders, which may be associated with chronic inflammation include Alzheimer's disease, congestive heart failure, stroke, aortic valve stenosis, arteriosclerosis, osteoporosis, Parkinson's disease, infections, inflammatory bowel disease (IBD), allergic contact dermatitis and other eczemas, systemic sclerosis, transplantation and multiple sclerosis. Some of the aforementioned diseases, disorders and conditions for which a compound of the present disclosure may be particularly efficacious (due to, for example, limitations of current therapies) are described in more detail hereafter.
- The term “autoimmune disease” refers to a disease or condition in which a subject's immune system has an aberrant immune response against a substance that does not normally elicit an immune response in a healthy subject. Examples of autoimmune diseases that may be treated with a compound, pharmaceutical composition, or method described herein include acne vulgaris, acute disseminated encephalomyelitis, acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, Aicardi-Goutières syndrome (AGS), alopecia areata, alopecia totalis, amyloidosis, ankylosing spondylitis, anti-GBM/anti-TBM nephritis, antiphospholipid syndrome, autoimmune angioedema, autoimmune aplastic anemia, autoimmune dysautonomia, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease, autoimmune myocarditis, autoimmune oophoritis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura, autoimmune thyroid disease, autoimmune urticaria, axonal or neuronal neuropathies, balo disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Castleman disease, celiac disease, Chagas disease, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), chronic active hepatitis, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy, chronic recurrent multifocal ostomyelitis, Churg-Strauss syndrome, cicatricial pemphigoid/benign mucosal pemphigoid, Crohn's disease, Cogans syndrome, cold agglutinin disease, congenital heart block, coxsackie myocarditis, CREST disease, Cushing's disease, demyelinating neuropathies, depression, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, Dressler's syndrome, dry eye syndrome DES (keratoconjunctivitis sicca), endometriosis, eosinophilic esophagitis, eosinophilic fasciitis, erythema nodosum, essential mixed cryoglobulinemia, experimental allergic encephalomyelitis, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis, graft-versus-host disease (GVDH), Graves' disease, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schonlein purpura, herpes gestationis, hidradenitis suppurativa, hypogammaglobulinemia, idiopathic thrombocytopenic purpura, IgA nephropathy, IgG4-related sclerosing disease, inflammatory bowel disease (IBD), immunoregulatory lipoproteins, inclusion body myositis, interstitial cystitis, juvenile arthritis, juvenile diabetes (Type 1 diabetes), juvenile dermatomyositis (JDM), juvenile myositis, Kawasaki syndrome, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, ligneous conjunctivitis, linear IgA disease, lupus, lyme disease, chronic, Meniere's disease, microscopic polyangiitis, mixed connective tissue disease, Mooren's ulcer, Mucha-Habermann disease, multiple sclerosis (MS), myasthenia gravis, myositis, narcolepsy, neuromyelitis optica, neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism, pediatric autoimmune neuropsychiatric disorders associated with streptococcus, paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria p, Parry Romberg syndrome, Parsonnage-Turner syndrome, Pars planitis (peripheral uveitis), pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, polycystic ovary syndrome (PCOS), Type I, II, & III autoimmune polyglandular syndromes, polymyalgia rheumatica, polymyositis, postmyocardial infarction syndrome, postpericardiotomy syndrome, progesterone dermatitis, primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, plaque psoriasis, idiopathic pulmonary fibrosis, pyoderma gangrenosum, pure red cell aplasia, Raynauds phenomenon, reactive Arthritis, reflex sympathetic dystrophy, Reiter's syndrome, relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjogren's syndrome, sperm & testicular autoimmunity, stiff person syndrome, stimulator of interferon genes (STING)-associated vasculopathy with onset during infancy (SAVI), subacute bacterial endocarditis, Susac's syndrome, sympathetic ophthalmia, systemic lupus erythematosus (SLE), Takayasu's arteritis, temporal arteritis/Giant cell arteritis, thrombocytopenic purpura, Tolosa-Hunt syndrome, transplant rejection (allograft transplant rejection), transverse myelitis, Type 1 diabetes, ulcerative colitis, undifferentiated connective tissue disease, uveitis, vasculitis, vesiculobullous dermatosis, vitiligo, or Wegener's granulomatosis.
- The term “immune-mediated disease” refers to chronic inflammatory diseases perpetuated by antibodies and cellular immunity. Immune-mediated diseases include, for example, but not limited to, asthma, allergies, arthritis (e.g., rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis), juvenile arthritis, inflammatory bowel diseases (e.g., ulcerative colitis and Crohn's disease), endocrinopathies (e.g., type 1 diabetes and Graves' disease), neurodegenerative diseases (e.g., multiple sclerosis (MS)), autistic spectrum disorder, depression, Alzheimer's disease, Guillain-Barre syndrome, obsessive-compulsive disorder, optic neuritis, retinal degeneration, dry eye syndrome DES, Sjogren's syndrome, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Huntington's Disease, Guillain-Barre syndrome, myasthenia gravis, and chronic idiopathic demyelinating disease (CID)), vascular diseases (e.g., autoimmune hearing loss, systemic vasculitis, and atherosclerosis), and skin diseases (e.g., acne vulgaris dermatomyositis, pemphigus, systemic lupus erythematosus (SLE), discoid lupus erthematosus, scleroderma, psoriasis, plaque psoriasis, vasculitics, vitiligo and alopecias). Hashimoto's thyroiditis, pernicious anemia, Cushing's disease, Addison's disease, chronic active hepatitis, polycystic ovary syndrome (PCOS), celiac disease, pemphigus, transplant rejection (allograft transplant rejection), graft-versus-host disease (GVDH).
- The term “cancer” as used herein refers to all types of cancer, neoplasm or malignant tumors found in mammals, e.g., humans, including hematological cancers leukemia, and lymphomas, T-ALL, large B-cell lymphoma, solid cancers such as carcinomas and sarcomas. Exemplary cancers include blood cancer, brain cancer, glioma, glioblastoma, neuroblastoma, prostate cancer, colorectal cancer, pancreatic cancer, cervical cancer, gastric cancer, ovarian cancer, lung cancer, and cancer of the head. Exemplary cancers include cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus, medulloblastoma, colorectal cancer, pancreatic cancer. Additional examples include penile, skin—non-melanoma, anal, hepatobiliary, esophagogastric, uterine sarcoma, gastrointestinal stromal tumor, salivary gland, peripheral nervous system, soft tissue sarcoma, bone, renal, myeloproliferative neoplasms, thyroid carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, skin cutaneous melanoma, colon adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, breast invasive carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, metastatic leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, round cell liposarcoma or prostate cancer.
- In certain embodiments of the use, the disease or disorder is selected from: inflammatory bowel disease, psoriasis, vitiligo, atopic dermatitis, systemic lupus erythematosus, asthma, diabetic nephropathy, chronic myelogenous leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), breast cancer and ovarian cancer.
- Isotopically-labeled compounds are also within the scope of the present disclosure. As used herein, an “isotopically-labeled compound” refers to a presently disclosed compound including pharmaceutical salts and prodrugs thereof, each as described herein, in which one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds presently disclosed include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F, and 36Cl, respectively.
- By isotopically-labeling the presently disclosed compounds, the compounds may be useful in drug and/or substrate tissue distribution assays. Tritiated (3H) and carbon-14 (14C) labeled compounds are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (2H) can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds presently disclosed, including pharmaceutical salts, esters, and prodrugs thereof, can be prepared by any means known in the art.
- Further, substitution of normally abundant hydrogen (1H) with heavier isotopes such as deuterium can afford certain therapeutic advantages, e.g., resulting from improved absorption, distribution, metabolism and/or excretion (ADME) properties, creating drugs with improved efficacy, safety, and/or tolerability. Benefits may also be obtained from replacement of normally abundant 12C with 13C. (See, WO 2007/005643, WO 2007/005644, WO 2007/016361, and WO 2007/016431.)
- Stereoisomers (e.g., cis and trans isomers) and all optical isomers of a presently disclosed compound (e.g., R and S enantiomers), as well as racemic, diastereomeric and other mixtures of such isomers are within the scope of the present disclosure.
- Compounds of the present invention are, subsequent to their preparation, preferably isolated and purified to obtain a composition containing an amount by weight equal to or greater than 95% (“substantially pure”), which is then used or formulated as described herein. In certain embodiments, the compounds of the present invention are more than 99% pure. Solvates and polymorphs of the compounds of the invention are also contemplated herein. Solvates of the compounds of the present invention include, for example, hydrates.
- Any appropriate route of administration can be employed, for example, parenteral, intravenous, subcutaneous, intramuscular, intraventricular, intracorporeal, intraperitoneal, rectal, or oral administration. Most suitable means of administration for a particular patient will depend on the nature and severity of the disease or condition being treated or the nature of the therapy being used and on the nature of the active compound.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds described herein or derivatives thereof are admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (i) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (ii) binders, as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, (iii) humectants, as for example, glycerol, (iv) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate, (v) solution retarders, as for example, paraffin, (vi) absorption accelerators, as for example, quaternary ammonium compounds, (vii) wetting agents, as for example, cetyl alcohol, and glycerol monostearate, (viii) adsorbents, as for example, kaolin and bentonite, and (ix) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethyleneglycols, and the like. Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others known in the art.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers, such as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, and fatty acid esters of sorbitan, or mixtures of these substances, and the like. Besides such inert diluents, the composition can also include additional agents, such as wetting, emulsifying, suspending, sweetening, flavoring, or perfuming agents.
- Materials, compositions, and components disclosed herein can be used for, can be used in conjunction with, can be used in preparation for, or are products of the disclosed methods and compositions. It is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutations of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a method is disclosed and discussed and a number of modifications that can be made to a number of molecules including in the method are discussed, each and every combination and permutation of the method, and the modifications that are possible are specifically contemplated unless specifically indicated to the contrary. Likewise, any subset or combination of these is also specifically contemplated and disclosed. This concept applies to all aspects of this disclosure including, but not limited to, steps in methods using the disclosed compositions. Thus, if there are a variety of additional steps that can be performed, it is understood that each of these additional steps can be performed with any specific method steps or combination of method steps of the disclosed methods, and that each such combination or subset of combinations is specifically contemplated and should be considered disclosed.
- Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
- Isomeric mixtures containing any of a variety of isomer ratios may be utilized in accordance with the present invention. For example, where only two isomers are combined, mixtures containing 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0 isomer ratios are contemplated by the present invention. Those of ordinary skill in the art will readily appreciate that analogous ratios are contemplated for more complex isomer mixtures.
- If, for instance, a particular enantiomer of a compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic methods well known in the art, and subsequent recovery of the pure enantiomers.
- A series of analogues were designed, synthesized and tested. Examples of such compounds are provided below.
- Certain abbreviations are listed below.
-
- Methanol: MeOH
- Dichloromethane: DCM
- Petroleum ether: PE
- Ethyl acetate: EtOAc
- Triethylamine: TEA
- Sodium hydroxide: NaOH
- Nitrogen: N2
- Thin-Layer Chromatography: TLC
- High Performance Liquid Chromatography: HPLC
- N,N-Diisopropylethylamine: DIPEA
- N,N-Dimethylformamide: DMF
- 4-Methylmorpholine: NMM
- Room temperature: RT
- Hours: hrs
- X-Phos: 2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl
- Xant-phos: 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene
- Exemplary methods for prep-HPLC are provided below.
- Method A: NH4HCO3:
- (Column: XBridge Prep C18 5 μm OBD 19*150 mm, PN 186002979; mobile phase: CH3CN in water (0.1% NH4HCO3) from 20% to 60%, flow rate: 15 mL/min).
- Method B: TFA:
- (Column: XBridge Prep C18 5 μm OBD 19*150 mm, PN 186002979; mobile phase: CH3CN in water (0.1% formic acid) from 15% to 40%, flow rate: 15 mL/min)
- Method 1: Analysis was performed on an Agilent 1260 series HPLC-6120MS. UHPLC Long Gradient Equivalent 5% to 95% acetonitrile (containing 0.02% NH4OAc) in water run time of 6.5 minutes with a flow rate of 1.5 mL/min. A XBridge C18 column (5 μm, 4.6*50 mm; PN 186003113) was used at a temperature of 40° C.
- Method 2: Analysis was performed on an Agilent 1200 series HPLC-6120MS. UHPLC Long Gradient Equivalent 5% to 95% acetonitrile (containing 0.1% trifluoroacetic acid) in water run time of 6.5 minutes with a flow rate of 1.5 mL/min. A XBridge C18 column (5 μm, 4.6*50 mm; PN 186003113) was used at a temperature of 40° C.
- Method 3: Analysis was performed on an Agilent 1260 series HPLC-6120MS. UHPLC Long Gradient Equivalent 5% to 95% acetonitrile (containing 0.02% NH4OAc) in water run time of 6.5 minutes with a flow rate of 2 mL/min. A Diamonsil Plus C18 column (5 μm, 4.6*30 mm Cat #99436) was used at a temperature of 40° C.
-
- A mixture of compound 1a (3.0 g, 18.40 mmol), (4-hydroxyphenyl)boronic acid (4.46 g, 20.24 mmol), Na2CO3 (3.90 g, 36.8 mmol) and Pd(dppf)Cl2 (942 mg, 1.288 mmol) in 1,4-dioxane/H2O (24 mL/6 mL) was stirred at 60° C. under N2 overnight. The mixture was cooled down to RT and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE:EtOAc=2:1) to give the product (2.22 g, 55% yield) as a white solid. LC-MS (Method 2): tR=1.34 min, m/z (M+H)+=221.1.
- A mixture of compound 1b (500 mg, 2.27 mmol), 1-cyclopropyl-1H-pyrazol-4-amine (418 mg, 3.40 mmol), Pd2(dba)3 (145 mg, 0.1589 mmol), X-Phos (151 mg, 0.32 mmol) and Cs2CO3 (1.11 g, 3.40 mmol) in 1,4-dioxane (10 mL) was stirred at 100° C. under N2 for 3 hrs. The mixture was cooled down to RT and concentrated. The residue was purified by column chromatography on silica gel (eluent: DCM:MeOH=30:1) to give the product (366 mg, 53% yield) as an off-white solid. LC-MS (Method 1): tR=2.89 min, m/z (M+H)+=308.0.
- To a solution of compound 1d (2.0 g, 15.7 mmol) in MeOH (30 mL) was added NaBH4 (898 mg, 23.6 mmol) in portions. The mixture was stirred at 0° C.—RT for 2 hrs. The mixture was quenched with acetone (2 mL) and concentrated under reduced pressure. The residue was diluted with DCM (10 mL) and filtered. The filtrate was concentrated to give the crude product (1.23 g, 79% yield) as colorless oil. 1H NMR (400 MHz, DMSO-d6) δ 5.45 (t, J=5.6 Hz, 1H), 3.36 (d, J=6.0 Hz, 2H), 1.22 (s, 6H).
- To a solution of compound 1e (300 mg, 3.03 mmol) and TEA (2.17 g, 21.4 mmol) in DCM (4 mL) was dropwise added MsCl (1.47 g, 12.84 mmol) at 0° C. The mixture was stirred at 0° C.—RT under N2 for 1 hour. The mixture was added water (20 mL volume) and extracted with DCM (30 mL*2). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to give the crude product (600 mg, 100% yield) as yellow oil. 1H NMR (400 MHz, CDCl3) δ 4.12 (s, 2H), 3.12 (s, 3H), 1.45 (s, 6H).
- A mixture of compound 1c (80 mg, 0.261 mmol), compound if (139 mg, 0.783 mmol) and Cs2CO3 (170 mg, 0.522 mmol) in DMF (1.5 mL) was stirred at 100° C. overnight. The mixture was cooled down to RT and filtered. The filtrate was concentrated and purified by prep-HPLC (Method A) to give the product (51.9 mg, 51% yield) as a light yellow solid. LC-MS (Method 1): tR=3.51 min, m/z (M+H)+=389.2. 1H NMR (400 MHz, DMSO-d6) δ 9.28 (s, 1H), 8.30 (s, 1H), 7.90 (s, 1H), 7.69 (d, J=8.4 Hz, 2H), 7.47 (s, 1H), 7.13 (d, J=8.8 Hz, 2H), 4.10 (s, 2H), 3.67-3.62 (m, 1H), 2.21 (s, 3H), 1.44 (s, 6H), 0.98-0.91 (m, 4H).
-
- Compound 2 (12.1 mg) was synthesized in 15% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 1c (65 mg, 0.211 mmol) and 3-cyanocyclobutyl methanesulfonate (129 mg, 0.741 mmol) as starting materials. LC-MS (Method 1): tR=3.75 min, m/z (M+H)+=387.2. 1H NMR (400 MHz, DMSO-d6) δ 9.28 (s, 1H), 8.30 (s, 1H), 7.89 (s, 1H), 7.66 (d, J=8.0 Hz, 2H), 7.48 (s, 1H), 6.99 (d, J=8.8 Hz, 2H), 5.09-5.03 (m, 0.8H), 4.80-4.77 (m, 0.2H), 3.67-3.62 (m, 1H), 3.49-3.43 (m, 2H), 3.15-3.10 (m, 0.2H), 2.99-2.92 (m, 0.4H), 2.88-2.82 (m, 1.4H), 2.43-2.35 (m, 1H), 2.20 (s, 3H), 0.99-0.89 (m, 4H).
-
- Compound 3 (27.8 mg) was synthesized in 39% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 1c (55 mg, 0.179 mmol) and (1-cyanocyclobutyl)methyl methanesulfonate (140 mg, 0.719 mmol) as starting materials. LC-MS (Method 1): tR=3.47 min, m/z (M+H)+=401.2. 1H NMR (400 MHz, DMSO-d6) δ 9.29 (s, 1H), 8.30 (s, 1H), 7.90 (s, 1H), 7.69 (d, J=8.4 Hz, 2H), 7.47 (s, 1H), 7.13 (d, J=8.8 Hz, 2H), 4.34 (s, 2H), 3.67-3.62 (m, 1H), 2.54-2.53 (m, 2H), 2.32-2.25 (m, 2H), 2.21 (s, 3H), 2.14-2.11 (m, 2H), 0.97-0.91 (m, 4H).
-
- Compound 4a (375 mg) was synthesized in 49% yield by utilizing a similar preparative procedure to the first step of Example 1 with compound 1a (523 mg, 3.21 mmol) and (3-fluoro-4-hydroxyphenyl)boronic acid (500 mg, 3.21 mmol) as starting materials. LC-MS (Method 2): tR=1.42 min, m/z (M+H)+=239.0.
- Compound 4b (190 mg) was synthesized in 37% yield by utilizing a similar preparative procedure to the second step of Example 1 with compound 4a (375 mg, 1.576 mmol) and 1-cyclopropyl-1H-pyrazol-4-amine (233 mg, 1.891 mmol) as starting materials. LC-MS (Method 1): tR=1.45 min, m/z (M+H)+=326.1.
- Compound 4 (27.2 mg) was synthesized in 22% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 4b (95 mg, 0.292 mmol) and 2-cyano-2-methylpropyl methanesulfonate (155 mg, 0.877 mmol) as starting materials. LC-MS (Method 1): tR=4.07 min, m/z (M+H)+=407.2. 1H NMR (400 MHz, DMSO-d6) δ 9.33 (s, 1H), 8.33 (s, 1H), 7.90 (s, 1H), 7.62 (dd, J=1.6, 14.0 Hz, 1H), 7.52 (d, J=8.0 Hz, 1H), 7.47 (s, 1H), 7.34 (t, J=8.8 Hz, 1H), 4.19 (s, 2H), 3.67-3.63 (m, 1H), 2.22 (s, 3H), 1.45 (s, 6H), 1.00-0.91 (m, 4H).
-
- Compound 5 (34.5 mg) was synthesized in 28% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 4b (100 mg, 0.307 mmol) and (1-cyanocyclopropyl)methyl methanesulfonate (162 mg, 0.922 mmol) as starting materials. LC-MS (Method 1): tR=3.60 min, m/z (M+H)+=405.1. 1H NMR (400 MHz, DMSO-d6) δ 9.33 (s, 1H), 8.33 (s, 1H), 7.89 (s, 1H), 7.61 (d, J=12.4 Hz, 1H), 7.51 (d, J=8.8 Hz, 1H), 7.47 (s, 1H), 7.26 (t, J=8.4 Hz, 1H), 4.20 (s, 2H), 3.66-3.63 (m, 1H), 2.22 (s, 3H), 1.453-1.40 (m, 2H), 1.22-1.19 (m, 2H), 1.00-0.89 (m, 4H). 19F NMR (376 MHz, DMSO-d6) δ −134.28.
-
- A mixture of compound 4a (300 mg, 1.26 mmol), 1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-amine (318 mg, 1.89 mmol) and TsOH (105 mg, 0.63 mmol) in n-BuOH (2 mL) was stirred at 120° C. for 6 hrs. The mixture was cooled to RT, diluted with DCM (30 mL) and concentrated to give a residue. The residue was diluted with DCM (10 mL) and H2O (10 mL), and extracted with DCM (10 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated to give a crude product (224 mg, 48% yield) as a green solid. LC-MS (Method 2): tR=1.41 min, m/z (M+H)+=370.1.
- Compound 6 (43.7 mg) was synthesized in 45% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 6a (80 mg, 0.217 mmol) and (1-cyanocyclopropyl)methyl methanesulfonate (114 mg, 0.650 mmol) as starting materials. LC-MS (Method 1): tR=3.16 min, m/z (M+H)+=449.2. 1H NMR (400 MHz, DMSO-d6) δ 9.32 (s, 1H), 8.32 (s, 1H), 7.91 (s, 1H), 7.62 (d, J=12.4 Hz, 1H), 7.52 (t, J=6.0 Hz, 2H), 7.26 (t, J=8.8 Hz, 1H), 4.35-4.30 (m, 1H), 4.20 (s, 2H), 3.96-3.93 (m, 2H), 3.48-3.42 (m, 2H), 2.22 (s, 3H), 1.96-1.85 (m, 4H), 1.43-1.40 (m, 2H), 1.22-1.19 (m, 2H). 19F NMR (376 MHz, DMSO-d6) δ −134.29.
-
- Compound 7 (36.8 mg) was synthesized in 60% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 6a (50 mg, 0.14 mmol) and 2-cyano-2-methylpropyl methanesulfonate (72 mg, 0.41 mmol) as starting materials. LC-MS (Method 1): tR=3.531 min, m/z (M+H)+=451.2. 1H NMR (400 MHz, DMSO-d6) δ 9.32 (s, 1H), 8.32 (s, 1H), 7.91 (s, 1H), 7.62 (d, J=12.4 Hz, 1H), 7.53 (t, J=10.4 Hz, 2H), 7.33 (t, J=8.4 Hz, 1H), 4.37-4.29 (m, 1H), 4.19 (s, 2H), 3.94 (d, J=11.2 Hz, 2H), 3.48-3.42 (m, 2H), 2.22 (s, 3H), 1.96-1.87 (m, 4H), 1.45 (s, 6H). 19F NMR (376 MHz, DMSO-d6) δ −134.83.
-
- To a solution of compound 8a (1.0 g, 5.096 mmol) and TEA (1.55 g, 15.288 mmol) in DCM (10 mL) was added cyclopropanecarbonyl chloride (692 mg, 6.625 mmol) dropwise at 0° C. The mixture was stirred at RT for 1 hr. The mixture was diluted with DCM (100 mL) and washed with water (30 mL). The separated organic layers were washed with brine, dried over Na2SO4 and filtered. The filtrate was concentrated and purified by FCC (eluent: DCM:MeOH=50:1) to give the product (1.08 g, 80% yield) as a white solid. LC-MS (Method 2): tR=1.25 min, m/z (M+H)+=265.1.
- To a solution of compound 8b (500 mg, 1.89 mmol) in MeOH (6 mL) was added Pd/C (100 mg, 10% Pd/C wetted with ca. 55% water). The mixture was stirred at RT under H2 (1 atm) overnight. The mixture was filtered. The filtrate was concentrated to give the crude product (472 mg, 100% yield) as brown oil. LC-MS (Method 2): tR=0.76 min, m/z (M+H)+=235.1.
- Compound 8d (479 mg) was synthesized in 87% yield by utilizing a similar preparative procedure to the first step of Example 6 with compound 4a (300 mg, 1.26 mmol) and compound 8c (442 mg, 1.89 mmol) as starting materials. LC-MS (Method 2): tR=1.38 min, m/z (M+H)+=437.2.
- Compound 8 (30.3 mg) was synthesized in 32% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 8d (80 mg, 0.183 mmol) and (1-cyanocyclopropyl)methyl methanesulfonate (96 mg, 0.549 mmol) as starting materials. LC-MS (Method 1): tR=3.73 min, m/z (M+H)+=516.3. 1H NMR (400 MHz, DMSO-d6) δ 9.33 (s, 1H), 8.32 (s, 1H), 7.91 (s, 1H), 7.62 (d, J=12.4 Hz, 1H), 7.52 (t, J=6.8 Hz, 2H), 7.25 (t, J=8.8 Hz, 1H), 4.45-4.32 (m, 3H), 4.20 (s, 2H), 3.28-3.23 (m, 2H), 2.81-2.70 (m, 1H), 2.22 (s, 3H), 2.07-1.98 (m, 2H), 1.87-1.65 (m, 2H), 1.43-1.40 (m, 2H), 1.22-1.19 (m, 2H), 0.72-0.70 (m, 4H). 19F NMR (376 MHz, DMSO-d6) δ −134.24.
-
- A solution of compound 9a (1.91 g, 6.45 mmol) in a solution of HCl(g) in MeOH (2M, 20 mL) and DCM (5 mL) was stirred at RT for 2 hrs. The mixture was concentrated and purified by prep-HPLC to give the product (840 mg, 60% yield) as a white solid. LC-MS (Method 2): tR=0.49 min, m/z (M+H)+=197.3.
- To a solution of 1-methylcyclopropanecarboxylic acid (500 mg, 5.0 mmol) in DCM (20 mL) was added oxalyl dichloride (760 mg, 6.0 mml) followed by 1 drop of DMF at 0° C. After stirring for 2 hrs at RT, the reaction mixture was concentrated to afford 1-methylcyclopropanecarbonyl chloride. To a solution of compound 9b (840 mg, 3.01 mmol) and TEA (1.09 g, 10.83 mmol) in THF (4 mL) was added 1-methylcyclopropanecarbonyl chloride (590 mg, 5.00 mmol). The mixture was stirred at RT for 1 hr. The mixture was diluted with H2O (20 mL) and extracted with DCM (30 mL*2). The combined organic layers were washed with brine, concentrated and purified by FCC (eluent: DCM:MeOH=50:1) to give the product (400 mg, 40% yield) as a yellow solid. LC-MS (Method 2): tR=1.28 min, m/z (M+H)+=279.4.
- To a solution of compound 9c (400 mg, 1.35 mmol) in MeOH (10 mL) was added Pd/C (100 mg, 10% Pd/C wetted with ca. 55% water). The mixture was stirred at 50° C. under H2 (50 psi) for 2 hrs. The mixture was filtered. The filtrate was concentrated to give the crude product (360 mg, 100% yield) as brown oil. LC-MS (Method 2): tR=0.95 min, m/z (M+H)+=249.1.
- Compound 9e (321 mg) was synthesized in 69% yield by utilizing a similar preparative procedure to the first step of Example 6 with compound 4a (247 mg, 1.04 mmol) and compound 9d (442 mg, 1.89 mmol) as starting materials. LC-MS (Method 2): tR=1.40 min, m/z (M+H)+=451.2.
- Compound 9 (19.9 mg) was synthesized in 24% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 9e (72 mg, 0.16 mmol) and (1-cyanocyclopropyl)methyl methanesulfonate (84 mg, 0.48 mmol) as starting materials. LC-MS (Method 1): tR=3.65 min, m/z (M+H)+=530.3. 1H NMR (400 MHz, DMSO-d6) δ 9.35 (s, 1H), 8.32 (s, 1H), 7.93 (s, 1H), 7.62 (d, J=12.0 Hz, 1H), 7.53-7.50 (m, 2H), 7.25 (t, J=8.4 Hz, 1H), 4.37-4.32 (m, 3H), 4.20 (s, 2H), 3.08-2.88 (m, 2H), 2.22 (s, 3H), 2.05-2.02 (m, 2H), 1.80-1.71 (m, 2H), 1.43-1.40 (m, 2H), 1.24 (s, 3H), 1.22-1.19 (m, 2H), 0.82-0.79 (m, 2H), 0.56-0.53 (m, 2H). 19F NMR (376 MHz, DMSO-d6) δ −134.27.
-
- A mixture of compound 10a (510 mg, 2.45 mmol), (1-cyanocyclopropyl)methyl methanesulfonate (472 mg, 2.70 mmol) and Cs2CO3 (1.60 g, 4.93 mmol) in 16 mL of acetonitrile was stirred at 100° C. for 2 hrs. After cooling down to RT, the mixture was concentrated and the residue was purified by chromatography on silica gel (elute: PE:EtOAc from 20:1 to 10:1) to afford the title product as colorless oil (555 mg, 79% yield). 1H NMR (400 MHz, DMSO-d6) δ 7.58-7.51 (m, 2H), 4.13 (s, 2H), 1.36-1.32 (m, 2H), 1.11-1.08 (m, 2H).
- A mixture of compound 10b (555 mg, 1.93 mmol), bis(pinacolato)diboron (637 mg, 2.51 mmol), Pd(dppf)Cl2 (141 mg, 0.193 mmol) and KOAc (378 mg, 3.86 mmol) in 14 mL of 1,4-dixoane was stirred at 80° C. for 16 hrs under N2 atmosphere. After cooling down to RT, the mixture was filtered and the filtrate was concentrated to afford the title product as a yellow solid (645 mg, crude, 100% yield). LC-MS (Method 1): tR=1.88 min, m/z (M+18)+=353.2.
- Compound 10d (490 mg) was synthesized in 76% yield by utilizing a similar preparative procedure to the first step of Example 1 with compound 10c (645 mg, 3.21 mmol) and 2,4-dichloro-5-methylpyrimidine (314 mg, 1.93 mmol) as starting materials. LC-MS (Method 2): tR=1.63 min, m/z (M+H)+=336.1.
- Compound 10 (54 mg) was synthesized in 21% yield by utilizing a similar preparative procedure to the second step of Example 1 with compound 10d (200 mg, 0.597 mmol) and 1-cyclopropyl-1H-pyrazol-4-amine (110 mg, 0.895 mmol) as starting materials. LC-MS (Method 1): tR=2.33 min, m/z (M+H)+=423.1. 1H NMR (400 MHz, DMSO-d6) δ 9.38 (s, 1H), 8.37 (s, 1H), 7.89 (s, 1H), 7.52-7.47 (m, 3H), 4.24 (s, 2H), 3.67-3.62 (m, 1H), 2.21 (s, 3H), 1.38-1.35 (m, 2H), 1.16-1.13 (m, 2H), 1.00-0.89 (m, 4H).
-
- Compound 11a (1.0 g) was synthesized in 100% yield by utilizing a similar preparative procedure to the first step of Example 1 with compound 1a (1.36 g, 8.36 mmol) and 2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.0 g, 4.18 mmol) as starting materials. LC-MS (Method 2): tR=1.42 min, m/z (M+H)+=240.0.
- A mixture of 11a (200 mg, 0.84 mmol), 1-cyclopropyl-1H-pyrazol-4-amine (204 mg, 1.66 mmol) and DIPEA (322 mg, 2.50 mmol) in NMP (0.5 mL) was stirred at 170° C. for 1 hour under microwave. The mixture was diluted with water (5 mL) and extracted with EtOAc (15 mL*3). The separated organic layer was washed with brine (20 mL) and concentrated. The residue was purified by FCC (PE:EtOAc=2:1) to afford the title compound (130 mg, 48% yield) as yellow solid. 1H NMR (400 MHz, CDCl3-d6) δ 8.69 (s, 1H), 8.32 (s, 1H), 7.94 (dd, J=2.4, 8.4 Hz, 1H), 7.88 (s, 1H), 7.48 (s, 1H), 7.46 (d, J=8.4 Hz, 1H), 6.78 (s, 1H), 3.59-3.55 (m, 1H), 2.27 (s, 3H), 1.13-1.12 (m, 2H), 1.00-0.99 (m, 2H).
- To a solution of 1-(hydroxymethyl)cyclopropanecarbonitrile (35 mg, 0.36 mmol) in THF (1 mL) was added NaH (11 mg, 0.28 mmol, 60% in mineral oil) at 0° C. After stirring for 2 hrs at 0° C.—RT, compound 11b (60 mg, 0.18 mmol) was added to the reaction mixture. Then the reaction was stirred for 8 hrs at 80° C. After cooling to RT, the mixture was diluted with water (10 mL) and extracted with EtOAc (20 mL*3). The separated organic layer was concentrated. The residue was purified by prep-HPLC to afford title compound (10 mg, 14% yield) as yellow solid. LC-MS (Method 1): tR=3.60 min, m/z (M+H)+=388.2; 1H NMR (400 MHz, CDCl3) δ 8.43 (s, 1H), 8.28 (s, 1H), 7.95 (dd, J=2.4, 8.8 Hz, 1H), 7.89 (s, 1H), 7.50 (s, 1H), 6.96 (d, J=8.4 Hz, 1H), 6.75 (s, 1H), 4.40 (s, 2H), 3.59-3.56 (m, 1H), 2.28 (s, 3H), 1.43-1.40 (m, 2H), 1.18-1.11 (m, 4H), 1.02-0.99 (m, 2H).
-
- A mixture of 4a (500 mg, 2.1 mmol), 1-methyl-1H-pyrazol-4-amine (295 mg, 3.0 mmol) and conc. H2SO4 (1 drop) in n-BuOH (3 mL) was stirred at 120° C. for 2 hours. The reaction mixture was concentrated and purified by silica gel column (DCM:MeOH=20:1) to give the product (357 mg, 57% yield) as a brown solid. LC-MS (Method 3): tR=1.28 min, m/z (M+H)+=300.1.
- A mixture of 12a (100 mg, 0.34 mmol), K2CO3 (94 mg, 0.68 mmol) and BuOH (26 mg, 0.34 mmol) in acrylonitrile (1.8 g, 34 mmol) was stirred at 120° C. under microwave for 6 hours. The mixture was cooled to RT and concentrated. The residue was purified by Prep-HPLC to afford the title product (4.3 mg, 4% yield) as a yellow solid. LC-MS (Method 1): tR=3.37 min, m/z (M+H)+=353.1. 1H NMR (400 MHz, DMSO-d6) δ 9.33 (s, 1H), 8.32 (s, 1H), 7.82 (s, 1H), 7.60 (dd, J=1.2, 12.8 Hz, 1H), 7.51 (d, J=8.0 Hz, 1H), 7.48 (s, 1H), 7.33 (t, J=8.8 Hz, 1H), 4.36 (t, J=6.0 Hz, 2H), 3.78 (s, 3H), 3.09 (t, J=5.6 Hz, 2H), 2.21 (s, 3H).
-
- A solution of compound 8a (1.0 g, 5.096 mmol) and TEA (1.55 g, 15.288 mmol) in DCM (10 mL) was stirred at 0° C. for 10 minutes. Then the mixture was added acetic anhydride (676 mg, 6.625 mmol). The mixture was stirred at RT for 4 hrs. The mixture was diluted with H2O (50 mL) and extracted with DCM (50 mL*3). The combined organic layers were washed with brine, concentrated and purified by FCC (eluent: DCM MeOH=30:1) to give the product (963 g, 79% yield) as a white solid. LC-MS (Method 2): tR=1.06 min, m/z (M+H)+=239.1.
- To a solution of compound 13a (460 mg, 1.93 mmol) in MeOH (6 mL) was added Pd/C (100 mg, 10% Pd/C wetted with ca. 55% water). The mixture was stirred at RT under H2 (1 atm) overnight. The mixture was filtered. The filtrate was concentrated to give the crude product (432 mg, 100% yield) as brown oil. 1H NMR (400 MHz, CDCl3) δ 7.16 (s, 1H), 7.02 (s, 1H), 4.70 (d, J=13.2 Hz, 1H), 4.22-4.18 (m, 1H), 3.92 (d, J=14.0 Hz, 1H), 3.24-3.17 (m, 1H), 2.76-2.71 (m, 1H), 2.12 (s, 3H), 1.97-1.83 (m, 4H).
- Compound 13c (479 mg) was synthesized in 87% yield by utilizing a similar preparative procedure to the first step of Example 6 with compound 4a (350 mg, 1.49 mmol) and compound 13b (402 mg, 1.93 mmol) as starting materials. LC-MS (Method 2): tR=1.17 min, m/z (M+H)+=411.0.
- Compound 13 (19.4 mg) was synthesized in 20% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 13c (80 mg, 0.195 mmol) and (1-cyanocyclopropyl)methyl methanesulfonate (102 mg, 0.585 mmol) as starting materials. LC-MS (Method 1): tR=3.39 min, m/z (M+H)+=490.3. 1H NMR (400 MHz, DMSO-d6) δ 9.33 (s, 1H), 8.32 (s, 1H), 7.91 (s, 1H), 7.62 (d, J=12.4 Hz, 1H), 7.52 (t, J=6.4 Hz, 2H), 7.25 (t, J=8.8 Hz, 1H), 4.45-4.31 (m, 2H), 4.20 (s, 2H), 3.90 (d, J=13.6 Hz, 1H), 3.18 (t, J=12.4 Hz, 1H), 2.70 (t, J=12.8 Hz, 1H), 2.22 (s, 3H), 2.03-1.97 (m, 5H), 1.89-1.79 (m, 1H), 1.73-1.63 (m, 1H), 1.22-1.19 (m, 2H), 0.72-0.70 (m, 2H). 19F NMR (376 MHz, DMSO-d6) δ −134.27.
-
- A mixture of compound 11a (380 mg, 1.58 mmol), 1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-amine (530 mg, 3.17 mmol) and DIPEA (611 mg, 4.74 mmol) in NMP (1 mL) was stirred at 170° C. for 3 hrs in microwave. After cooling down to RT, the mixture was diluted with water (3 mL) and extracted with EtOAc (10 mL*3). The separated organic layer was washed with brine (5 mL*3) and concentrated. The residue was purified by FCC (PE/EtOAc=2/1) to afford the title compound (330 mg, 57% yield) as a yellow solid. LC-MS (Method 2): tR=1.49 min, m/z (M+H)+=371.1.
- To a solution of 1-(hydroxymethyl)cyclopropanecarbonitrile (37 mg, 0.38 mmol) in THF (1 mL) was added NaH (11 mg, 0.26 mmol, 60% in mineral oil) at RT. After stirring for 2 hrs at RT, compound 14a (70 mg, 0.19 mmol) was added to the reaction. The mixture was stirred for 18 hrs at 80° C. After cooling down to RT, the mixture was diluted with water (1 mL) and extracted with EtOAc (5 mL*3). The combined organic layers were concentrated and the residue was purified by prep-HPLC (Method A) to afford the title compound (17.5 mg, 22% yield) as a yellow solid. LC-MS (Method 1): tR=3.45 min, m/z (M+H)+=432.2; H NMR (400 MHz, CDCl3) δ 8.43 (s, 1H), 8.28 (s, 1H), 7.96 (dd, J=2.4, 8.8 Hz 1H), 7.91 (s, 1H), 7.55 (s, 1H), 6.96 (d, J=8.4 Hz, 1H), 6.78 (m, 1H), 4.40 (s, 2H), 4.33-4.29 (m, 1H), 4.13-4.10 (m, 2H), 3.58-3.51 (m, 2H), 2.29 (s, 3H), 2.12-2.07 (m, 4H), 1.43-1.40 (m, 2H), 1.19-1.16 (m, 2H).
-
- Compound 15a (200 mg) was synthesized in 25% yield by utilizing a similar preparative procedure to the second step of Example 4 with compound 1b (500 mg, 2.26 mmol) and 1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-amine (377 mg, 2.26 mmol) as starting materials. LC-MS (Method 2): tR=1.38 min, m/z (M+H)+=352.1.
- A mixture of compound 15a (50 mg, 0.14 mmol), compound if (50 mg, 0.28 mmol), Cs2CO3 (93 mg, 0.28 mmol) in DMF (1 mL) was stirred at 120° C. for 2 hours. The mixture was cooled down to RT, diluted with H2O (10 mL) and extracted with EtOAc (10 mL). The separated organic layer was concentrated. The residue was purified by prep-HPLC (Method A) to give the title compound (30 mg, 50% yield) as white solid. LC-MS (Method 1): tR=3.75 min, m/z (M+H)+=433.3. 1H NMR (400 MHz, DMSO-d6) δ 9.28 (s, 1H), 8.30 (s, 1H), 7.91 (s, 1H), 7.69 (d, J=8.4 Hz, 2H), 7.55 (s, 1H), 7.13 (d, J=8.8 Hz, 2H), 4.34-4.31 (m, 1H), 4.10 (s, 2H), 3.96-3.93 (m, 2H), 3.48-3.38 (m, 2H), 2.21 (s, 3H), 1.96-1.87 (m, 4H), 1.44 (s, 6H).
-
- Compound 16b (300 mg) was synthesized in 89% yield by utilizing a similar preparative procedure to the fourth step of Example 1 with compound 16a (200 mg, 1.77 mmol) as starting materials. 1H NMR (400 MHz, CDCl3) δ 4.68-4.63 (m, 1H), 3.11 (s, 3H), 1.43 (d, J=4.8 Hz, 3H), 1.41-1.39 (m, 6H).
- Compound 16 (4 mg) was synthesized in 6% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 16b (53 mg, 0.28 mmol) and compound 15a (50 mg, 0.14 mmol) as starting materials. LC-MS (Method 1): tR=2.93 min, m/z (M+H)+=447.2. 1H NMR (400 MHz, CD3OD) δ 8.27 (s, 1H), 8.05 (s, 1H), 7.70 (d, J=8.8 Hz, 2H), 7.64 (s, 1H), 7.13 (d, J=8.8 Hz, 2H), 4.53-4.48 (m, 1H), 4.40-4.32 (m, 1H), 4.09-4.06 (m, 2H), 3.63-3.55 (m, 2H), 2.28 (s, 3H), 2.09-2.04 (m, 4H), 1.51-1.45 (m, 9H).
-
- Compound 17a (200 mg) was synthesized in 40% yield by utilizing a similar preparative procedure to second step of Example 1 with compound 1b (300 mg, 1.36 mmol) and 1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-amine (294 mg, 1.631 mmol) as starting materials. LC-MS (Method 2): tR=1.19 min, m/z (M+H)+=365.2.
- Compound 17 (6.9 mg) was synthesized in 11% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 17a (50 mg, 0.137 mmol) and 2-cyanopropan-2-yl methanesulfonate (49 mg, 0.277 mmol) as starting materials. LC-MS (Method 1): tR=3.48 min, m/z (M+H)+=446.2. 1H NMR (400 MHz, DMSO-d6) δ 9.27 (s, 1H), 8.29 (s, 1H), 7.88 (s, 1H), 7.69 (d, J=8.4 Hz, 2H), 7.54 (s, 1H), 7.12 (d, J=8.8 Hz, 2H), 4.09 (s, 2H), 4.00-4.07 (m, 1H), 2.83 (d, J=11.6 Hz, 2H), 2.51 (s, 3H), 2.50 (s, 3H), 2.18 (t, J=10.4 Hz, 2H), 1.84-2.05 (m, 4H), 1.44 (s, 6H).
-
- Compound 18a (500 mg) was synthesized in 86% yield by utilizing a similar preparative procedure to the second step of Example 1 with compound 4a (364 mg, 1.53 mmol) and 1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-amine (330 mg, 1.83 mmol) as starting materials. LC-MS (Method 2): tR=1.36 min, m/z (M+H)+=383.2.
- Compound 18 (12.7 mg) was synthesized in 13% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 18a (80 mg, 0.209 mmol) and 2-cyano-2-methylpropyl methanesulfonate (56 mg, 0.314 mmol) as starting materials. LC-MS (Method 1): tR=3.80 min, m/z (M+H)+=464.2. 1H NMR (400 MHz, DMSO-d6) δ 9.31 (s, 1H), 8.32 (s, 1H), 7.89 (s, 1H), 7.62 (d, J=13.6 Hz, 1H), 7.53 (d, J=4.8 Hz, 2H), 7.33 (t, J=8.4 Hz, 1H), 4.19 (s, 2H), 4.05-4.03 (m, 1H), 2.84 (d, J=11.6 Hz, 2H), 2.22 (s, 3H), 2.20 (s, 3H), 2.05 (t, J=10.8 Hz, 2H), 1.97-1.87 (m, 4H), 1.45 (s, 6H). 19F NMR (400 MHz, DMSO-d6) δ −134.84.
-
- Compound 19a (390 mg) was synthesized in 68% yield by utilizing a similar preparative procedure to the second step of Example 1 with compound 4a (400 mg, 1.68 mmol) and 1-(2-methoxyethyl)-1H-pyrazol-4-amine (284 mg, 2.02 mmol) as starting materials. LC-MS (Method 2): tR=1.40 min, m/z (M+H)+=344.2.
- Compound 19 (24.1 mg) was synthesized in 22% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 19a (87 mg, 0.25 mmol) and 2-cyano-2-methylpropyl methanesulfonate (67 mg, 0.38 mmol) as starting materials. LC-MS (Method 1): tR=3.31 min, m/z (M+H)+=425.2. 1H NMR (400 MHz, DMSO-d6) δ 9.33 (s, 1H), 8.33 (s, 1H), 7.88 (s, 1H), 7.61 (dd, J=2.0, 12.4 Hz, 1H), 7.52-7.50 (m, 2H), 7.34 (t, J=8.8 Hz, 1H), 4.19 (t, J=4.8 Hz, 4H), 3.65 (t, J=5.2 Hz, 2H), 3.23 (s, 3H), 2.23 (s, 3H), 1.45 (s, 6H).
-
- Compound 20 (16.0 mg) was synthesized in 17% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 18a (80 mg, 0.209 mmol) and (1-cyanocyclopropyl)methyl methanesulfonate (55 mg, 0.314 mmol) as starting materials. LC-MS (Method 1): tR=2.87 min, m/z (M+H)+=462.2. 1H NMR (400 MHz, DMSO-d6) δ 9.30 (s, 1H), 8.32 (s, 1H), 7.89 (s, 1H), 7.62 (d, J=12.0 Hz, 1H), 7.52-7.50 (d, J=9.6 Hz, 2H), 7.25 (t, J=8.8 Hz, 1H), 4.20 (s, 2H), 4.06-4.00 (m, 1H), 2.84 (d, J=11.2 Hz, 2H), 2.22 (s, 3H), 2.19 (s, 3H), 2.04 (t, J=11.2 Hz, 2H), 1.97-1.87 (m, 4H), 1.43-1.40 (m, 2H), 1.22-1.19 (m, 2H). 19F NMR (400 MHz, DMSO-d6) δ −134.30.
-
- Compound 21 (17.6 mg) was synthesized in 16% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 19a (87 mg, 0.25 mmol) and (1-cyanocyclopropyl)methyl methanesulfonate (67 mg, 0.38 mmol) as starting materials. LC-MS (Method 1): tR=3.61 min, m/z (M+H)+=423.2. 1H NMR (400 MHz, DMSO-d6) δ 9.33 (s, 1H), 8.33 (s, 1H), 7.88 (s, 1H), 7.61 (d, J=12.0 Hz, 1H), 7.51 (d, J=4.8 Hz, 2H), 7.26 (t, J=8.8 Hz, 1H), 4.19 (t, J=6.4 Hz, 4H), 3.65 (t, J=5.2 Hz, 2H), 3.23 (s, 3H), 2.22 (s, 3H), 1.43-1.40 (m, 2H), 1.22-1.19 (m, 2H).
-
- Compound 22b (540 mg) was synthesized in 36% yield by utilizing a similar preparative procedure to the first step of Example 10 with compound 22a (1.05 g, 5.49 mmol) and (1-cyanocyclopropyl)methyl methanesulfonate (1.44 g, 8.25 mmol) as starting materials. 1H NMR (400 MHz, CDCl3) δ 7.27-7.24 (m, 1H), 7.19 (d, J=8.4 Hz, 1H), 6.88 (d, J=8.4 Hz, 1H), 4.02 (s, 2H), 1.42-1.39 (m, 2H), 1.14-1.10 (m, 2H).
- Compound 22c (crude) was synthesized by utilizing a similar preparative procedure to the second step of Example 10 with compound 22b (440 mg, 1.63 mmol) and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (455 mg, 1.79 mmol) as starting materials. The crude product was used for next step without further purification.
- Compound 22d (358 mg) was synthesized in 68% yield by utilizing a similar preparative procedure to the third step of Example 10 with compound 22c (517 mg, 1.63 mmol) and 2,4-dichloro-5-fluoropyrimidine (327 mg, 1.96 mmol) as starting materials. LC-MS (Method 2): tR=1.67 min, m/z (M+H)+=322.0.
- Compound 22 (7.8 mg) was synthesized in 7% yield by utilizing a similar preparative procedure to the second step of Example 1 with compound 22d (80 mg, 0.25 mmol) and 1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-amine (50 mg, 0.299 mmol) as starting materials. LC-MS (Method 1): tR=3.58 min, m/z (M+H)+=453.2. 1H NMR (400 MHz, DMSO-d6) δ 9.55 (s, 1H), 8.54 (d, J=3.6 Hz, 1H), 7.94-7.86 (m, 3H), 7.57 (s, 1H), 7.33 (t, J=8.8 Hz, 1H), 4.37-4.33 (m, 1H), 4.24 (s, 2H), 3.96 (d, J=10.4 Hz, 2H), 3.46 (t, J=10.8 Hz, 2H), 1.96-1.90 (m, 4H), 1.43-1.42 (m, 2H), 1.23-1.21 (m, 2H). 19F NMR (376 MHz, DMSO-d6) δ −133.62, −153.22.
-
- A mixture of compound 22c (449 mg, 1.415 mmol), 2,4,5-trichloropyrimidine (306 mg, 1.698 mmol), Pd(PPh3)4 (164 mg, 0.1415 mmol) and Na2CO3 (300 mg, 2.83 mmol) in 1,4-dioxane/H2O (6 mL/1.5 mL) was stirred at 90° C. under N2 for 2.5 hrs. The mixture was cooled down to RT and filtered. The filtrate was concentrated and the residue was purified by column chromatography on silica gel (eluent: PE:EtOAc=6:1) to give the product (317 mg, 67% yield) as a yellow solid. LC-MS (Method 2): tR=1.73 min, m/z (M+H)+=338.1.
- A mixture of compound 23a (80 mg, 0.237 mmol), 1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-amine (48 mg, 0.285 mmol), Pd2(dba)3 (22 mg, 0.0237 mmol), X-Phos (23 mg, 0.0474 mmol) and Cs2CO3 (116 mg, 0.356 mmol) in 1,4-dioxane (1 mL) was stirred at 100° C. under N2 overnight. The mixture was cooled down to RT and filtered. The filtrate was concentrated and the residue was purified by prep-HPLC (Method A) to give the product (5.9 mg, 5% yield) as a yellow solid. LC-MS (Method 1): tR=2.77 min, m/z (M+H)+=469.1. 1H NMR (400 MHz, DMSO-d6) δ 9.76 (s, 1H), 8.52 (s, 1H), 7.91 (s, 1H), 7.78-7.70 (m, 2H), 7.56 (s, 1H), 7.29 (t, J=8.8 Hz, 1H), 4.38-4.31 (m, 1H), 4.22 (s, 2H), 3.94 (d, J=11.6 Hz, 2H), 3.48-3.42 (m, 2H), 1.96-1.84 (m, 4H), 1.43-1.40 (m, 2H), 1.22-1.19 (m, 2H). 19F NMR (376 MHz, DMSO-d6) δ −134.17.
-
- Compound 24 (10 mg) was synthesized in 10% yield by utilizing a similar preparative procedure to the second step of Example 1 with compound 22d (80 mg, 0.25 mmol) and 1-cyclopropyl-1H-pyrazol-4-amine (36.9 mg, 0.3 mmol) as starting materials. LC-MS (Method 1): tR=3.84 min, m/z (M+H)+=409.2; 1H NMR (400 MHz, CD3OD) δ 8.37 (d, J=4.4 Hz, 1H), 7.99-7.93 (m, 3H), 7.59 (s, 1H), 7.24 (t, J=8.4 Hz, 1H), 4.19 (s, 2H), 3.65-3.60 (m, 1H), 1.43 (dd, J=5.2, 7.2 Hz, 2H), 1.25 (dd, J=6.0, 7.6 Hz, 2H), 1.09-1.04 (m, 4H).
-
- To a mixture of 4-bromo-2-fluorophenol (482 mg, 2.524 mmol) and compound if (670 mg, 3.785 mmol) in DMF (10 mL) was added Cs2CO3 (1.645 g, 5.046 mmol). The mixture was stirred at 120° C. for 16 hrs. The mixture was cooled down to RT, filtered and the filtrate was concentrated to afford the residue. The residue was washed with PE/EtOAc/DCM (10 mL, v:v:v=1:1:1). The filtrate was concentrated to afford the product (800 mg, 99.6% yield) as brown oil. 1H NMR (400 MHz, CDCl3) δ 7.28-7.21 (m, 1H), 7.21-7.18 (m, 1H), 6.87 (t, J=8.8 Hz, 1H), 3.94 (s, 2H), 1.49 (s, 6H).
- A mixture of compound 25b (400 mg, 1.471 mmol) and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (411 mg, 1.618 mmol) in 1,4-dioxane (10 mL) was added Pd(dppf)Cl2 (215 mg, 0.294 mmol) and KOAc (288 mg, 2.939 mmol) under N2. The mixture was stirred at 80° C. for 3 hrs. The reaction mixture was used to the next step without purification.
- To the reaction mixture of step 2 was added 2,4-dichloro-5-fluoropyrimidine (184 mg, 1.102 mmol), Na2CO3 (234 mg, 2.21 mmol), H2O (1 mL), 1,4-dioxane (3 mL) and Pd(dppf)Cl2 (81 mg, 0.11 mmol) under N2. The mixture was stirred at 80° C. for 1 hour. The mixture was cooled down to RT, filtered and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (PE:EtOAc=10:1) to afford the product (160 mg, 34% yield for three steps) as a white solid. LC-MS (Method 2): tR=1.51 min, m/z (M+H)+=323.9.
- To a mixture of compound 25d (70 mg, 0.22 mmol), 1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-amine (51 mg, 0.31 mmol), Xant-phos (21 mg, 0.04 mmol) in 1,4-dioxane (3 mL) was added Cs2CO3 (141 mg, 0.43 mmol) and Pd2(dba)3 (20 mg, 0.02 mmol) under N2. The mixture was stirred at 110° C. for 16 hrs. The mixture was filtered and the filtrate was concentrated. The crude product was purified by prep-HPLC (Method A) to afford the product (10.2 mg, 10.4% yield) as a yellow solid. LC-MS (Method 1): tR=3.22 min, m/z (M+H)+=455.2. 1H NMR (400 MHz, DMSO-d6) δ 9.60 (s, 1H), 8.58 (d, J=5.2 Hz, 1H), 7.98-7.91 (m, 3H), 7.60 (s, 1H), 7.44 (t, J=12.0 Hz, 1H), 4.43-4.36 (m, 1H), 4.25 (s, 2H), 3.99 (d, J=14.8 Hz, 2H), 3.53-3.37 (m, 2H), 2.01-1.92 (m, 4H), 1.43 (s, 6H).
-
- Compound 26a (0.65 g) was synthesized in 47% yield by utilizing a similar preparative procedure to the first step of Example 1 with compound 25c (1.29 g, 4.04 mmol) and 2,4,5-trichloropyrimidine (728 mg, 4.04 mmol) as starting materials. LC-MS (Method 2): tR=1.76 min, m/z (M+H)+=340.0.
- Compound 26 (4.1 mg) was synthesized in 3% yield by utilizing a similar preparative procedure to the second step of Example 1 with compound 26a (90 mg, 0.26 mmol) and 1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-amine (53 mg, 0.32 mmol) as starting materials. The title compound was purified by prep-HPLC (method B). LC-MS (Method 1): tR=3.99 min, m/z (M+H)+=471.2. 1H NMR (400 MHz, DMSO-d6) δ 9.78 (s, 1H), 8.53 (s, 1H), 7.92 (s, 1H), 7.91-7.73 (m, 2H), 7.57 (s, 1H), 7.40-7.35 (m, 1H), 4.38-4.32 (m, 1H), 4.42 (s, 2H), 3.95 (d, J=10.4 Hz, 2H), 3.48-3.42 (m, 2H), 1.98-1.86 (m, 4H), 1.45 (s, 6H).
-
- Compound 27 (10 mg) was synthesized in 10% yield by utilizing a similar preparative procedure to the second step of Example 1 with compound 23a (80 mg, 0.24 mmol) and 1-cyclopropyl-1H-pyrazol-4-amine (35 mg, 0.29 mmol) as starting materials. LC-MS (Method 1): tR=2.87 min, m/z (M+H)+=425.1; 1H NMR (400 MHz, CD3OD) δ 8.36 (s, 1H), 7.87 (s, 1H), 7.63 (t, J=7.2 Hz, 2H), 7.47 (s, 1H), 7.12 (t, J=8.4 Hz, 1H), 4.07 (s, 2H), 3.52-3.48 (m, 1H), 1.32 (dd, J=5.2, 7.6 Hz, 2H), 1.13 (dd, J=5.2, 7.6 Hz, 2H), 0.96-0.89 (m, 4H).
-
- Compound 28 (15.1 mg) was synthesized in 25% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 13c (50 mg, 0.22 mmol) and compound if (65 mg, 0.366 mmol) as starting materials. LC-MS (Method 1): tR=3.35 min, m/z (M+H)+=492.2. 1H NMR (400 MHz, DMSO-d6) δ 9.35 (s, 1H), 8.32 (s, 1H), 7.91 (s, 1H), 7.62 (d, J=12.4 Hz, 1H), 7.54-7.52 (m, 2H), 7.33 (t, J=8.4 Hz, 1H), 4.45-4.33 (m, 2H), 4.19 (s, 2H), 3.89 (d, J=14.0 Hz, 1H), 3.21-3.15 (m, 1H), 2.69 (t, J=12.8 Hz, 1H), 2.22 (s, 3H), 2.03 (s, 3H), 2.00-1.94 (m, 2H) 1.89-1.79 (m, 1H), 1.73-1.62 (m, 1H), 1.45 (s, 6H). 19F NMR (376 MHz, DMSO-d6) δ −134.83.
-
- Compound 29b (1.1 g) was synthesized in 85% yield by utilizing a similar preparative procedure to the first step of Example 1 with compound 29a (1.0 g, 5.46 mmol) and (4-hydroxyphenyl)boronic acid (0.68 g, 4.92 mmol) as starting materials. 1H NMR (400 MHz, DMSO-d6) δ 8.83 (s, 1H), 8.14 (s, 1H), 7.88 (d, J=8.8 Hz, 2H), 7.26 (d, J=8.8 Hz, 2H).
- Compound 29c (380 mg) was synthesized in 80% yield by utilizing a similar preparative procedure to the second step of Example 1 with compound 29b (300 mg, 1.24 mmol) and 1-methyl-1H-pyrazol-4-amine (144 mg, 1.48 mmol) as starting materials. LC-MS (Method 2): tR=1.56 min, m/z (M+H)+=302.0.
- Compound 29 (12.9 mg) was synthesized in 10% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 29c (100 mg, 0.33 mmol) and compound if (117 mg, 0.66 mmol) as starting materials. LC-MS (Method 1): tR=3.85 min, m/z (M+H)+=383.2. 1H NMR (400 MHz, CDCl3) δ 8.37 (s, 1H), 7.89 (d, J=8.7 Hz, 2H), 7.81 (s, 1H), 7.50 (s, 1H), 7.03 (d, J=8.8 Hz, 2H), 3.98 (s, 2H), 3.89 (s, 3H), 1.56 (s, 6H).
-
- Compound 30b (160 mg) was synthesized in 30% yield by utilizing a similar preparative procedure to the second step of Example 1 with compound 4a (400 mg, 1.68 mmol) and compound 30a (280 mg, 2.02 mmol) as starting materials. LC-MS (Method 2): tR=1.25 min, m/z (M+H)+=325.1.
- Compound 30 (4.7 mg) was synthesized in 6% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 30b (70 mg, 0.22 mmol) and compound if (57 mg, 0.32 mmol) as starting materials. LC-MS (Method 1): tR=3.61 min, m/z (M+H)+=406.2. 1H NMR (400 MHz, CDCl3) δ 8.30 (s, 1H), 8.10 (s, 1H), 7.56 (s, 1H), 7.46-7.39 (m, 2H), 7.09 (t, J=8.0 Hz, 1H), 6.90 (s, 1H), 5.04 (s, 2H), 4.05 (s, 2H), 2.28 (s, 3H), 1.54 (s, 6H).
-
- Compound 31 (95 mg) was synthesized in 100% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 30b (70 mg, 0.22 mmol) and (1-cyanocyclopropyl)methyl methanesulfonate (57 mg, 0.32 mmol) as starting materials. LC-MS (Method 1): tR=2.99 min, m/z (M+H)+=404.2. 1H NMR (400 MHz, CDCl3) δ 8.34 (s, 1H), 8.15 (s, 1H), 7.73 (s, 1H), 7.58-7.50 (m, 2H), 7.25 (t, J=10.8 Hz, 1H), 5.31 (s, 2H), 4.20 (s, 2H), 2.31 (s, 3H), 1.48-1.44 (m, 2H), 1.29-1.25 (m, 2H).
-
- A solution of compound 29b (200 mg, 0.84 mmol), 1-cyclopropyl-1H-pyrazol-4-amine (155 mg, 1.26 mmol) and TsOH (15 mg, 0.084 mmol) in 1,4-dioxane (2 mL) was stirred at 100° C. overnight. The mixture was concentrated in vacuo. The residue was purified by flash chromatography (PE:EtOAc=2:1) to give the compound (120 mg, 44% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.00 (s, 1H), 9.66 (s, 1H), 8.46 (s, 1H), 7.90 (s, 1H), 7.75 (d, J=8.8 Hz, 2H), 7.50 (s, 1H), 6.90 (d, J=8.8 Hz, 2H), 3.68-3.66 (m, 1H), 0.98-0.92 (m, 4H).
- Compound 32 (49.6 mg) was synthesized in 33% yield by utilizing a similar preparative procedure to the final step of Example 1 with compound 32a (120 mg, 0.37 mmol) and 2-cyano-2-methylpropyl methanesulfonate (131 mg, 0.74 mmol) as starting materials. LC-MS (Method 1): tR=3.74 min, m/z (M+H)+=409.2. 1H NMR (400 MHz, DMSO-d6) δ 9.72 (s, 1H), 8.50 (s, 1H), 7.90-7.84 (m, 3H), 7.50 (s, 1H), 7.16 (d, J=8.8 Hz, 2H), 4.11 (s, 2H), 3.69-3.65 (m, 1H), 1.44 (s, 6H), 1.01-0.90 (m, 4H).
-
- A mixture of 33a (5.0 g, 17.24 mmol) and t-BuONa (2.15 g, 22.41 mmol) in DMF (6 mL) was stirred at 0° C. for 10 min. CH3I (2.94 g, 20.69 mmol) was added dropwise to the reaction mixture. The mixture was stirred at 100° C. for 2 hrs. Another t-BuONa (496 mg, 5.17 mmol) and CH3I (489 mg, 3.45 mmol) were added. The mixture was stirred at RT for another 2 hrs. The mixture was diluted with H2O (30 mL), extracted with EtOAc (50 mL*3). The separated organic layers were washed with brine and concentrated to give the crude product (5.22 g, 99% yield) as brown oil. 1H NMR (400 MHz, CDCl3) δ 7.28-7.24 (m, 2H), 7.12-7.08 (m, 1H), 3.17 (s, 3H), 1.40 (s, 9H). 19F NMR (376 MHz, CDCl3) δ −117.58.
- A solution of 33b (5.22 g, 17.17 mmol) in a solution of HCl(g) in EtOAc (35 mL, 2 M) was stirred at RT for 2 hrs. The mixture was concentrated. The residue was diluted with NH3(g) in MeOH (3 M, 15 mL). The mixture was stirred at RT for 10 mins and concentrated. The residue was diluted with DCM (20 mL) and filtered. The filtrate was concentrated to give the crude product (3.37 g, 96% yield) as a brown solid. 1H NMR (400 MHz, CDCl3) δ 7.13-7.08 (m, 2H), 6.53 (t, J=8.0 Hz, 1H), 3.92 (s, 1H), 2.85 (s, 3H). 19F NMR (376 MHz, CDCl3) δ −134.45.
- A mixture of 33c (1.0 g, 4.90 mmol), (1-cyanocyclopropyl)methyl methanesulfonate (1.29 g, 7.35 mmol) and DIPEA (1.26 g, 9.80 mmol) in DMF (2 mL) was stirred at 130° C. for 48 hrs. After cooling down to RT, the mixture was diluted with EtOAc (20 mL) and washed with brine. The separated organic layer was concentrated. The residue was purified by FCC (eluent: PE:EtOAc=20:1) to give the product (740 mg, 53% yield) as green oil. 1H NMR (400 MHz, CDCl3) δ 7.19-7.14 (m, 2H), 6.89 (t, J=9.2 Hz, 1H), 3.28 (s, 2H), 3.00 (s, 3H), 1.27-1.24 (m, 2H), 0.90-0.87 (m, 2H). 19F NMR (376 MHz, CDCl3) δ −119.15.
- A mixture of 33d (200 mg, 0.709 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (270 mg, 1.064 mmol), Pd(dppf)Cl2 (104 mg, 0.142 mmol) and KOAc (139 mg, 1.418 mmol) in 1,4-dioxane (3 mL) was stirred at 100° C. under N2 overnight. After cooling down to RT, the mixture was concentrated and purified by FCC (eluent: PE:EtOAc=2:1) to give the product (229 mg, 98% yield) as a white solid. LC-MS (Method 3): tR=1.75 min, m/z (M+H)+=331.2.
- A mixture of 33e (206 mg, 0.624 mmol), 2,4-dichloro-5-methylpyrimidine (102 mg, 0.624 mmol), Pd(dppf)Cl2 (91 mg, 0.125 mmol) and Na2CO3 (132 mg, 1.248 mmol) in 1,4-dioxane/H2O (4 mL/1 mL) was stirred at 90° C. under N2 for 5 hrs. After cooling down to RT, the mixture was concentrated and purified by FCC (eluent: PE:EtOAc=2:1) to give the product (125 mg, 61% yield) as light yellow oil. LC-MS (Method 3): tR=1.60 min, m/z (M+H)+=331.1.
- A mixture of 33f (125 mg, 0.379 mmol), 1-cyclopropyl-1H-pyrazol-4-amine (51 mg, 0.417 mmol), Pd2(dba)3 (35 mg, 0.0379 mmol), X-phos (36 mg, 0.0758 mmol) and Cs2CO3 (247 mg, 0.758 mmol) in 1,4-dioxane (3 mL) was stirred at 100° C. under N2 for 4 hrs. After cooling down to RT, the mixture was concentrated and purified by FCC (eluent: DCM:MeOH=30:1) to give the crude product. The crude product was purified by prep-HPLC (Method A) to give the product (53.8 mg, 34% yield) as a yellow solid. LC-MS (Method 1): tR=3.49 min, m/z (M+H)+=418.2. 1H NMR (400 MHz, DMSO-d6) δ 9.29 (s, 1H), 8.30 (s, 1H), 7.90 (s, 1H), 7.53-7.48 (m, 3H), 7.15 (t, J=8.8 Hz, 1H), 3.67-3.63 (m, 1H), 3.37 (s, 2H), 3.00 (s, 3H), 2.24 (s, 3H), 1.29-1.26 (m, 2H), 1.05-1.00 (m, 2H), 0.99-0.96 (m, 2H), 0.95-0.91 (m, 2H). 19F NMR (376 MHz, DMSO-d6) δ −122.12.
-
- A mixture of 34a (5.0 g, 24.87 mmol), acrylonitrile (1.32 g, 24.87 mmol) and DABCO (1.09 g, 4.97 mmol) was stirred at 90° C. for 6 hrs. After cooling down to RT., the mixture was diluted with H2O (50 mL), extracted with DCM (50 mL*3). The combined organic layers were washed with brine (50 mL) and concentrated. The residue was purified by FCC (eluent: PE:EtOAc=30:1) to give the product as a yellow solid (1.25 g, 21% yield). 1H NMR (400 MHz, DMSO-d6) δ 7.54 (s, 1H), 7.51 (d, J=2.4 Hz, 1H), 7.46 (dd, J=2.4, 8.4 Hz, 1H), 6.87 (d, J=8.8 Hz, 1H), 4.92 (d, J=1.6 Hz, 2H).
- A mixture of 34b (940 mg, 3.98 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.52 g, 5.97 mmol), KOAc (781 mg, 7.96 mmol) and Pd(dppf)Cl2 (582 mg, 0.796 mmol) in 1,4-dioxane (19 mL) was stirred at 100° C. under N2 for 5 hrs. The mixture was concentrated and the residue was purified by FCC (eluent: PE:EtOAc=30:1) to give the product (890 mg, 79% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 7.63 (s, 1H), 7.59-7.57 (m, 2H), 6.88 (d, J=8.8 Hz, 1H), 4.92 (d, J=1.6 Hz, 2H), 1.29 (d, J=5.2 Hz, 12H).
- A mixture of 34c (890 mg, 3.14 mmol), 2,4-dichloro-5-methylpyrimidine (538 mg, 3.30 mmol), Na2CO3 (666 mg, 6.28 mmol) and Pd(dppf)Cl2 (230 mg, 0.314 mmol) in 1,4-dioxane/H2O (18 mL/4.5 mL) was stirred at 100° C. under N2 for 3 hrs. After cooling down to RT., the mixture was concentrated, purified by FCC (eluent: PE:EtOAc=4:1) to give the product (475 mg, 53% yield) as a yellow solid. LC-MS (Method 3): tR=1.56 min, m/z (M+H)+=284.0
- A mixture of 34d (475 mg, 1.674 mmol), 1-cyclopropyl-1H-pyrazol-4-amine (206 mg, 1.674 mmol), Pd2(dba)3 (153 mg, 0.1674 mmol), X-phos (159 mg, 0.3348 mmol) and Cs2CO3 (1.09 mg, 3.348 mmol), in 1,4-dioxane (10 mL) was stirred at 100° C. under N2 overnight After cooling down to RT., the mixture was concentrated and the residue was purified by FCC (eluent: PE:EtOAc=2:1) to give the product (330 mg, 53% yield) as a white solid. LC-MS (Method 1): tR=2.66 min, m/z (M+H)+=371.1
- To a mixture of 34e (50 mg, 0.135 mmol) in EtOAc (10 mL) was added Pd/C (40 mg, 10% Pd/C wetted with ca. 55% water). The mixture was stirred under H2 (50 Psi) at 50° C. for 48 hrs. The mixture was filtered. The filtrate was concentrated to give a crude product. The crude was purified by the prep-HPLC (method A) to give the product (16.0 mg, 32% yield) as a white solid. LC-MS (Method 1): tR=2.91 min, m/z (M+H)+=373.1. 1H NMR (400 MHz, DMSO-d6) δ 9.29 (s, 1H), 8.30 (s, 1H), 7.92 (s, 1H), 7.54-7.51 (m, 2H), 7.45 (s, 1H), 6.96 (d, J=8.4 Hz, 1H), 4.45-4.41 (m, 1H), 4.31-4.28 (m, 1H), 3.66-3.62 (m, 2H), 3.28-3.24 (m, 1H), 3.12-3.07 (m, 1H), 2.22 (s, 3H), 1.00-0.90 (m, 4H).
-
- To a solution of 35a (2.2 g, 18.4 mmol) and 4-bromo-2-fluoroaniline (2.5 g, 13.2 mmol) in EtOH (40 mL) and water (8 mL) was added formaldehyde (8 mL, 37% wt in water) dropwise. The mixture was stirred at RT for 30 minutes. The mixture was filtered. The filter cake was washed with EtOH and dried to give the crude product (3.2 g, 73% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.06 (d, J=8.4 Hz, 1H), 7.63 (d, J=8.0 Hz, 1H), 7.51 (t, J=7.6 Hz, 1H), 7.38 (t, J=7.6 Hz, 1H), 7.13-7.09 (m, 2H), 7.04 (t, J=8.4 Hz, 1H), 6.10 (d, J=6.8 Hz, 2H), 5.17 (br s, 1H).
- To a solution of 35b (900 mg, 2.80 mmol) and Yb(OTf)3 (348 mg, 5.61 mmol) in DCM (10 mL) was added a solution of ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane (731 mg, 4.21 mmol) in DCM (2 mL). The mixture was stirred at 0° C. to RT overnight. The mixture was concentrated. The residue was purified by FCC (eluent: PE:EtOAc=40:1) to give the product (470 mg, 55% yield) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.11-7.06 (m, 2H), 6.58 (t, J=4.8 Hz, 1H), 4.22 (br s, 1H), 3.68 (s, 3H), 3.23 (d, J=6.4 Hz, 2H), 1.26 (s, 6H).
- To a solution of 35c (1.0 g, 3.28 mmol) in DMF (7 mL) was added NaH (328 mg, 8.20 mmol, 60% in mineral oil) in batches at 0° C. After stirring for 40 minutes, iodomethane 700 mg, 4.92 mmol) in DMF (1 mL) was added dropwise at 0° C. The mixture was stirred at R.T. for 3 hrs. The mixture was diluted with H2O (20 mL), extracted with EtOAc (20 mL*3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and the filtrate was concentrated to give a crude product (1.1 g, 100% yield) as a yellow solid. LC-MS (Method 3): tR=1.83 min, m/z (M+H)+=320.0.
- To a mixture of 35d (1.1 g, 3.46 mmol) in MeOH/THF/H2O (8 mL/4 mL/4 mL) was added LiOH.H2O (726 mg, 17.29 mmol). The mixture was stirred at 50° C. for 4 hours. After cooling to RT, the mixture was adjusted to pH 3˜4 by 2N aq. HCl. The mixture was extracted with DCM (30 mL*3). The combined organic layers were concentrated to give a crude product (1.03 g, 100% yield) as a yellow solid, which was used for next step directly. LC-MS (Method 3): tR=1.58 min, m/z (M+H)+=306.1.
- To a solution of 35e (1.03 g, 3.39 mmol) in THF (10 mL) was added NMM (1.03 g, 10.66 mmol) and methy chloroformate (644 mg, 6.78 mmol) at 0° C. The mixture was stirred at 0° C. for 1 hour. The solid was filtered and the filtrate was dropwise added a solution of NH3(g) in THF (3 M, 5 mL). The resultant mixture was stirred at 0° C. to RT for 2 hours and concentrated to give a crude product (1.1 g, 100% yield) as yellow oil. LC-MS (Method 3): tR=1.55 min, m/z (M+H)+=305.0.
- To a mixture of 35f (1.1 g, 3.46 mmol) and TEA (1.1 g, 10.89 mmol) in DCM (10 mL) was added TFAA (1.14 g, 5.45 mmol) at 0° C. for 2 hours. The mixture was diluted with water (20 mL), and extracted with DCM (30 mL*2). The combined organic layers were washed with brine (20 mL) and concentrated. The residue was purified by FCC (PE:EtOAc=20:1) to give the product (540 mg, 52% yield) as yellow oil. LC-MS (Method 3): tR=1.88 min, m/z (M+H)+=287.0.
- Compound 35h (280 mg) was synthesized in 80% yield by utilizing a similar preparative procedure to the second step of Example 25 with 35g (300 mg, 1.056 mmol) and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (402 mg, 1.585 mmol) as starting materials. LC-MS (Method 3): tR=1.98 min, m/z (M+H)+=333.2.
- Compound 35i (60 mg) was synthesized in 43% yield by utilizing a similar preparative procedure to the third step of Example 25 with 35h (140 mg, 0.422 mmol) and 2,4-dichloro-5-methylpyrimidine (69 mg, 0.422 mmol) as starting materials. LC-MS (Method 3): tR=1.87 min, m/z (M+H)+=333.1.
- Compound 35 (13.7 mg) was synthesized in 18% yield by utilizing a similar preparative procedure to the final step of Example 25 with 35i (60 mg, 0.181 mmol) and 1-cyclopropyl-1H-pyrazol-4-amine (24 mg, 0.199 mmol) as starting materials. LC-MS (Method 1): tR=4.22 min, m/z (M+H)+=420.2. 1H NMR (400 MHz, DMSO-d6) δ 9.27 (s, 1H), 8.29 (s, 1H), 7.89 (s, 1H), 7.51-7.47 (m, 3H), 7.22 (t, J=9.2 Hz, 1H), 3.67-3.62 (m, 1H), 3.58 (s, 2H), 3.13 (s, 3H), 2.24 (s, 3H), 1.31 (s, 6H), 1.00-0.98 (m, 2H), 0.97-0.89 (m, 2H). 19F NMR (376 MHz, DMSO-d6) δ −121.84.
-
- Compound 36a (270 mg) was synthesized in 85% yield by utilizing a similar preparative procedure to the third step of Example 25 with 35h (300 mg, 0.904 mmol) and 2,4,5-trichloropyrimidine (182 mg, 0.994 mmol) as starting materials. LC-MS (Method 3): tR=1.78 min, m/z (M+H)+=353.0.
- Compound 36 (19.9 mg) was synthesized in 6% yield by utilizing a similar preparative procedure to the final step of Example 25 with 36a (270 mg, 0.767 mmol) and 1-cyclopropyl-1H-pyrazol-4-amine (104 mg, 0.844 mmol) as starting materials. LC-MS (Method 1): tR=3.76 min, m/z (M+H)+=440.1. 1H NMR (400 MHz, DMSO-d6) δ 9.69 (s, 1H), 8.48 (s, 1H), 7.89 (s, 1H), 7.70-7.63 (m, 2H), 7.51 (s, 1H), 7.23 (t, J=9.2 Hz, 1H), 3.69-3.66 (m, 1H), 3.63 (s, 2H), 3.15 (s, 3H), 1.31 (s, 6H), 1.01-0.96 (m, 2H), 0.95-0.90 (m, 2H). 19F NMR (376 MHz, DMSO-d6) δ −121.77.
-
- To a solution of 35c (470 mg, 1.56 mmol) in THF (2 mL) and MeOH (2 mL) was added aq. LiOH.H2O (197 mg, 4.69 mmol in 1 mL of water). The mixture was stirred at 30° C. for 2 hrs. The mixture was diluted with water (50 mL) and extracted with EtOAc (50 mL*2). The separated aqueous layer was adjusted to pH 4˜5 by 1N aq. HCl and extracted with EtOAc (50 mL). The separated organic layer was dried over Na2SO4, filtered and concentrated to give the crude product (430 mg, 96% yield) as yellow oil. 1H NMR (400 MHz, DMSO-d6) δ 12.38 (br s, 1H), 7.27 (dd, J=11.6, 2.4 Hz, 1H), 7.11 (d, J=8.4 Hz, 1H), 6.81 (t, J=9.2 Hz, 1H), 5.20 (br s, 1H), 3.22 (d, J=6.0 Hz, 2H), 1.13 (s, 6H).
- To a solution of 37a (430 mg, 1.48 mmol) in THF (5 mL) was added NMM (450 mg, 4.45 mmol) followed by methyl chloroformate (282 mg, 2.97 mmol) at 0° C. The mixture was stirred at 0° C. to RT for 1 hour. The mixture was filtered. Then a solution of NH3(g) in THF (5 mL, 4M) was added to the filtrate. The mixture was stirred at 0° C. to RT overnight. The mixture was diluted with water (50 mL) and extracted with EtOAc (50 mL*2). The combined organic phases were dried over Na2SO4, filtered and concentrated to give the crude product (400 mg, 93% yield) as yellow oil. 1H NMR (400 MHz, DMSO-d6) δ 7.26 (dd, J=11.6, 2.4 Hz, 1H), 7.19 (s, 1H), 7.11 (dd, J=8.8, 2.0 Hz, 1H), 6.94 (s, 1H), 6.80 (t, J=9.2 Hz, 1H), 5.17-5.14 (m, 1H), 3.12 (d, J=6.0 Hz, 2H), 1.12 (s, 6H).
- To a solution of 37b (350 mg, 1.21 mmol) and TEA (367 mg, 3.63 mmol) in DCM (5 mL) was added TFAA (381 mg, 1.82 mmol) at 0° C. The mixture was stirred at 0° C. to 25° C. for 30 minutes. The mixture was diluted with sat. NaHCO3 (50 mL), extracted with EtOAc (50 mL*2). The combined organic phases were dried over Na2SO4, filtered and concentrated to give the crude product (274 mg, 84% yield) as yellow oil. 1H NMR (400 MHz, DMSO-d6) δ 7.29 (dd, J=11.6, 2.4 Hz, 1H), 7.12 (dd, J=8.4, 1.6 Hz, 1H), 6.96 (t, J=9.2 Hz, 1H), 5.95-5.92 (m, 1H), 3.31 (s, 2H), 1.31 (s, 6H).
- Compound 37d (300 mg, crude) was synthesized in 93% yield by utilizing a similar preparative procedure to the second step of Example 25 with 37c (274 mg, 1.01 mmol) and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (258 mg, 1.01 mmol) as starting materials. LC-MS (Method 3): tR=1.88 min, m/z (M+H)+=319.2.
- Compound 37e (170 mg crude) was synthesized in 57% yield by utilizing a similar preparative procedure to the third step of Example 25 with 37d (300 mg, 0.94 mmol) and 2,4-dichloro-5-methylpyrimidine (231 mg, 1.42 mmol) as starting materials. LC-MS (Method 3): tR=1.74 min, m/z (M+H)+=319.1.
- Compound 37 (14.8 mg, crude) was synthesized in 17% yield by utilizing a similar preparative procedure to the final step of Example 25 with 37e (69 mg, 0.22 mmol) and 1-cyclopropyl-1H-pyrazol-4-amine (40 mg, 0.33 mmol) as starting materials. LC-MS (Method 1): tR=3.66 min, m/z (M+H)+=406.2. 1H NMR (400 MHz, DMSO-d6) δ 9.22 (s, 1H), 8.25 (s, 1H), 7.90 (s, 1H), 7.50-7.42 (m, 3H), 7.11 (t, J=9.2 Hz, 1H), 6.19 (t, J=4.8 Hz, 1H), 3.67-3.62 (m, 1H), 3.42 (d, J=6.8 Hz, 2H), 2.25 (s, 3H), 1.36 (s, 6H), 1.00-0.89 (m, 4H).
-
- A mixture of 1b (500 mg, 2.27 mmol), 1-methyl-1H-pyrazol-4-amine (264 mg, 2.72 mmol) and conc. H2SO4 (1 drop) in n-BuOH (3 mL) was stirred at 120° C. for 2 hours. The reaction mixture was concentrated and purified by silica gel column (DCM:MeOH=20:1) to give the product (348 mg, 55% yield) as a brown solid. 1H NMR (400 MHz, DMSO-d6) δ 9.81 (s, 1H), 9.22 (s, 1H), 8.26 (s, 1H), 7.83 (s, 1H), 7.56 (d, J=8.4 Hz, 2H), 7.48 (s, 1H), 6.88 (d, J=8.8 Hz, 2H), 3.78 (s, 3H), 2.20 (s, 3H).
- Compound 38 (26.7 mg) was synthesized in 26% yield by utilizing a similar preparative procedure to the final step of Example 1 with 38a (80 mg, 0.28 mmol) and 2-cyano-2-methylpropyl methanesulfonate (74 mg, 0.42 mmol) as starting materials. LC-MS (Method 1): tR=3.66 min, m/z (M+H)+=363.2. 1H NMR (400 MHz, DMSO-d6) δ 9.29 (s, 1H), 8.29 (s, 1H), 7.83 (s, 1H), 7.68 (d, J=8.8 Hz, 2H), 7.48 (s, 1H), 7.12 (d, J=8.4 Hz, 2H), 4.09 (s, 2H), 3.78 (s, 3H), 2.21 (s, 3H), 1.44 (s, 6H).
-
- To a mixture of benzyl 4-hydroxypiperidine-1-carboxylate (10.0 g, 42.50 mmol) and TEA (8.6 g, 85.15 mmol) in DCM (120 mL) was added MsCl (5.4 g, 47.16 mmol) at RT. After stirring at RT for 18 hrs, the reaction mixture was diluted with H2O (50 mL) and extracted with DCM (40 mL*3). The combined organic layers were concentrated to afford the crude product (13.2 g, 99%) as brown oil. 1H NMR (400 MHz, CDCl3) δ 7.38-7.30 (m, 5H), 5.13 (s, 2H), 4.93-4.87 (m, 1H), 3.78-3.72 (m, 2H), 3.45-3.39 (m, 2H), 3.30 (s, 3H), 1.97-1.96 (m, 2H), 1.88-1.82 (m, 2H).
- To a mixture of 39b (13.5 g, 43.13 mmol) and 4-nitro-1H-pyrazole (4.14 g, 36.64 mmol) in DMF (150 mL) was added Cs2CO3 (14.06 g, 43.13 mmol). The reaction was stirred for 20 hrs at 120° C. After cooling to RT, the reaction mixture was filtered and the filtrate was diluted with H2O (80 mL). The mixture was extracted with EtOAc (80 mL*2) and the combined organic layers were concentrated to dryness. The residue was purified by column chromatography on silica gel (PE:EtOAc=1:1) to afford the product (7.11 g, 58%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.14 (s, 1H), 8.08 (s, 1H), 7.40-7.32 (m, 5H), 5.15-5.12 (m 2H), 4.35-4.28 (m, 3H), 2.98-2.95 (m, 2H), 2.20-2.17 (m, 2H), 1.94-1.92 (m, 2H).
- Compound 39c (7.11 g, 21.55 mmol) was dissolved in EtOH (120 mL). NH4Cl (5.76 g, 107.66 mmol) was dissolved in H2O (25 mL). The above two solutions were mixed together and warmed to 60° C. Fe powder (4.22 g, 75.36 mmol) was added to the mixture. The mixture was stirred at 80° C. for 3 hrs. After cooling to RT, the reaction mixture was filtered and the filtrate was concentrated. The residue was diluted with H2O (60 mL) and extracted with EtOAc (60 mL*3). The combined organic layers were concentrated to dryness to give the crude product (6.4 g, 98%) as purple oil. LC-MS (Method 3): tR=1.25 min, m/z (M+H)+=301.1.
- To a mixture of 39d (756 mg, 2.52 mmol) and 4a (500 mg, 2.10 mmol) in 1,4-dioxane (5 mL) and NMP (5 mL) was added conc. H2SO4 (5 drops). The mixture was stirred at 120° C. for 16 hrs. After cooling to RT, the reaction mixture was diluted with H2O (40 mL) and extracted with EtOAc (30 mL*3). The combined organic layers were concentrated and the residue was purified by column chromatography on silica gel (DCM MeOH=30:1) to afford the product (0.8 g, 76%) as green solid. LC-MS (Method 3): tR=1.61 min, m/z (M+H)+=503.2.
- Compound 39f (55 mg) was synthesized in 31% yield by utilizing a similar preparative procedure to the final step of Example 1 with 39e (150 mg, 0.30 mmol) and 2-cyano-2-methylpropyl methanesulfonate (79 mg, 0.45 mmol) as starting materials. LC-MS (Method 3): tR=1.78 min, m/z (M+H)+=584.3.
- Compound 39f (55 mg, 0.09 mmol) was dissolved in MeOH (2 mL) followed by the addition of Pd/C (24 mg, 10% wt, wetted with ca. 55% water) and Pd(OH)2/C (24 mg, 20% wt dihydroxypalladium on charcoal). The above mixture was stirred under H2 (1 atm) at 40° C. for 6 hours. The mixture was filtered and the filtrate was concentrated. The residue was purified by Prep-HPLC (Method A) to give the title product (5.6 mg, 14% yield). LC-MS (Method 1): tR=3.33 min, m/z (M+H)+=450.3. 1HNMR (400 MHz, CD3OD) δ 8.17 (s, 1H), 7.94 (s, 1H), 7.53 (s, 1H), 7.44 (dd, J=2.4, 12.0 Hz, 1H), 7.39 (d, J=8.4 Hz, 1H), 7.16 (t, J=8.4 Hz, 1H), 4.34-4.29 (m, 1H), 4.03 (s, 2H), 3.36 (d, J=13.2 Hz, 2H), 3.03-2.96 (m, 2H), 2.17-2.15 (m, 5H), 2.10-2.01 (m, 2H), 1.42 (s, 6H).
-
- To a mixture of 1,1,1-trifluoropropan-2-ol (5.0 g, 43.86 mmol) and TEA (8.86 g, 87.72 mmol) in DCM (100 mL) was added MsCl (5.5 g, 48.24 mmol) at 0° C. The mixture was warmed to RT and stirred for 2 hours. The mixture was diluted with DCM (300 mL), washed with H2O (300 mL*3), dried over Na2SO4 and filtered. The filtrate was concentrated to afford the title product (7.38 g, 88%) as yellow oil. 1HNMR (400 MHz, CDCl3) δ 5.02-4.98 (m, 1H), 3.11 (s, 3H), 1.58 (d, J=6.4 Hz, 3H).
- To a mixture of 4-nitro-1H-pyrazole (3.62 g, 32.03 mmol) and 40b (7.38 g, 38.44 mmol) in DMF (100 mL) was added K2CO3 (8.84 g, 64.06 mmol). The mixture was stirred at 120° C. under N2 for 18 hours. The mixture was cooled down to RT and concentrated to dryness. The residue was purified by flash chromatography on silica gel (PE:EtOAc=8:1) to afford the title product (3.1 g, crude, 46%) as yellow oil. 1HNMR (400 MHz, CDCl3) δ 8.30 (s, 1H), 8.13 (s, 1H), 4.94-4.91 (m, 1H), 1.82 (d, J=6.8 Hz, 3H).
- Compound 40d (1.2 g) was synthesized in 45% yield by utilizing a similar preparative procedure to the second step of Example 8 with 40c (3.1 g crude, 14.83 mmol) as starting material. LC-MS (Method 1): tR=0.38 min, m/z (M+H)+=180.1.
- To a mixture of 4a (100 mg, 0.42 mmol) and 40d (90 mg, 0.50 mmol) in n-BuOH (10 mL) was added cat. H2SO4 (0.5 mL, 1 drop in 1 mL n-BuOH). The mixture was stirred at 120° C. overnight After cooling down to RT, the mixture was concentrated to dryness and purified by prep-HPLC (method A) to afford the title product (60 mg, 38% yield) as a yellow solid. LC-MS (Method 1): tR=1.51 min, m/z (M+H)+=382.2.
- Compound 40 (5.4 mg) was synthesized in 7% yield by utilizing a similar preparative procedure to the final step of Example 1 with 40e (60 mg, 0.16 mmol) and 2-cyano-2-methylpropyl methanesulfonate (49 mg, 0.24 mmol) as starting materials. LC-MS (Method 1): tR=3.41 min, m/z (M+H)+=463.1. 1H NMR (400 MHz, CD3OD) δ 8.32 (s, 1H), 8.14 (s, 1H), 7.70 (s, 1H), 7.58 (d, J=2.0 Hz, 1H), 7.55-7.51 (m, 2H), 7.28 (t, J=8.4 Hz, 1H), 5.11-5.04 (m, 1H), 4.15 (s, 2H), 2.30 (s, 3H), 1.74 (d, J=6.8 Hz, 3H), 1.54 (s, 6H). 19F NMR (376 MHz, CD3OD) δ −77.67, −136.00.
-
- A mixture of 38a (226 mg, 0.68 mmol), K2CO3 (187 mg, 1.36 mmol) and t-BuOH (52 mg, 0.68 mmol) in acrylonitrile (2 ml) was stirred at 120° C. under microwave for 6 hours. The mixture was cooled to RT and concentrated. The residue was purified by Prep-HPLC to afford the title product (27.7 mg, 12% yield) as a yellow solid. LC-MS (Method 1): tR=3.07 min, m/z (M+H)+=335.2. 1H NMR (400 MHz, DMSO-d6) δ 9.30 (s, 1H), 8.30 (s, 1H), 7.83 (s, 1H), 7.68 (d, J=8.4 Hz, 2H), 7.48 (s, 1H), 7.11 (t, J=8.8 Hz, 2H), 4.27 (t, J=6.0 Hz, 2H), 3.78 (s, 3H), 3.05 (t, J=6.4 Hz, 2H), 2.21 (s, 3H).
-
- A mixture of 4-bromoaniline (200 mg, 1.16 mmol), (1-cyanocyclopropyl)methyl methanesulfonate (305 mg, 1.74 mmol) and DIPEA (300 mg, 2.32 mmol) in DMF (1 mL) was stirred at 120° C. for 3 hours. The mixture was cooled down to R.T. and concentrated to dryness. The residue was purified by flash chromatography on silica gel (PE:EtOAc=5:1) to afford the title product (100 mg, 34%) as a yellow solid. LC-MS (Method 3): tR=1.40 mi, m/z (M+H)+=251.1.
- Compound 42c (119 mg) was synthesized in 100% yield by utilizing a similar preparative procedure to the second step of Example 10 with 42b (100 mg, 0.4 mmol) and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (102 mg, 0.4 mmol) as starting materials. LC-MS (Method 3): tR=1.60 min, m/z (M+H)+=299.2.
- Compound 42d (70 mg) was synthesized in 59% yield by utilizing a similar preparative procedure to the third step of Example 10 with 42c (119 mg, 0.4 mmol) and 2,4-dichloro-5-methylpyrimidine (98 mg, 0.6 mmol) as starting materials. LC-MS (Method 3): tR=1.50 min, m/z (M+H)+=299.1.
- Compound 42 (6 mg) was synthesized in 7% yield by a utilizing similar preparative procedure to the final step of Example 10 with 42d (70 mg, 0.23 mmol) and 1-cyclopropyl-1H-pyrazol-4-amine (43 mg, 0.35 mmol) as starting materials. LC-MS (Method 1): tR=3.76 min, m/z (M+H)+=386.2. 1H NMR (400 MHz, CDCl3) δ 8.21 (s, 1H), 7.92 (s, 1H), 7.58 (d, J=8.4 Hz, 2H), 7.49 (s, 1H), 6.71 (d, J=8.8 Hz, 2H), 6.66 (s, 1H), 4.15 (t, J=5.2 Hz, 1H), 3.59-3.55 (m, 1H), 3.39 (d, J=6.0 Hz, 2H), 2.28 (s, 3H), 1.35-1.32 (m, 2H), 1.15-1.11 (m, 2H), 1.05-1.01 (m, 2H), 1.00-0.96 (m, 2H).
-
- Compound 43a (120 mg) was synthesized in 53% yield by utilizing a similar preparative procedure to the second step of Example 1 with 42d (120 mg, 0.4 mmol) and 39d (180 mg, 0.6 mmol) as starting materials. LC-MS (Method 3): tR=1.64 min, m/z (M+H)+=563.3.
- A mixture of 43a (80 mg, 0.14 mmol) in MeOH (10 mL) was added Pd/C (40 mg, 10% wt, wetted with ca. 55% water) and Pd(OH)2/C (40 mg, 20% wt) and one drop of formaldehyde (37% solution). The mixture was stirred at 40° C. under H2 (1 atm) for 16 hrs. The reaction mixture was filtered and the filtrate was concentrated to afford a residue. The residue was purified by prep-HPLC (Method A) to afford the product (6 mg, 10% yield). LC-MS (Method 1): tR=3.83 min, m/z (M+H)+=443.2. 1H NMR (400 MHz, CDCl3) δ 8.20 (s, 1H), 7.94 (s, 1H), 7.57 (d, J=8.4 Hz, 2H), 7.52 (s, 1H), 6.71 (d, J=8.8 Hz, 2H), 6.69 (s, 1H), 4.17-4.07 (m, 1H), 3.40 (d, J=6.0 Hz, 2H), 3.02-2.96 (m, 2H), 2.34 (s, 3H), 2.28 (s, 3H), 2.19-2.06 (m, 6H), 1.35-1.32 (m, 2H), 1.05-1.02 (m, 2H).
-
- Compound 44a (126 mg) was synthesized in 79% yield by utilizing a similar preparative procedure to the second step of Example 42 with 42c (150 mg, 0.50 mmol) and 2,4,5-trichloropyrimidine (137 mg, 0.75 mmol) as starting materials. 1H NMR (400 MHz, CDCl3) δ 8.52 (s, 1H), 7.96 (d, J=8.8 Hz, 2H), 6.69 (d, J=8.8 Hz, 2H), 4.37 (t, J=6.0 Hz, 1H), 3.40 (d, J=6.0 Hz, 2H), 1.36-1.33 (m, 2H), 1.27-1.24 (m, 2H).
- Compound 44b (60 mg) was synthesized in 26% yield by utilizing a similar preparative procedure to the third step of Example 42 with 44a (96 mg, 0.30 mmol) and benzyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate (136 mg, 0.50 mmol) as starting materials. LC-MS (Method 3): tR=1.67 min, m/z (M+H)+=583.3.
- A mixture of 44b (60 mg, 0.1 mmol) in MeOH (2 mL) was added Pd/C (24 mg, 10% wt, wetted with ca. 55% water) and Pd(OH)2/C (24 mg, 20% dihydroxypalladium on charcoal wt) under H2 (1 atm) at 40° C. for 6 hours. The mixture was filtered and the filtrate was concentrated. The residue was purified by Prep-HPLC (Method A) to give the title product (1.5 mg, 3% yield) as a yellow solid. LC-MS (Method 1): tR=3.20 min, m/z (M+H)+=449.2. 1H NMR (400 MHz, CD3OD) δ 8.20 (s, 1H), 7.94 (s, 1H), 7.75 (d, J=8.4 Hz, 2H), 7.51 (s, 1H), 6.69 (d, J=8.8 Hz, 2H), 4.19-4.12 (m, 1H), 3.32 (s, 2H), 3.13-3.10 (m, 2H), 2.73-2.67 (m, 2H), 2.04-2.01 (m, 2H), 1.88-1.78 (m, 2H), 1.18-1.15 (m, 2H), 1.00-0.97 (m, 2H).
-
- To a mixture of 4a (500 mg, 2.1 mmol) and 1-methyl-1H-pyrazol-4-amine (295 mg, 2.55 mmol) in n-BuOH (8 mL) was added cat. H2SO4 (0.5 mL, 1 drop in 1 mL n-BuOH). The mixture was stirred at 120° C. overnight. After cooling down to RT, the mixture was concentrated to dryness and purified by prep-HPLC (Method A) to afford the title product as a yellow solid (357 mg, 47% yield). LC-MS (Method 3): tR=1.28 min, m/z (M+H)+=300.1.
- A mixture of 45a (50 mg, 0.17 mmol), CH3I (29 mg, 0.20 mmol) and K2CO3 (47 mg, 0.34 mmol) in DMF (1 mL) was stirred at 30° C. for 2 hours. The mixture was concentrated and purified by prep-HPLC (Method A) to get the product (5.4 mg, 10% yield) as a white solid. LC-MS (Method 1): tR=3.34 min, m/z (M+H)+=314.2. 1H NMR (400 MHz, DMSO-d6) δ 9.30 (s, 1H), 8.31 (s, 1H), 7.82 (s, 1H), 7.58-7.51 (m, 2H), 7.48 (s, 1H), 7.29 (t, J=8.8 Hz, 1H), 3.91 (s, 3H), 3.78 (s, 3H), 2.21 (s, 3H).
-
- Compound 46 (4.3 mg) was synthesized in 8% yield by utilizing a similar preparative procedure to the final step of Example 45 with 45a (50 mg, 0.17 mmol) and iodoethane (33 mg, 0.21 mmol) as starting materials. LC-MS (Method 1): tR=3.36 min, m/z (M+H)+=328.2. 1H NMR (400 MHz, DMSO-d6) δ 9.30 (s, 1H), 8.31 (s, 1H), 7.82 (s, 1H), 7.58-7.49 (m, 3H), 7.28 (t, J=8.8 Hz, 1H), 4.22-4.17 (m, 2H), 3.79 (s, 3H), 2.22 (s, 3H), 1.39 (t, J=6.8 Hz, 3H).
-
- Compound 47 (4.3 mg) was synthesized in 8% yield by utilizing a similar preparative procedure to the final step of Example 45 with 45a (50 mg, 0.17 mmol) and 2-iodopropane (36 mg, 0.21 mmol) as starting materials. LC-MS (Method 1): tR=3.01 min, m/z (M+H)+=342.2. 1H NMR (400 MHz, DMSO-d6) δ 9.29 (s, 1H), 8.31 (s, 1H), 7.82 (s, 1H), 7.55 (dd, J=2.0, 12.0 Hz, 1H), 7.50-7.48 (m, 2H), 7.28 (t, J=8.8 Hz, 1H), 4.76-4.73 (m, 1H), 3.78 (s, 3H), 2.22 (s, 3H), 1.33 (d, J=6.0 Hz, 6H).
-
- Compound 48 (4.9 mg) was synthesized in 8% yield by utilizing a similar preparative procedure to the final step of Example 45 with 45a (50 mg, 0.17 mmol) and 1-bromopropane (26 mg, 0.21 mmol) as starting materials. LC-MS (Method 1): tR=3.99 min, m/z (M+H)+=342.2. 1H NMR (400 MHz, DMSO-d6) δ 9.30 (s, 1H), 8.31 (s, 1H), 7.82 (s, 1H), 7.55 (dd, J=2.0, 12.0 Hz, 1H), 7.50-7.49 (m, 2H), 7.28 (t, J=8.8 Hz, 1H), 4.08 (t, J=6.4 Hz, 2H), 3.78 (s, 3H), 2.22 (s, 3H), 1.83-1.74 (m, 2H), 1.01 (t, J=7.2 Hz, 3H).
-
- Compound 49a (40 mg) was synthesized in 42% yield by utilizing a similar preparative procedure to the first step of Example 45 with 4a (70 mg, 0.30 mmol) and 1-isopropyl-1H-pyrazol-4-amine (74 mg, 0.59 mmol) as starting materials. LC-MS (Method 3): tR=1.47 min, m/z (M+H)+=328.1.
- Compound 49 (10 mg) was synthesized in 23% yield by utilizing a similar preparative procedure to the final step of Example 45 with 49a (40 mg, 0.12 mmol) and iodoethane (23 mg, 0.15 mmol) as starting materials. LC-MS (Method 1): tR=3.54 min, m/z (M+H)+=356.2. 1H NMR (400 MHz, CDCl3) δ 8.26 (s, 1H), 7.90 (s, 1H), 7.51 (s, 1H), 7.47 (d, J=12.8 Hz, 1H), 7.41 (d, J=8.4 Hz, 1H), 7.03 (t, J=8.4 Hz, 1H), 6.92 (s, 1H), 4.49-4.42 (m, 1H), 4.18 (q, J=6.8 Hz, 2H), 2.28 (s, 3H), 1.52-1.47 (m, 9H).
-
- Compound 50a (510 mg) was synthesized in 69% yield by utilizing a similar preparative procedure to the first step of Example 1 with 1a (500 mg, 3.01 mmol) and (4-ethoxyphenyl)boronic acid (491 mg, 3.01 mmol) as starting materials. 1H NMR (400 MHz, DMSO-d6) δ 8.64 (s, 1H), 7.69 (d, J=9.2 Hz, 2H), 7.07 (d, J=9.2 Hz, 2H), 4.11 (q, J=7.2 Hz, 2H), 2.37 (s, 3H), 1.36 (t, J=6.8 Hz, 3H).
- Compound 50 (3.6 mg) was synthesized in 4% yield by utilizing a similar preparative procedure to the first step of Example 45 with 50a (70 mg, 0.28 mmol) and 1-methyl-1H-pyrazol-4-amine (33 mg, 0.34 mmol) as starting materials. LC-MS (Method 1): tR=3.56 min, m/z (M+H)+=310.2. 1H NMR (300 MHz, CDCl3) δ 8.28 (s, 1H), 7.90 (s, 1H), 7.64 (d, J=8.7 Hz, 2H), 7.53 (s, 1H), 7.03 (d, J=8.7 Hz, 2H), 6.78 (s, 1H), 4.11 (q, J=6.9 Hz, 2H), 3.92 (s, 3H), 2.31 (s, 3H), 1.36 (t, J=6.9 Hz, 3H).
- Compounds were tested against JAK1, JAK2, JAK2V617F and TYK2.
- Assay Formats: JAK activity was determined in the reaction buffer 50 mM HEPES, 0.01% Brij35, 10 mM MgCl2, 2 mM DTT by a microfluidic assay. The phosphorylation of a FAM labeled peptide substrate was monitored in the Caliper EZ Reader II (Perkin Elmer). The assay condition for each batch of enzyme (Carna Biosciences) was optimized to obtain 10% conversion rate of peptide substrate.
- The test compounds were dissolved in DMSO to a stock concentration of 10 mM. 3-fold serially diluted compounds with top concentration of 5 μM were pre-incubated with JAK1, JAK2, JAK2V617F or TYK2 for 10 min at ambient temperature. The final DMSO concentration of assay mixture was 1%. FAM labeled peptide substrate (final concentration 3 μM) and ATP (1 mM concentration) were sequentially added to initiate the kinase reaction at 28° C. The reaction was stopped by adding 50 mM EDTA. The reaction time for JAK1, JAK2, JAK2V617F and TYK2 was 120 min, 20 min, 30 min and 10 min, respectively.
- The well in the test plate without enzyme was defined as 100% inhibition. And the well without compound but with equivalent DMSO was defined as no inhibition. The percent inhibition was calculated by the following formula.
-
% Inhibition=(Conversionmax−Conversionsample)/(Conversionmax−Conversionmin)*100 Conversionmax means the conversion rate in the positive well without addition of compound Conversionmin means the conversion rate in the well without addition of enzyme Conversionsample means the conversion rate of test compounds - The dose-response (percent inhibition) curve was plotted and IC50 values were determined by GraphPad software.
- Exemplary results are summarized in Table 1.
-
TABLE 1 Summary of Exemplary Structures Example Structure IUPAC name Mol Weight 1 3-(4-(2-((1-cyclopropyl-1H-pyrazol-4- yl)amino)-5-methylpyrimidin-4- yl)phenoxy)-2,2- dimethylpropanenitrile 388.46 2 3-(4-(2-((1-cyclopropyl-1H-pyrazol-4- yl)amino)-5-methylpyrimidin-4- yl)phenoxy)cyclobutanecarbonitrile 386.45 3 1-((4-(2-((1-cyclopropyl-1H-pyrazol-4- yl)amino)-5-methylpyrimidin-4- yl)phenoxy)methyl)cyclobutane- carbonitrile 400.48 4 3-(4-(2-((1-cyclopropyl-1H-pyrazol-4- yl)amino)-5-methylpyrimidin-4-yl)-2- fluorophenoxy)-2,2- dimethylpropanenitrile 406.46 5 1-((4-(2-((1-cyclopropyl-1H-pyrazol-4- yl)amino)-5-methylpyrimidin-4-yl)-2- fluorophenoxy)methyl)cyclopropane- carbonitrile 404.44 6 1-((2-fluoro-4-(5-methyl-2-((1- (tetrahydro-2H-pyran-4-yl)-1H- pyrazol-4-yl)amino)pyrimidin-4- yl)phenoxy)methyl)cyclopropane- carbonitrile 448.49 7 3-(2-fluoro-4-(5-methyl-2-((1- (tetrahydro-2H-pyran-4-yl)-1H- pyrazol-4-yl)amino)pyrimidin-4- yl)phenoxy)-2,2- dimethylpropanenitrile 450.51 8 1-((4-(2-((1-(1- (cyclopropanecarbonyl)piperidin-4-yl)- 1H-pyrazol-4-yl)amino)-5- methylpyrimidin-4-yl)-2- fluorophenoxy)methyl)cyclopropane- carbonitrile 515.58 9 1-((2-fluoro-4-(5-methyl-2-((1-(1-(1- methylcyclopropanecarbonyl)piperidin- 4-yl)-1H-pyrazol-4- yl)amino)pyrimidin-4- yl)phenoxy)methyl)cyclopropane- carbonitrile 529.61 10 1-((4-(2-((1-cyclopropyl-1H-pyrazol-4- yl)amino)-5-methylpyrimidin-4-yl)- 2,6- difluorophenoxy)methyl)cyclopropane carbonitrile 422.43 11 1-(((5-(2-((l-cyclopropyl-1H-pyrazol- 4-yl)amino)-5-methylpyrimidin-4- yl)pyridin-2- yl)oxy)methyl)cyclopropanecarbonitrile 387.44 12 3-(2-fluoro-4-(5-methyl-2-((1-methyl- 1H-pyrazol-4-yl)amino)pyrimidin-4- yl)phenoxy)propanenitrile 352.37 13 1-((4-(2-((1-(1-acetylpiperidin-4-yl)- 1H-pyrazol-4-yl)amino)-5- methylpyrimidin-4-yl)-2- fluorophenoxy)methyl)cyclopropane- carbonitrile 489.54 14 1-(((5-(5-methyl-2-((1-(tetrahydro-2H- pyran-4-yl)-1H-pyrazol-4- yl)amino)pyrimidin-4-yl)pyridin-2- yl)oxy)methyl)cyclopropanecarbonitrile 431.49 15 2,2-dimethyl-3-(4-(5-methyl-2-((1- (tetrahydro-2H-pyran-4-yl)-1H- pyrazol-4-yl)amino)pyrimidin-4- yl)phenoxy)propanenitrile 432.52 16 2,2-dimethyl-3-(4-(5-methyl-2-((1- (tetrahydro-2H-pyran-4-yl)-1H- pyrazol-4-yl)amino)pyrimidin-4- yl)phenoxy)butanenitrile 446.54 17 2,2-dimethyl-3-(4-(5-methyl-2-((1-(1- methylpiperidin-4-yl)-1H-pyrazol-4- yl)amino)pyrimidin-4- yl)phenoxy)propanenitrile 445.56 18 3-(2-fluoro-4-(5-methyl-2-((1-(1- methylpiperidin-4-yl)-1H-pyrazol-4- yl)amino)pyrimidin-4-yl)phenoxy)-2,2- dimethylpropanenitrile 463.55 19 3-(2-fluoro-4-(2-((1-(2-methoxyethyl)- 1H-pyrazol-4-yl)amino)-5- methylpyrimidin-4-yl)phenoxy)-2,2- dimethylpropanenitrile 424.47 20 1-((2-fluoro-4-(5-methyl-2-((1-(1- methylpiperidin-4-yl)-1H-pyrazol-4- yl)amino)pyrimidin-4- yl)phenoxy)methyl)cyclopropane- carbonitrile 461.53 21 1-((2-fluoro-4-(2-((1-(2- methoxyethyl)-1H-pyrazol-4- yl)amino)-5-methylpyrimidin-4- yl)phenoxy)methyl)cyclopropane- carbonitrile 422.45 22 1-((2-fluoro-4-(5-fluoro-2-((1- (tetrahydro-2H-pyran-4-yl)-1H- pyrazol-4-yl)amino)pyrimidin-4- yl)phenoxy)methyl)cyclopropane- carbonitrile 452.46 23 1-((4-(5-chloro-2-((1-(tetrahydro-2H- pyran-4-yl)-1H-pyrazol-4- yl)amino)pyrimidin-4-yl)-2- fluorophenoxy)methyl)cyclopropane- carbonitrile 468.91 24 1-((4-(2-((1-cyclopropyl-1H-pyrazol-4- yl)amino)-5-fluoropyrimidin-4-yl)-2- fluorophenoxy)methyl)cyclopropane- carbonitrile 408.40 25 3-(2-fluoro-4-(5-fluoro-2-((1- (tetrahydro-2H-pyran-4-yl)-1H- pyrazol-4-yl)amino)pyrimidin-4- yl)phenoxy)-2,2- dimethylpropanenitrile 454.47 26 3-(4-(5-chloro-2-((1-(tetrahydro-2H- pyran-4-yl)-1H-pyrazol-4- yl)amino)pyrimidin-4-yl)-2- fluorophenoxy)-2,2- dimethylpropanenitrile 470.93 27 1-((4-(5-chloro-2-((l-cyclopropyl-1H- pyrazol-4-yl)amino)pyrimidin-4-yl)-2- fluorophenoxy)methyl)cyclopropane carbonitrile 424.86 28 3-(4-(2-((1-(1-acetylpiperidin-4-yl)- 1H-pyrazol-4-yl)amino)-5- methylpyrimidin-4-yl)-2- fluorophenoxy)-2,2- dimethylpropanenitrile 491.56 29 3-(4-(5-chloro-2-((1-methyl-1H- pyrazol-4-yl)amino)pyrimidin-4- yl)phenoxy)-2,2- dimethylpropanenitrile 382.85 30 3-(4-(2-((1-(cyanomethyl)-1H-pyrazol- 4-yl)amino)-5-methylpyrimidin-4-yl)- 2-fluorophenoxy)-2,2- dimethylpropanenitrile 405.43 31 1-((4-(2-((1-(cyanomethyl)-1H- pyrazol-4-yl)amino)-5- methylpyrimidin-4-yl)-2- fluorophenoxy)methyl)cyclopropane- carbonitrile 403.41 32 3-(4-(5-chloro-2-((1-cyclopropyl-1H- pyrazol-4-yl)amino)pyrimidin-4- yl)phenoxy)-2,2- dimethylpropanenitrile 408.88 33 1-(((4-(2-((1-cyclopropyl-1H-pyrazol- 4-yl)amino)-5-methylpyrimidin-4-yl)- 2- fluorophenyl)(methyl)amino)methyl) cyclopropanecarbonitrile 417.48 34 6-(2-((1-cyclopropyl-1H-pyrazol-4- yl)amino)-5-methylpyrimidin-4- yl)chroman-3-carbonitrile 372.42 35 3-((4-(2-((1-cyclopropyl-1H-pyrazol-4- yl)amino)-5-methylpyrimidin-4-yl)-2- fluorophenyl)(methyl)amino)-2,2- dimethylpropanenitrile 419.50 36 3-((4-(5-chloro-2-((1-cyclopropyl-1H- pyrazol-4-yl)amino)pyrimidin-4-yl)-2- fluorophenyl)(methyl)amino)-2,2- dimethylpropanenitrile 439.92 37 3-((4-(2-((1-cyclopropyl-1H-pyrazol-4- yl)amino)-5-methylpyrimidin-4-yl)-2- fluorophenyl)amino)-2,2- dimethylpropanenitrile 405.47 38 2,2-dimethyl-3-(4-(5-methyl-2-((1- methyl-1H-pyrazol-4- yl)amino)pyrimidin-4- yl)phenoxy)propanenitrile 362.43 39 3-(2-fluoro-4-(5-methyl-2-((1- (piperidin-4-yl)-1H-pyrazol-4- yl)amino)pyrimidin-4-yl)phenoxy)-2,2- dimethylpropanenitrile 449.52 40 3-(2-fluoro-4-(5-methyl-2-((1-(1,1,1- trifluoropropan-2-yl)-1H-pyrazol-4- yl)amino)pyrimidin-4-yl)phenoxy)-2,2- dimethylpropanenitrile 462.44 41 3-(4-(5-methyl-2-((1-methyl-1H- pyrazol-4-yl)amino)pyrimidin-4- yl)phenoxy)propanenitrile 334.37 42 1-(((4-(2-((1-cyclopropyl-1H-pyrazol- 4-yl)amino)-5-methylpyrimidin-4- yl)phenyl)amino)methyl)cyclopropane carbonitrile 385.46 43 1-(((4-(5-methyl-2-((1-(1- methylpiperidin-4-yl)-1H-pyrazol-4- yl)amino)pyrimidin-4- yl)phenyl)amino)methyl)cyclopropane carbonitrile 442.56 44 1-(((4-(5-chloro-2-((1-(piperidin-4-yl)- 1H-pyrazol-4-yl)amino)pyrimidin-4- yl)phenyl)amino)methyl)cyclopropane carbonitrile 448.95 -
TABLE 2 Summary of IC50 (nM) JAK1 JAK2 J2V617F TYK2 (5 nM) (1 mM (0.25 nM) (2.5 nM) (2.5 nM) Example ATP) (1 mM ATP) (1 mM ATP) (1 mM ATP) 1 4.8 0.27 3.1765 12 2 72.74 — 170.9 — 3 8.862 — 28.12 21.88 4 <2.5 0.4254 <1.25 <1.25 5 3.325 — <1.25 3.263 6 7.417 — <1.25 <1.25 7 <2.5 — <1.25 <1.25 8 6.197 — <1.25 — 9 7.06 — <1.25 — 10 124 — 113 — 11 65.07 — 138.5 217.9 12 19.6 32.3 — 64.73 13 5.578 — <1.25 — 14 201.6 — 163.4 351.4 15 5.712 — <1.25 — 16 39.2 — 6.33 — 17 <2.5 <0.25 <1.25 <1.25 18 <2.5 0.4273 — <1.25 19 <2.5 <0.25 <1.25 <1.25 20 <2.5 0.2513 — <1.25 21 7.31 <0.25 <1.25 <1.25 22 136 — 56.8 — 23 13.63 — <1.25 — 24 84.15 — 111 — 25 32.05 — 32.05 — 26 6.171 — <1.25 — 27 5.528 — 1.491 — 28 <2.5 — <1.25 — 29 14.1 3.4 — 41.4 30 <2.5 0.3 — — 31 7.938 3.2 — — 32 28.9 0.9 — 106 33 10.84 <0.25 6.163 30.04 34 135.9 58.84 — — 35 72.09 1.664 — — 36 103 4.6 — — 37 14.51 0.7413 — <1.25 38 7.494 1.094 — 2.617 39 <2.5 0.3768 — <1.25 40 <2.5 0.6541 — 1.785 41 19.64 32.33 — 64.73 42 19.24 27.41 — 102.4 43 26.78 3.121 — 98.45 44 35.25 1.457 — 173 -
TABLE 3A Certain Literature Compounds Example Structure IUPAC name Mol. Weight 45 4-(3-fluoro-4-methoxyphenyl)-5- methyl-N-(1-methyl-1H-pyrazol- 4-yl)pyrimidin-2-amine 313.33 46 4-(4-ethoxy-3-fluorophenyl)-5- methyl-N-(1-methyl-1H-pyrazol- 4-yl)pyrimidin-2-amine 327.36 47 4-(3-fluoro-4-isopropoxyphenyl)- 5-methyl-N-(1-methyl-1H- pyrazol-4-yl)pyrimidin-2-amine 341.38 48 4-(3-fluoro-4-propoxyphenyl)-5- methyl-N-(1-methyl-1H-pyrazol- 4-yl)pyrimidin-2-amine 341.38 49 4-(4-ethoxy-3-fluorophenyl)-N- (1-isopropyl-1H-pyrazol-4-yl)-5- methylpyrimidin-2-amine 355.41 50 4-(4-ethoxyphenyl)-5-methyl-N- (1-methyl-1H-pyrazol-4- yl)pyrimidin-2-amine 309.36 -
TABLE 3B Exemplary Testing Data of Literature Compounds JAK1 JAK2 J2V617F TYK2 (5 nM) (0.25 nM) (2.5 nM) (2.5 nM) Example (1 mM ATP) (1 mM ATP) (1 mM ATP) (1 mM ATP) 45 109.9 121.5 206.1 — 46 40.63 60.63 86.27 74.86 47 48.61 61.3 84.18 — 48 25.7 39.63 59.98 — 49 52.58 80.7 103.3 41.25 50 150.5 200.6 342.6 157.1 - Applicant's disclosure is described herein in preferred embodiments with reference to the Figures, in which like numbers represent the same or similar elements. Reference throughout this specification to “one embodiment,” “an embodiment,” or similar language means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases “in one embodiment,” “in an embodiment,” and similar language throughout this specification may, but do not necessarily, all refer to the same embodiment.
- The described features, structures, or characteristics of Applicant's disclosure may be combined in any suitable manner in one or more embodiments. In the description, herein, numerous specific details are recited to provide a thorough understanding of embodiments of the invention. One skilled in the relevant art will recognize, however, that Applicant's composition and/or method may be practiced without one or more of the specific details, or with other methods, components, materials, and so forth. In other instances, well-known structures, materials, or operations are not shown or described in detail to avoid obscuring aspects of the disclosure.
- In this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural reference, unless the context clearly dictates otherwise.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. Methods recited herein may be carried out in any order that is logically possible, in addition to a particular order disclosed.
- References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made in this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes. Any material, or portion thereof, that is said to be incorporated by reference herein, but which conflicts with existing definitions, statements, or other disclosure material explicitly set forth herein is only incorporated to the extent that no conflict arises between that incorporated material and the present disclosure material. In the event of a conflict, the conflict is to be resolved in favor of the present disclosure as the preferred disclosure.
- The representative examples are intended to help illustrate the invention, and are not intended to, nor should they be construed to, limit the scope of the invention. Indeed, various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including the examples and the references to the scientific and patent literature included herein. The examples contain important additional information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof.
Claims (39)
1. A compound having the structural formula (I):
wherein
L is O or NR4′;
X is N or CRx, wherein Rx is R′, halogen, CN or OR′;
Y is N or CRY, wherein RY is R′, halogen, CN or OR′;
each of Z1 and Z2 is independently selected from N and CR′, provided that one of Z1 and Z2 is N and the other is CR′;
R1 is hydrogen, halogen, CN, C1-C6 unsubstituted or substituted alkyl or OR′;
R2 is a C1-C16 aliphatic group optionally comprising one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with one or more of halogen, OR′, NRR′, CN, CONRR′, NRCOR′ and C1-C6 alkyl, which is in turn optionally substituted with F, OR′ or NRR′;
R3 is R′ or halogen;
each of R4 and R4′, when L is NR4′, is selected from hydrogen and C1-C16 aliphatic groups optionally comprising one or more heteroatoms selected from N, O, S and P, and R4 and R4′ together may form a 3- to 7-membered ring, having 0 to 3 heteroatoms selected from O, N and S, and wherein each of R4 and R4′ is optionally substituted with CN, CF3 or OR′; provided that if one of R4 and R4′ is hydrogen, the other is not hydrogen; and
each R and R′ is independently hydrogen or a C1-C12 unsubstituted or substituted alkyl group,
or a pharmaceutically acceptable form or an isotope derivative thereof.
4. The compound of claim 1 , wherein X is CRx, wherein Rx is H, halogen, C1-C6 unsubstituted or substituted alkyl or alkoxy.
5. The compound of claim 1 , wherein X is CH.
6. The compound of claim 1 , wherein X is N.
7. The compound of claim 1 , wherein Y is CRY, wherein RY is H, halogen, C1-C6 unsubstituted or substituted alkyl or alkoxy.
8. The compound of claim 1 , wherein Y is CH.
9. The compound of claim 1 , wherein Y is N.
10. The compound of claim 1 , wherein Z1 is CH and Z2 is N.
11. The compound of claim 1 , wherein R4 comprises a linear, branched or cyclic C1-C12 unsubstituted or substituted alkyl group.
12. The compound of claim 1 , wherein R4 comprises a 3- to 7-membered ring having 0 to 3 heteroatoms selected from O, N and S.
13-21. (canceled)
22. The compound of claim 1 , wherein R4 is a C3, C4 or C5 alkyl group substituted with CN.
23-27. (canceled)
30. The compound of claim 1 , wherein R1 is F, Cl or a C1-C3 alkyl.
31-33. (canceled)
34. The compound of claim 1 , wherein R2 is a C1-C6 aliphatic group with 0 to 2 carbon atoms replaced by one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with a CN or CF3 group.
35. The compound of claim 1 , wherein R2 is a C7-C16 aliphatic group with 0 to 3 carbon atoms replaced by one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with a CN or CF3 group.
36. The compound of claim 1 , wherein R2 comprises a C3-C16 cyclic alkyl with 0 to 8 carbon atoms replaced by one or more heteroatoms selected from N, O, S and P, optionally substituted with a CN or CF3 group.
37-42. (canceled)
43. The compound of claim 1 , wherein R2 is:
44. The compound of claim 43 , wherein each of m and n is 2.
45. The compound of claim 43 , wherein Z3 is N.
46-49. (canceled)
50. The compound of claim 43 , wherein Z3 is O.
51. (canceled)
52. A compound selected from:
53-56. (canceled)
57. A pharmaceutical composition comprising a compound according to claim 1 , effective to treat or reduce one or more diseases or disorders, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
58-62. (canceled)
63. The pharmaceutical composition of any one of claims 57 -62, being suitable for oral administration, topical administration or GI-restricted administration.
64-70. (canceled)
71. A unit dosage form comprising a pharmaceutical composition according to claim 57 .
72. (canceled)
73. A method for treating or reducing a disease or disorder, comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula (I):
wherein
L is O or NR4′;
X is N or CRx, wherein Rx is R′, halogen, CN or OR′;
Y is N or CRY, wherein RY is R′, halogen, CN or OR′;
each of Z1 and Z2 is independently selected from N and CR′, provided that one of Z1 and Z2 is N and the other is CR′;
R1 is hydrogen, halogen, CN, C1-C6 unsubstituted or substituted alkyl or OR′;
R2 is a C1-C16 aliphatic group optionally comprising one or more heteroatoms selected from N, O, S and P, wherein the aliphatic group is optionally substituted with one or more of halogen, OR′, NRR′, CN, CONRR′, NRCOR′ and C1-C6 alkyl, which is in turn optionally substituted with F, OR′ or NRR′;
R3 is R′ or halogen;
each of R4 and R4′, when L is NR4′, is selected from hydrogen and C1-C16 aliphatic groups optionally comprising one or more heteroatoms selected from N, O, S and P, and R4 and R4′ together may form a 3- to 7-membered ring, having 0 to 3 heteroatoms selected from O, N and S, and wherein each of R4 and R4′ is optionally substituted with CN, CF3 or OR′; provided that if one of R4 and R4′ is hydrogen, the other is not hydrogen; and
each R and R′ is independently hydrogen or a C1-C12 unsubstituted or substituted alkyl group,
or a pharmaceutically acceptable form or an isotope derivative thereof, effective to treat, prevent, or reduce one or more of inflammatory diseases, immune-mediated diseases, cancer, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
74-93. (canceled)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2019/081742 | 2019-04-08 | ||
PCT/CN2019/081742 WO2020206588A1 (en) | 2019-04-08 | 2019-04-08 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
PCT/CN2020/083779 WO2020207414A1 (en) | 2019-04-08 | 2020-04-08 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/083779 A-371-Of-International WO2020207414A1 (en) | 2019-04-08 | 2020-04-08 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/377,741 Continuation US20240083882A1 (en) | 2019-04-08 | 2023-10-06 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220259182A1 true US20220259182A1 (en) | 2022-08-18 |
Family
ID=72751495
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/437,989 Pending US20220259182A1 (en) | 2019-04-08 | 2020-04-08 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
US18/377,741 Pending US20240083882A1 (en) | 2019-04-08 | 2023-10-06 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/377,741 Pending US20240083882A1 (en) | 2019-04-08 | 2023-10-06 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
Country Status (8)
Country | Link |
---|---|
US (2) | US20220259182A1 (en) |
EP (1) | EP3953347A4 (en) |
JP (1) | JP2022529309A (en) |
KR (1) | KR20210151105A (en) |
CN (1) | CN113993861B (en) |
CA (1) | CA3134902A1 (en) |
IL (1) | IL287014A (en) |
WO (2) | WO2020206588A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240083882A1 (en) * | 2019-04-08 | 2024-03-14 | Lynk Pharmaceuticals Co. Ltd. | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020118683A1 (en) * | 2018-12-14 | 2020-06-18 | Lynk Pharmaceuticals Co. Ltd. | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
CN117624130A (en) * | 2020-09-30 | 2024-03-01 | 百济神州有限公司 | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014500254A (en) * | 2010-11-09 | 2014-01-09 | セルゾーム リミティッド | Pyridine compounds and their aza analogs as TYK2 inhibitors |
CN103732067A (en) * | 2011-04-12 | 2014-04-16 | 美国阿尔茨海默病研究所公司 | Compounds,compositions and therapeutic uses thereof |
DE102011112978A1 (en) * | 2011-09-09 | 2013-03-14 | Merck Patent Gmbh | benzonitrile derivatives |
GB201303109D0 (en) * | 2013-02-21 | 2013-04-10 | Domainex Ltd | Novel pyrimidine compounds |
EP3089966B1 (en) * | 2013-12-31 | 2020-10-21 | EstryX Pharma Limited | New substituted biphenyl analogues as dual inhibitors of aromatase and sulfatase |
KR101846475B1 (en) * | 2015-04-27 | 2018-04-09 | 주식회사 녹십자 | COMPOUNDS AS TNIK, IKKε AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME |
WO2020206588A1 (en) * | 2019-04-08 | 2020-10-15 | Lynk Pharmaceuticals Co., Ltd. | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
-
2019
- 2019-04-08 WO PCT/CN2019/081742 patent/WO2020206588A1/en active Application Filing
-
2020
- 2020-04-08 CN CN202080026011.0A patent/CN113993861B/en active Active
- 2020-04-08 CA CA3134902A patent/CA3134902A1/en active Pending
- 2020-04-08 JP JP2021555343A patent/JP2022529309A/en active Pending
- 2020-04-08 US US17/437,989 patent/US20220259182A1/en active Pending
- 2020-04-08 EP EP20787550.1A patent/EP3953347A4/en active Pending
- 2020-04-08 KR KR1020217033750A patent/KR20210151105A/en unknown
- 2020-04-08 WO PCT/CN2020/083779 patent/WO2020207414A1/en unknown
-
2021
- 2021-10-05 IL IL287014A patent/IL287014A/en unknown
-
2023
- 2023-10-06 US US18/377,741 patent/US20240083882A1/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240083882A1 (en) * | 2019-04-08 | 2024-03-14 | Lynk Pharmaceuticals Co. Ltd. | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20210151105A (en) | 2021-12-13 |
EP3953347A4 (en) | 2023-01-18 |
CA3134902A1 (en) | 2020-10-15 |
JP2022529309A (en) | 2022-06-21 |
US20240083882A1 (en) | 2024-03-14 |
WO2020207414A1 (en) | 2020-10-15 |
TW202104208A (en) | 2021-02-01 |
WO2020206588A1 (en) | 2020-10-15 |
EP3953347A1 (en) | 2022-02-16 |
CN113993861A (en) | 2022-01-28 |
CN113993861B (en) | 2024-05-14 |
IL287014A (en) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11981663B2 (en) | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | |
US20240083882A1 (en) | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | |
US11851431B2 (en) | Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof | |
US11440904B2 (en) | Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof | |
US20210403460A1 (en) | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | |
TWI839504B (en) | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | |
US20200140444A1 (en) | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | |
WO2023108536A1 (en) | Tyk2 inhibitors and compositions and methods thereof | |
TWI842766B (en) | Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: LYNK PHARMACEUTICALS CO. LTD., CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WAN, ZHAOKUI;VAZQUEZ, MICHAEL LAWRENCE;LI, XIAODONG;SIGNING DATES FROM 20190430 TO 20190812;REEL/FRAME:065821/0158 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |